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Abstract
Atherosclerosis is a chronic inflammatory disease regulated by T-cell subsets. Recently, Thl7 
cells have been shown to be critical in exacerbating atherosclerosis in humans and mice. 
Possible mechanisms of Thl7 cell differentiation from mouse CD4^ T-cells via oxLDL- 
treated dendritic cells (DCs) and smooth muscle cells (SMCs) were investigated. The 
possibility of direct interaction of oxLDL with Thl7 cells followed by the effect of Thl7 
cells induction in vivo on the atherosclerotic plaque development in apoE'^’ were examined.
It was demonstrated that an atherogenic stimuli, oxLDL induced maturation of DCs by up- 
regulating the expression of maturation markers CD40, CD86 and MHC class II which 
facilitated the differentiation of CD4^ T-cells into Thl7 cells. The addition of IL-6 and TGF- 
p during CD4^ T-cells co-cultured with oxLDL-treated DCs increased the expression of IL- 
17A on CD4^0Ryt^ expressing cells. On the other hand. Mitomycin C (MMC) treatment on 
oxLDL-treated DCs and co-cultured with CD4^ T-cells reduced the expression of IL-17A on 
CD4^0Ryt^ expressing cells.
The current study also showed that oxLDL induced the secretion of IL-6, TGF-p and IL-23 
by SMCs after 24 hours of incubation. Exogenous IL-6 and TGF-P increased IL-17A 
expression on CD4^CD25" expressing cells and also IL-17F expression on both CD4^CD25* 
expressing cells and CD4^0Ryt^ expressing cells when CD4^ T-cells co-cultured with 
oxLDL-treated SMCs.
We then investigated the possible direct interaction between oxLDL with Thl7 cells. The 
results showed that treated Thl7 cells induced expression of CD36. The current study also 
demonstrated that treated Thl7 cell induced culture also increased the expression of p-STAT- 
3 and secretion of Thl 7 cell related cytokines, IL-17A  and IL-17F.
Finally, the current study demonstrated that pertussis toxin (PTx), anti-CD25 (PC61) and a 
combination of both treatments increased Thl 7 cells in the splenocytes of female apoE'^' mice 
fed with high fat diet (HFD). The serum cholesterol also was significantly higher in the 
treated mice. Furthermore, the plaque size significantly increased in mice that were treated 
with PC6I and combinations of PTx and PC61, but no changes were observed in the collagen 
content.
Taken together, the findings suggest that the level of IL-6 and TGF-P secreted by oxLDL- 
treated DCs and SMCs may influence Thl 7 cell differentiation. The possible engagement of 
oxLDL by Thl7 cells via CD36 may activate STAT-3, which in turn may mediate the release 
of IL-17A and IL-17F. The induction of Thl 7 cells following respective treatments in the 
apoE‘^‘ mice fed with HFD displayed close correlation between high cholesterol levels and 
thus increase atherosclerotic plaque development. Therefore, Thl 7 cells may be a potential 
target for modulation of atherogenesis.
II
Declaration
This work has not been accepted in substance for any degree and is not concurrently 
submitted in candidature for any degree.
Statement 1
This thesis is the result of my own investigations, except where otherwise stated. Other 
sources are acknowledged by footnotes giving explicit references. References are appended.
Statement 2
I hereby give consent for my thesis, if accepted, to be available for photocopying and for 
inter-library loan, and for the title and the summary to be made available to outside 
organisation.
Ill
Acknowledgements
All praises and gratitude is to Allah, Lord to whom every single creature in the heavens and 
the earth belongs to. May peace and blessings be upon our prophet Muhammad S.A.W, his 
family and companions.
A bouquet of appreciation to my supervisor. Dr. Ernesto Oviedo-Orta for his invaluable 
guidance, criticism and support throughout my study. I would also acknowledge the valuable 
technical advices and discussions provided by our research fellow. Dr Alexandra Bermudez- 
Fajardo and Dr. Emmanuel Dupont. I am also thankful to Dr. Fiona Green who became my 
interim supervisor after Dr. Ernesto left the university and helped a lot in completing my Phd 
thesis.
I am very grateful to Universiti Sains Malaysia for awarding me the Academic Scheme of 
Training Scholarship (ASTS), which provided the financial support throughout my study.
My special appreciation is extended to all the members and ex-members of the my research 
group especially Ms. Natalia Milioti, Dr. Crysoula Pyriedes, Dr. Sama Attiyyah, Dr. Rehab 
Al-Kadri, Dr. Anne Katrine and Dr. Rueban Jacob Isaac. The fiiendship that I have 
established with the members of this research group will always be remembered and 
treasured.
Last but not least, I am extremely indebted to my beloved wife. Nor Azreen Zulkafli and our 
gorgeous daughters, Aleesha Rafhanah and Afi*eena Raihanah, for their love, patience, 
support and understanding during “trying time” in the UK. My special thanks to my mum, 
Hasmah Awang and all my families for their warm love, which perked my spirit up and kept 
me striving during difficult and trying times.
IV
Publications arising from the thesis
Conference abstract
• Rafeezul Mohamed, A.Bermudez-Fajardo, E, Oviedo-Orta. Thl 7 cells induction 
accelerated atherosclerosis development in the apoE'^" mice. Atherosclerosis 2010. 
Vol. 213. Issue 1, page elO.
Conference attendance and presentations
• Poster presentation at the Autumn Meeting of British Atherosclerosis Society, 
University of Oxford (2010)
• Poster presentation at the 2"  ^Cardiovascular Symposium, University of Surrey (2010)
• Poster presentation at the Research Festival, Faculty of Health and Medical Science, 
University of Surrey (2010)
• Oral presentation at the 17^ National Conference on Medical and Health Sciences, 
Health Campus, Science University of Malaysia, Kelantan, Malaysia (2012)
Prizes
• First place of oral presentation for basic science category at 17* National Conference 
on Medical and Health Sciences, Health Campus, Science University of Malaysia, 
Kelantan, Malaysia (2012)
V
Table of Contents
Abstract.....................................................................................................................................I
Declaration.............................................................................................................................HI
Acknowledgement.................................................................................................................IV
Publication arising from the thesis.......................................................................................V
List of Abbreviation.............................................................................................................XII
List of Figures.....................................................................................................................XVI
List of Tables....................................................................................................................XVIII
CHAPTER 1 INTRODUCTION........................................................................................... 1
1.1 Introduction.......................................................................................................................2
1.2 Cardiovascular disease (CVD) and atherosclerosis: An overview................................ 2
1.2.1 Atherosclerosis...........................................................................................................2
1.2.1.1 Risk factor of atherosclerosis........................................................................ 3
1.2.1.2 T-cell autoantigens in atherosclerosis...........................................................4
1.2.1.3 Atherosclerotic plaque formation.................................................................. 7
1.2.1.4 Diversity of T-cells in atherosclerosis......................................................... 11
1.2.1.5 T-helper cells in atherosclerosis.................................................................. 11
1.1.1.6 Thl/Th2vsThl7......................................................................................... 16
1.3 Thl7ceUs..............................................................................................  17
1.3.1 Background.............................................................................................................. 17
1.3.2 Differentiation of Thl 7 cells.................................................................................... 17
1.3.3 Characteristic of Thl7 cells...................................................................................... 18
1.3.4 Thl 7 cells in atherosclerosis.................................................................................... 21
1.4 Hypothesis, aims and objectives of the study................................................................ 23
CHAPTER 2 MATERIALS AND METHODS.................................................................. 25
2.1 Materials........................................................................................................................26
2.1.1 General reagents.....................................................................................................26
2.1.1.1 Health and safety....................................................................................... 26
2.1.1.2 Instruments and software....................................................................................26
VI
2.1.2 C57BL/6 apoE'^’mice...............................................................................................26
2.1.3 Cell culture...............................................................................................................27
2.1.3.1 Cell culture reagents....................................................................................27
2.1.3.2 General solutions.........................................................................................27
2.1.3.2.1 Composition of general buffers, solutions and reagents........... 27
2.2 General methodology......................................................................................................28
2.2.1 Isolation of low density lipoprotein (LDL)..............................................................28
2.2.2 CD4+ T-cells isolation  .................................................................................29
2.2.2.1 Splenocytes isolation...................................................................................29
2.2.2.2 Isolation of CD4+T-cells.............................................................................29
2.2.2.3 Cell viability analysis and quantification.................................................... 30
2.2.3 Polymerase Chain Reaction (PCR)......................................................................... .30
2.2.3.1 Total RNA extraction.................................................................................. 30
2.2.3.2 cDNA synthesis...........................................................................................31
2.2.3.3 Polymerase Chain Reaction (PCR)............................................................. 31
2.2.4 DNA agarose gel electrophoresis............................................................................. 32
2.2.4.1 Preparation of agarose gel........................................................................... 32
2.2.4.2 Agarose gel electrophoresis......................................................................... 32
2.2.4.3 Densitometric analysis of PCR products..................................................... 32
2.2.5 Flow cytometry analysis........................................................................................... 33
2.2.5.1 Cell surface and intracellular staining......................................................... 33
2.2.5.2 Gating strategies for the analysis of Thl 7 cells.......................................... 35
2.2.6 Enzyme linked immunoabsorbent assays (ELISA).................................................. 47
2.3 Statistical analysis...........................................................................................................48
CHAPTER 3 EFFECT OF OXTOISED LOW DENSITY LIPOPROTEIN-LOADED 
DENDRITIC CELLS ON TH17 CELLS........................................................................... 49
3.1 Dendritic cells (DCs).....................................................................................................50
3.1.1 Introduction.............................................................................................................. 50
3.1.2 DCs and atherosclerosis........................................................................................... 50
3.1.3 Recruitment of DCs into the vessel wall.................................................................. 51
VII
3.1.4 Maturation of DCs by oxLDL..................................................................................52
3.1.5 Maturation of DCs by PTx and a combination of oxLDL and PTx......................... 53
3.1.5 Engagement of mature DCs with T-cells induce T-cell differentiation................... 53
3.2 Aim....................................................................................................................................54
3.3 Objectives.........................................................................................................................54
3.4 Materials and methods....................................................................................................55
3.4.1 Animals....................................................................................................................55
3.4.2 Isolation of CD4^ T-cells.........................................................................................55
3.4.3 Generation of bone marrow-derived dendritic cells (BMDC)................................. 55
3.4.4 In vitro cell culture...................................................................................................56
3.4.5 Measurement of cytokine by ELISA........................................................................ 57
3.4.6 Detection of DCs maturation markers by flow cytometry analysis......................... 58
3.4.6.1 Gating strategy............................................................................................ 59
3.4.7 Detection of Thl 7 cells by flow cytometry analysis................................................ 65
3.5 Results..............................................................................................................................66
3.5.1 OxLDL and PTx induce the expression of DCs maturation markers and 
pro/anti-inflammatory cytokines............................................................................. 66
3.5.2 OxLDL and PTx-loaded DCs stimulate Thl 7 cells induction in vitro..................... 74
3.5.2.1 CD4^ T-cells co-culture with oxLDL and PTx-loaded DCs....................... 74
3.5.2.2 CD4^ T-cells co-culture vrith oxLDL and PTx-loaded DCs with
addition of IL-6 and TGF-p........................................................................ 79
3.5.2.3 CD4^ T-cells co-culture with oxLDL and PTx-loaded DCs which 
inactivated with MMC............................................................................... 84
3.5.2.4 CD4^ T-cells co-culture with oxLDL and PTx-loaded DCs which
which inactivated by MMC and addition of IL-6 and TGF-p.....................89
3.5.3 The effect of exogenous IL-6 and TGF-p, MMC inhibition and both on the 
differentiation of Thl 7 cells in vitro....................................................................... 94
3.6 Discussion.........................................................................................................................96
VIII
CHAPTER 4 SMOOTH MUSCLE CELL-DERIVED CYTOKINES DRIVE TH17 
CELLS INDUCTION IN VITRO....................................................................................... 101
4.1 Smooth muscle cells (SMCs) in atherosclerosis.......................................................... 102
4.1.1 SMCs residing regions........................................................................................... 102
4.1.2 Phenotypic features of SMCs within atherosclerotic plaques.................................102
4.1.3 Pathogenic role of SMCs in atherosclerosis........................................................... 103
4.1.3.1 Retention of monocytes and macrophages.................................................103
4.1.4 Lipid uptake by SMCs............................................................................................ 103
4.1.5 Expression of MHC class II by SMCs................................................................... 104
4.1.6 Thl7 cells and SMCs............................................................................................. 104
4.2 Aim.................................................................................................................................. 104
4.3 Objectives....................................................................................................................... 105
4.4 Materials and methods................................................................................................. .106
4.4.1 Animals.................................................................................................................. 106
4.4.2 Isolation of SMCs................................................................................................... 106
4.4.2.1 Passaging the SMCs.................................................................................. 106
4.4.2.2 Characterisation of the SMCs................................................................... 106
4.4.3 Isolation of CD4^ T-cells........................................................................................107
4.4.4 In vitro cell culture 1.............................................................................................. 107
4.4.5 In vitro cell culture 2.............................................................................................. 107
4.4.6 Cytokines determination........................................................................................ 108
4.4.7 Detection of Thl 7 cells by flow cytometry analysis...............................................108
4.5 Results............................................................................................................................ 109
4.5.1 Characterisation of SMCs...................................................................................... 109
4.5.2 OxLDL highly induced the secretion of IL-6, TGF-p and IL-23 by SMCs
after 24 hours......................................................................................................... 110
4.5.3 IL-6 and TGF-p secreted both by oxLDL-treated SMCs and exogenous IL-6 and 
TGF-P did not induce the expression of IL-17A and IL-17F on CD4^CCR6^ 
expressing cells and CD4’^ 0Ryt^ expressing cells...............................................112
4.5.4 Co-culture of CD4^ T-cells with oxLDL-treated SMCs with exogenous IL-6 and
IX
TGF-P increased the expression of IL-17A and IL-17F on CD4^CCR6^ expressing 
ceils and CD4’*R0Ryt^ expressing cells............................................................... 115
4.6 Discussion.....................................................................................................................118
CHAPTER 5 STUDY OF THE DHŒCT EFFECT OF OXTOISED LOW DENSITY
LIPOPROTEIN ON TH17 CELLS................................................................................... 122
5.1 Introduction................................................................................................................... 123
5.2 Aim.................................................................................................................................. 125
5.3 Objectives....................................................................................................................... 125
5.4 Materials and methods.................................................................................................. 126
5.4.1 Animals.................................................................................................................. 126
5.4.2 Isolation of CD4^ T-cells....................................................................................... 126
5.4.3 In vitro cell culture................................................................................................. 126
5.4.4 Cytokine determination.......................................................................................... 127
5.4.5 Flow cytometry analysis of TLR-2, TLR-4 and CD36...........................................127
5.4.5.1 Gating strategy.......................................................................................... 128
5.4.6 Intracellular detection of p-STAT-3........................................................................132
5.4.6.1 Cell lysate preparation..............................   132
5.4.6.1.1 Measurement of protein concentration.....................................133
5.4.6.2 Assay procedure.........................................................................................133
5.5 Results............................................................................................................................ 135
5.5.1 No changes on TLR-4 and TLR-2 expression level in all culture conditions 135
5.5.2 CD36 expression levels increased m Thl7 cell induced cell culture and
TCR treated CD4....................................................................................................135
5.5.3 Stimulation of CD4^ T-cells induced expression of p-STAT-3..............................139
5.5.4 Stimulation of CD4^ T-cells induced the secretion of IL-17A and IL-17...............141
5.6 Discussion....................................................................................................................... 142
CHAPTER 6 THE ROLE OF TH17 CELLS IN ATHEROSCLEROSIS
DEVELOPMENT IN APOE MICE.................................................................................146
6.1 Introduction................................................................................................................. 147
X
6.2 Aim................................................................................................................................. 148
6.3 Objectives.......................................................................................................................148
6.4 Materials and methods................................................................................................. 150
6.4.1 Animal and experimental design............................................................................150
6.4.2 Detection of Thl 7 cells by flow cytometry analysis.............................................. 150
6.4.3 Detection of cytokines and transcription factors mRNA by RT-PCR....................150
6.4.4 Plasma cytokine profile analysis............................................................................ 152
6.4.5 Lipid profile analysis..............................................................................................152
6.4.6 Analysis of atherosclerotic plaques and plaque vulnerability................................ 154
6.4.7 Morphometric analysis...........................................................................................160
6.5 Results............................................................................................................................ 162
6.5.1 A combination of PTx and PC61 increased IL-17A expression on CD4^CD25" 
expressing cells......................................................................................................162
6.5.2 PTx and PC61 treatment induced the mRNA expression Thl 7 but not
Thl/Th2 and Treg related genes............................................................................167
6.5.3 PTx and PC61 treatment increases the secretion of IL-17 in apoE' '^ mice
fed with HFD.........................................................................................................167
6.5.4 PTx and/or PC61-treated apoE' "^ mice fed with HFD had higher total cholesterol 
levels but not HDL and triglycerides.....................................................................171
6.5.5 PC61 alone or the combination of PTx and PC61 increased atherosclerotic lesion 
in the aortic sinus of apoE*^ * mice....................................................................... 172
6.5.6 No changed in the collagen content of the plaque developed in the aortic
sinus.......................................................................................................................172
6.6 Discussion.......................................................................................................................175
CHAPTER 7 GENERAL DISCUSSIONS AND FUTURE STUDIES............................180
7.1 General discussions....................................................................................................... 181
7.2 Future studies.................................................................................................................188
References............................................................................................................................ 191
XI
List of Abbreviations
ACS - Acute coronary syndrome 
AHA - America heart association 
AMI - Acute myocardial infarction 
APCs - Antigen presenting cells 
ApoB - Apolipoprotein B 
ApoE - Apolipoprotein E 
BMDC - Bone marrow dendritic cells 
bp - base pair
CBA - Cytometric beads array 
CCR - C-C chemokine receptor 
CD - Cluster of differentiation 
CD40L - CD40 ligands 
cDNA - complementary DNA 
CHD - Coronary heart disease 
CIA - Collagen induced arthritis 
CRP - C-reactive protein
CTLA-4 - Cytotoxic T lymphocyte associated antigen 4
CTLs - Cytotoxic T lymphocytes
CVD - Cardiovascular disease
DCs - Dendritic cells
DNA - Deoxyribose nucleic acid
EAE - Experimental autoimmune encephalitis
ECs - Endothelial cells
ECM - Extracellular matrix
EDTA - Ethylenediaminetetraacetic acid
ELISA - Enzyme linked immunosorbent assay
FACS - Fluorescence activated cell sorting
XII
FCS - Fetal calf serum
FITC - Fluorescein isothiocyanate
Foxp3 - Foxhead/winged helix transcription factor
FSC - Forward scatter
GAPDH - Glyceraldehyde 3-phosphate dehydrogenase
GM-CSF - Granulocyte-macrophage colony-stimulating factor
H&E - Haematoxylin and Eosin
HCD - High chow diet
HCL - Hydrochloride acid
HDL - High density lipoproteins
HFD-High fat diet
HSP65 - Heat shock protein 65
ICAM-1 - Intracellular adhesion molecule -1
IDL - Intermediate density lipoproteins
IFN - Interferon
IL - Interleukin
iTreg - inducible Treg cells
LAP - Latency associated peptide
LCD - Low chow diet
LDL - Low-density lipoprotein
LOX-1- Lectin-like oxidized LDL receptor-1
MCP-1 - Monocyte chemotactic protein-1
M-CSF - Macrophages colony stimulating factor
MDA - Malondialdehyde
Med - Median
MHC - Major histocompatibility complex 
MFI - Median fluorescence intensity 
MMC - Mitomycin C
XIII
MMP - Matrix metalloproteinase
NaNs - Sodium azide
NaOH - Natrium hydroxide
NK - Natural killer
NLL - Notch delta like ligands
OxLDL - Oxidised LDL
PAI-1 - Plasminogen activator inhibitor 1
PBS - Phosphate buffer saline
PDGF- Platelet derived growth factor
PECAM - Platelet endothelial cell adhesion molecule
PMA - Phorbol 12-myristate-13-acetate
pMHC - peptide-MHC
PMN - Polymorphonuclear cells (PMN)
PRRs - Pattern recognition receptors
PTx - Pertussis toxin
RNA - Ribonucleic acid
RORa - Retinoid orphan receptor alpha
RORyt - Retinoid related orphan receptor gamma
RPE - R-Phycoerytherin
RPMI-1640 - Roswell Park Memorial Institute-1640
RT-PCR - Reverse Transcriptase Polymerase chain reaction
sCD40L - soluble CD40 ligands
se n )  - Severe combined immunodeficiency
SMCs - Smooth muscle cells
SMC-a-actin - Smooth muscle alpha actin 
SM-MHC - Smooth muscle cells myosin heavy chain 
SOCS-3 - Suppressor of cytokine signaling-3 
SSC - Side scatter
XIV
STAT - Signal transducer activator of transcription
TAE - Tris acetate EDTA
TCR - T-cell receptor
Tfli - T follicular helper
TGF - Transforming growth factor
Th - T-helper
TLR - Toll like receptor
TMB - Tetramethylbenzidine
TNF - Tumour nuclear factor
Treg - T regulatory cells
VCAM-1- Vascular adhesion molecule 1
VEGF - Vascular endothelial growth factor
VLA-4 - Very late antigen-4
VLDL - Very low density lipoproteion
VSMC - Vascular smooth muscle cells
WHO - World Health Organisation
XV
List of Figures
Figure 1.1 Schematic diagram of the low-density-lipoprotein (LDL)...................................... 6
Figure 1.2 Stages of atherosclerotic plaque development........................................................10
Figure 1.3 T helper cells differentiation.................................................................................. 12
Figure 1.4 Thl 7 cells differentiation in mouse and man..........................................................18
Figure 1.5 Origin of Thl 7 cells and their differentiation into Thl cells................................. 20
Figure 2.1 The control tubes for CD4^/CD25'/IL-17A^/IL-17F  ^combination....................... 37
Figure 2.2 The gating strategies for CD4^CD25‘IL-17A^IL-17F^.......................................... 37
Figure 2.3 The control tubes for CD4VCD257IL-17AVIL-17F^ combination....................... 39
Figure 2.4 The gating strategies for CD4^CD25TL-17A^IL-17F^.......................................... 39
Figure 2.5 The control tubes for CD4^/RORyt^AL-17A^/IL-17F^ combination..................... 41
Figure 2.6 The gating strategies for CD4^/RORyt^/IL-17A^/IL-17F^.................................... 42
Figure 2.7 The control tubes for CD4^/RORyt^/IL-17A^/IL-17F^ combination..................... 43
Figure 2.8 The gating strategies for CD4^/R0Ryt^/IL-17A^/IL-17F^.................................... 44
Figure 2.9 The control tubes for CD4^/CCR6^/IL-17A^/IL-17F  ^combination...................... 46
Figure 2.10 The staining strategies for CD4^/CCR6^/IL-17A^/IL-17F^................................. 46
Figure 3.1 Recruitment of DCs into atherosclerotic plaques and differentiation of T-cell
subsets.....................................................................................................................................51
Figure 3.2 The control tubes for the combination of CDl lb CDl Ic CD40^......................... 60
Figure 3.3 The gating strategy for determination of maturation markers of DCs, CD40....... 61
Figure 3.4 The control tubes for the combination of CDl Ib^CDl lc^CD86^......................... 62
Figure 3.5 The gating strategy for determination of maturation markers of DCs, CD86....... 63
Figure 3.6 The control tubes for the combination of CDl Ib^CDl Ic^MHCII^...................... 64
Figure 3.7 The gating strategy for determination of maturation markers of DCs, CD86....... 65
Figure 3.8 The effect of oxLDL, PTx and a combination of both on DCs-expressing CD40.68 
Figure 3.9 The effect of oxLDL, PTx and a combination of both on DCs-expressing CD86.70 
Figure 3.10 The effect of oxLDL, PTx and a combination of both on DCs-expressing
MHC II....................................................................................................................................72
Figure 3.11 The effect of oxLDL, PTx and a combination of both on IL-6 and TGF-p
secretion by DCs.....................................................................................................................73
Figure 3.12 Effect of oxLDL, PTx and a combination of both on Thl7 cell differentiation...76 
Figure 3.13 Effect of oxLDL, PTx and a combination of both on Thl7 cell differentiation...78 
Figure 3.14 Effect of oxLDL, PTx and a combination of both on Thl 7 cell differentiation...81 
Figure 3.15 Effect of oxLDL, PTx and a combination of both on Thl 7 cell differentiation...83 
Figure 3.16 Effect of oxLDL, PTx and a combination of both on Thl7 cell differentiation... 86 
Figure 3.17 Effect of oxLDL, PTx and a combination of both on Thl 7 cell differentiation...88 
Figure 3.18 Effect of oxLDL, PTx and a combination of both on Thl7 cell differentiation...91 
Figure 3.19 Effect of oxLDL, PTx and a combination of both on Thl 7 cell differentiation...93 
Figure 3.20 The effect of exogenous IL-6 and TGF-p, MMC inhibition and both on the
differentiation of Thl 7 cells in vitro....................................................................................... 95
Figure 4.1 Overlay image of immunofluorescence of SMCs.................................................109
Figure 4.2 The effect of oxLDL-treated SMCs on cytokine secretion...................................111
Figure 4.3 The effect of cytokines secreted by oxLDL-treated SMCs and addition of
exogenous cytokines on the differentiation of Thl 7 cells......................................................113
Figure 4.4 The effect of cytokines secreted by oxLDL-treated SMCs and addition of
exogenous cytokines on the differentiation of Thl 7 cells......................................................114
Figure 4.5 Effect of cytokines secreted by oxLDL-treated SMCs and exogenous cytokines on 
Thl7 cell differentiation.........................................................................................................116
XVI
Figure 4.6 Effect of cytokines secreted by oxLDL-treated SMCs and exogenous cytokines on
Thl 7 cell differentiation........................................................................................................ 117
Figure 5.1 The control tubes for CD4^/CCR6^/TL-2^/TLR-4^ combination.........................129
Figure 5.2 Gating strategies for CD4/CCR6/TLR-2/TLR-4................................................. 130
Figure 5.3 The control tubes for CD4^/CCR6^/CD36^ combination.....................................131
Figure 5.4 Gating strategies for CD4/CCR6/CD36.............................................................. 132
Figure 5.5 The expression of TLR-2 and TLR-4 by Thl 7 cells............................................ 137
Figure 5.6 The expression of CD36 on Thl 7 cells................................................................ 139
Figure 5.7 The effect of oxLDL on pSTAT-3 expression......................................................140
Figure 5.8 Effect of oxLDL on the secretion of IL-7A and IL-17F.......................................141
Figure 6.1 Total cholesterol principle................................................................................... 153
Figure 6.2 Tyglycerides measurement principle................................................................... 153
Figure 6.3 The principle of HDL measurement.................................................................... 154
Figure 6.4 Effect of PTx, PC61 and the combination of both on the differentiation of Thl 7
cells........................................................................................................................................ 164
Figure 6.5 Effect of PTx, PC61 and combination of both on Thl 7 cell differentiation.........166
Figure 6.6 Representative gel electrophoresis for the mRNA expression of
Thl/Th2/Treg/Thl7 related genes in splenocytes from treated mice.....................................168
Figure 6.7 Effect of PTx, PC61 or a combination of both on the mRNA expression of Thl,
Th2, Treg and Thl 7 cells cytokines and transcription factors in apoE"^ " mice fed a HFD 169
Figure 6.8 Effect of PTx, PC61 or both on plasma levels of Thl, Th2 and Thl7 cytokines as
measured in apoE'^‘ mice fed a HFD..................................................................................... 170
Figure 6.9 Effect of PTx, PC61 and combination of both on plasma lipids profile on apoE' '^
mice fed with a HFD............................................   171
Figure 6.10 Effect of PTx, PC61 or both in atherosclerotic plaque size................................173
Figure 6.11 Effect of PTx, PC61 or both in atherosclerotic plaque collagen content............174
Figure 7.1 Summary of mechanism of Thl 7 cell differentiation from CD4^ T-cells, direct 
interaction of oxLDL with Thl 7 cells and the effect of Thl 7 cells induction on 
atherosclerotic plaque development...................................................................................... 187
XVII
List of Tables
Table 1.1 Novel risk factor involved in atherosclerosis............................................................ 3
Table 2.1 General buffers, solutions and reagents.................................................................. 28
Table 2.2 The antibodies and isotypes used for the analysis of Thl 7 cells by using flow
cytometry................................................................................................................................. 34
Table 3.1 Recipe for RPMI advanced medium and its supplements....................................... 57
Table 3.2 The antibodies and isotypes control for detection of DCs maturation markers...... 58
Table 6.1 The primer sequences and product size..................................................................151
XVIII
CHAPTER 1 
GENERAL INTRODUCTION
1.1 Introduction
Atherosclerosis is a chronic inflanunatory disease that involves the formation of arterial 
lesions in the innermost layer of the arterial walls called the intima due to inflammation, lipid 
accumulation, cell death and fibrosis (Hansson and Libby 2006). These lesions are known as 
atherosclerotic plaques, which can mature over time and gain new characteristics. At all 
stages of development the lesions consist of various immune cells such as macrophages, 
dendritic cells (DCs) and lymphocytes. Uncovering the mechanism by which specific 
immune cells are involved in the regulation of lesion development will provide greater 
knowledge in understanding the pathogenesis of atherosclerosis and for the development of 
novel therapeutic approaches.
1.2 Cardiovascular disease (CVD) and atherosclerosis: An overview
Cardiovascular disease (CVD) is the main cause of death in the UK in comparison to other 
diseases such as cancer and diabetes (BHF 2009-10). CVD claims almost 191,000 per year, 
and is responsible for approximately one in three deaths. Almost half (46%) of all deaths 
from CVD are due to coronary heart disease (CHD) and nearly a quarter (23%) are from 
stroke. CVD is also the main cause of premature death in the UK (death before the age of 75), 
brought about almost 50,000 premature deaths in 2008. It is estimated that by the year 2020, 
CVD will be the world’s leading cause of death and disability (WHO 2011). Furthermore, 
CVD is a disease that affects the heart and blood vessels (arteries and veins) (Myerburg 
1997). Atherosclerosis is the main cause of this disease, and is characterised by hardening of 
the arterial wall, deposition of fatty molecules and the recruitment of white blood cells at the 
intimai layer of blood vessels. This hardening and accumulation of lipids leads to narrowing 
of the lumen of the artery and subsequently obstructs blood flow that limits oxygen supply to 
various organs and tissues leading to other complications (Kumar 2002).
1.2.1. Atherosclerosis
Classification of atherosclerosis, which was first provided by the World Health Organization 
(WHO) in 1958, was based on the different stages of disease progression. These stages were 
designated as follows: fatty streak, atheroma, fibrous plaque, and complicated lesions 
(Gaudio 2006). The American Heart Association (AHA) in their recent classification defined 
atherosclerosis as a chronic inflammatory disease in the wall of large and medium sized 
arteries, and is the most common pathological change leading to CVD. Atherosclerosis is 
characterised by two essential hallmarks: firstly, the accumulation of oxidised lipoprotein in
the intima of arteries and secondly, inflammatory changes leading to plaque formation, 
finally causing thrombosis or stenosis (Hansson 2005). Disturbed blood flow areas are more 
prone to lesion formation due to the reduced activity of atheroprotective mechanisms such as 
the expression of the enzyme superoxide dismutase and increase of nitric oxide synthase 
activity, which inhibit oxidative stress and suppress the expression of adhesion molecules and 
other inflammatory pathways respectively (Topper 1999; Guilia Russoa 2002). Lesions occur 
at the branch and curvature points of the vascular system (Libby 2002).
1.2.1.1 Risk factor of atherosclerosis
Epidemiological studies have identified a number of risk factors involved in the development 
of atherosclerosis and its complications. Classical risk factors of the disease include 
hypercholesterolemia, tobacco smoking, hypertension, diabetes, male gender, age and family 
history (Dafloh 2010). In addition, novel risk factors have been recently described, and these 
are summarised in Table 1.1.
Table 1.1 Novel risk factor involved in atherosclerosis (Hackam 2003; Kullo 2005)
Risk factors Example
Inflammatory markers C-reactive protein (CRP), interleukins (IL-6), 
serum amyloid A, vascular and cellular adhesion 
molecules, soluble CD40 ligands (sCD40L) and 
number of leukocytes
Haemostasis/Thrombosis markers Fibrinogen, von Willebrand factor antigen, 
plasminogen activator inhibitor 1 (PAI-1), tissue- 
plasminogen activator factors, D-dimer, 
fibrinopeptide A and prothrombin fragment 1+2
Platelet-related factors Platelet aggregation, platelet activity and platelet 
size and volume
Lipid-related factors Low-density lipoprotein (LDL), lipoprotein A, 
remnant lipoproteins, apo-lipoproteins A1 and 
B, high-density lipoprotein subtypes and oxLDL
Other factors Homocysteine, lipoprotein-associated phosphor- 
lipase A2, micro-albuminuria, insulin resistance, 
apoE genotype, infectious agents: 
(Cytomegalovirus, Ch. pneumonia, H. pylori. 
Herpes simplex virus) and psychosocial factors.
However, growing evidences show that atherosclerosis can not be completely explained by 
all the traditional and other novel risk factors listed in the Table 1.1. Recent evidence support 
the assumption that atherosclerosis is an inflammatory autoimmune disease (Sherer Y 2006).
1.2.1.2 T-cell autoantigens in atherosclerosis
Although infectious agents have been linked with the activation of immune mechanisms, 
recent evidences show that the main antigenic targets in atherosclerosis are modified 
endogenous structures or autoantigens (Nilsson 2008; Shi 2010). It is showed that these 
autoimmune responses were initiated by removing the potential harmful antigens (Hansson 
2006). Three mechanisms have been suggested to explain the autoimmune phenomena. 
Firstly, the molecular mimicry theory where the autoimmune response is elicited by the initial 
activation of lymphocytes recognising epitopes derived from microorganisms that share 
sequence homology with self-molecules. Therefore, autoimmunity due to epitope mimicry 
may lead to disease in predisposed individuals (Blank 2004). Secondly, deteriorations in 
apoptosis killing and clearance can potentially restore apoptotic cells as a source of 
autoantigens which normally sequestered in the intracellular environment. Structural 
modification during cell death may impact the immunogenicity of clustered self-antigens at 
the surface of apoptotic bodies (Hall 2004). Thirdly, autoimmune response may be directed 
against altered self-structures by high affinity ligand binding or by chemical impairment due 
to environmental circumstances, such as oxidative stress (Stemme, Faber et al. 1995). There 
are several candidate autoantigens in atherosclerosis have been identified namely, oxLDL, 
heat shock protein (HSP) and beta 2-glycoprotein 1.
i) Oxidised LDL (oxLDL)
Researchers have placed great emphasis on oxLDL, which can induce autoimmune responses 
as it is a self modified antigen (Palinski 2000). LDL is a spherical particle that consists of a 
hydrophobic core of cholesteryl esters and triglycerides surrounded by an amphipathic 
monolayer of phospholipid and cholesterol with a single molecule of apolipoprotein B-lOO 
(apoB) (Chehin 2001) (Figure 1.1). The peroxidation of polyunsaturated fatty acids on 
phospholipids and cholesteryl esters results in the formation of reactive breakdown products, 
such as malondialdehyde (MDA) and 4-hydroxynonenal, which forms covalent adducts with 
amino acids containing free amino groups in apoB-100, creating immunogenic epitopes 
(Nilsson 2005). MDA adducts are the main modification inside oxLDL in vivo (Yla-Herttuala
1989). The detection of antibodies binding to oxLDL and MDA modified peptides from apoB 
as well as oxidised phospholipids in atherosclerotic mice and patients have served to 
demonstrate the immune response to oxLDL in atherosclerosis (Yla-Herttuala 1989; Horrko 
1999; Fredrikson 2003). The accumulation and retention of oxLDL molecules in the 
subendothelial space, triggered by interaction with the endothelium, initiates atherogenesis 
and promotes lesion development (Yla-Herttuala 1999). This is achieved by the induction of 
macrophage foam cell formation, SMCs migration and proliferation by the retained oxLDL 
particles, as well as the stimulation of the secretion of inflammatory cytokines and the 
expression of adhesion molecules that promote endothelial cell dysfunction and leukocyte 
extravasation (Olofsson 2005; Groyer 2006). Antigen presentation by DCs and macrophages 
epitopes such as malondialdehyde-lysine leads to clonal expansion of oxidised LDL-specific 
T-cells and expression of oxidised specific autoantibodies to oxidatively generated 
autoantibodies (Palinski 2000). Human atherosclerotic plaques populate by 10% of all T-cells 
specifically recognise oxLDL (Stemme, Faber et ah 1995). T-cells cloned fi*om human 
atherosclerotic plaques interact with oxLDL in major histocompatibility complex (MHC) 
class II dependent manner (Stemme, Faber et a l 1995).
il) Heat shock proteins
A second autoantigens that have been involved in atherosclerosis are the stress-induced heat 
shock proteins (HSP). HSP acts as molecular chaperons promoting refolding of denaturated 
proteins in stress cells (Wick 2004). Some of them have been associated in loading of 
immunogenic peptides to MHC class I and MHC class II (Javid 2007). In atherosclerotic 
lesion, antibodies to heat shock protein 65 (HSP65) that can cross react with human HSP60 
raised the possibility of microbial induced autoimmunity because of molecular mimicry 
between molecules on pathogen and self-proteins (Perschinka 2003). The cardiovascular 
patients have high antibody levels against HSP 60/65 and predict futher development of the 
disease (Xu 2002). In addition, plaque derived T-cells have been demonstrated to interact 
with microbes HSP65 (de Boer 2000; Mosorin 2000; Xu 2002). Parenteral immunisation of 
animal with HSP65 induces atherosclerosis development (Xu, Dietrich et al 1992; George, 
Shoenfeld et al 1999; Afek, George et al 2000) and transfer of lymphocytes fi-om HSP65- 
immunised mice accelerates fatty streak deposition in the recipient mice (George 2001). In 
contrast, mucosal administration of HSP65 in mice increases the suppression of antibody and 
T-cell responses against HSP65, and reduces atherosclerosis development in mice (Harats, 
Yacov et al 2002; Maron 2002).
Phospholipids
Uncstcrificd
cholesterol ♦
rriglyceridcs
Cholesterol
esters
Figure 1.1 Schematic diagram of the low-density-iipoprotein (LDL). The size of LDL particle is 
approxiamately 21-24 nm and acts as transporter of unesterified cholesterol, cholesterol ester, and 
triglycerides in the blood. The core of the particle composed of cholesterol ester and triglycerides. The 
outer layer contains of phospholipids and unesterified cholesterol in which a single protein is 
embedded, the apoliprotein B-100 (ApoB-100). In the subendothelial space, these components 
undergo oxidation process by free radicals during inflammation. They are also main targets for the 
engagement of the LDL by scavenger receptor, proteoglycans, and low density lipoprotein receptor 
(LDLr). During atherogenesis, a large number of IgM antibodies are secreted due to oxidative stress- 
modified phospholipid response, whereas IgG antibodies and T-cell clones are produced against 
ApoB-100. Figure and descriptions were from Natalia et al., 2008.
iii) Beta 2 glycoprotein 1
Beta 2 glycoprotein 1 (P2GP1) is a phospholipid-binding protein expressed by platelets, 
endothelial cells (ECs) and atherosclerotic plaques (George 1999). Vaccination of LDLr" " 
mice with P2GP1 leads to the development of brisk and sustained immune response to the 
human 62GPL These antibodies also bound immobilized mouse B2GPI, probably due to 
cross-reaction process. The LDLr"^ " mice developed significantly enhanced early 
atherosclerosis compared with their BALB/c immunized with ovalbumin. In addition, CD4^ 
lymphocytes were accumulate in the valvular and subendothelial regions of the aortic sinus of 
the p2GPI-immunized mice (George 1998). Transfer of p2GP-reactive lymphocytes fi*om 
P2GP1-immunised mice into LDL  ^ mice exacerbates atherosclerosis, whereby oral 
administration of this protein reduces atherosclerosis, suggesting the disease-aggravating 
properties of lymphocytes specific for this antigen (George 2000; George 2004).
1.2.1.3 Atherosclerotic plaque formation
The structure of normal arterial wall consists of three different layers namely the intima, the 
media and the adventitia (Figure 1.2a). The outermost layer is the adventitia, which contains 
connective tissues, fibroblasts, some SMCs, immune cells such as T-cells, monocytes and 
macrophages, and vasa vasorum that provides the oxygen supply required by the different 
cellular components of the wall. The middle layer is the media and it is predominantly 
composed of SMCs, which are responsible for maintaining the contractility of the vessel. The 
innermost layer of artery is the intima, which is made of ECs facing the lumen of the artery, 
connective tissue and occasional macrophages or SMCs. The most important quality of the 
intima is its smoothness and flexibility such that it does not obstruct the flow of blood. The 
external elastic laminae is situated between the adventitia and media, whereas internal elastic 
laminae separates media and intima (Lusis 2000).
i) Fatty streak development
The first stage of atherogenesis is the formation of a fatty streak (Figure 1.2b), which begins 
during childhood (Stary HC 1995). This first step is the deposition of lipoprotein particles, 
especially LDL in the arterial intima of the blood vessels (Witztum 1998; Berliner 2001). 
Lipoproteins are small particles involved in the transportation of cholesterol and triglycerides 
in the blood (Sacks 2006). The accumulation of lipoprotein particles in the vascular wall rely 
on the interaction between apoB; the main protein component of the LDL particles, and 
proteoglycans in the extracellular matrix (ECM) (Boren 1998). There are several types of 
circulating lipoproteins. They are the very low density lipoproteins (VLDL), the intermediate 
density lipoproteins (IDL), the aforementioned LDL, and the high density lipoproteins 
(HDL). Several molecules act as receptors for LDL, such as the Lectin-like oxidized LDL 
receptor-1 (LOX-1) expressed by ECs (Niu 2000), CD36 expressed by macrophages, and 
scavenger receptor class B type I (SR-BI) expressed in the liver and macrophages within 
atherosclerotic plaques (Hirano 1999; Chinetti 2000). LDL is modified by enzymes and 
oxygen radicals to form molecules such as oxLDL. OxLDL initiates inflammation by 
inducing ECs, to express leukocytes adhesion molecules such as vascular adhesion molecule 
(VCAM-1), intracellular adhesion molecule -1 (ICAM-1) and P- and E-selectin molecules; at 
the site prone for lesion formation. OxLDL triggers the secretion of pro-inflammatory 
cytokines such as Interleukin (IL)-lp, XL-la, tumor necrosis factor (TNF)-p and IL-6 by ECs 
which enhance the expression of adhesion molecules on ECs to create a vicious cycle (Libby
2002). Adhesion molecules facilitate the recruitment of leukocytes such as monocytes, 
lymphocytes, mast cells and neutrophils into the arterial wall (Dong 1998; Ross 1999; Lusis 
2000). Transmigration of leukocytes via ECs is mediated by chemotactic factors such as C5a 
(Shagdarsuren 2011). Several chemokines involved in this process are secreted by ECs, 
activated macrophages and SMCs (Gerszten 2000). The most common chemokine involved 
in the development of fatty streak is monocyte chemotactic protein-1 (MCP-1), which is 
expressed by monocyte during all stages of atherosclerosis development (Hansson 2004; 
Walch 2006). Upon entry, monocytes differentiate into macrophages in response to local 
macrophage-colony stimulating factor (M-CSF) (Napoli 1997; Yan 2007). Consequently, 
scavenger receptors, toll like receptors (TLRs), and subtypes of pattern recognition receptors 
(PRRs) are up-regulated and start to uptake lipid particles leading to foam cell formation and 
stimulate cellular signalling cascades to activate inflammation. Stimulation of macrophages 
by oxLDL also induces the release of cytokines that stimulate inflammation and activate both 
CD4^ T-cells and CD8  ^ T-cells. These cell types have been detected within atherosclerotic 
plaques at all stages of development (Frostegard, Ulfgren et al. 1999; Hansson and Libby
2006).
ii) Formation of the fibrous cap (early fibro-atheroma or complex lesions)
This stage starts between the ages of 20 to 30 years and continues throughout life (Stary HC 
1995; Burke 2000; Virmani 2000). Fibrous cap formation is asymptomatic and can either 
progress to a complex atheroma or regress to a simpler plaque (Hansson and Libby 2006). 
This stage is initiated by the migration and proliferation of SMCs into the intima or sub­
endothelial space (Libby 2002). SMCs secrete various ECM proteins such as collagen, fibrin 
and proteoglycan producing a fibrous cap (Ross 1999; Paulsson 2000). The increase of 
extracellular lipid accumulation together with activation of inflammatory cells, such as 
lymphocytes, natural killer (NK) cells and DCs as well as the release of apoptotic factors, 
leads to necrotic core formation that resides in the central part of the intima and represents 
30% to 50% of the arterial wall volume. The fibrous cap covers the necrotic core just beneath 
the endothelium (William Insull 2009). Once the lesion reaches this stage, there are two 
possibilities; either the fibrous cap remains intact which stabilise the plaque, or plaque 
development continues and becomes more vulnerable and prone to rupture (Libby 2002; 
Hansson and Libby 2006; William Insull 2009) (Figure 1.2c).
iii) Advanced atheroma and atherosclerotic plaque rupture
This stage of plaque development is clinically silent and occurs between the ages of 55 to 65 
years, until plaque rupture which leads to various clinical manifestations such as myocardial 
infarction and stroke (Moreno 2006; Cheruvu 2007; William Insull 2009). Histopathological 
studies have shown that the weak fibrous cap progresses to become atheroma (mature 
plaques) that leads to physical disruption of the protective fibrous cap, thus exposing clotting 
factors to pro-coagulants expressed in the lesions (Virmani 2000). The mechanism involved 
in the plaque rupture is the disruption of micro-vessels that develop within atherosclerotic 
plaques. During this stage, the vessels become weak, fragile and susceptible to micro­
haemorrhage that can lead to thrombosis. This causes thrombin generation, which stimulates 
SMCs migration and proliferation and induces platelets to secrete platelet derived growth 
factor (PDGF) and transforming growth factor (TGF-P), which in turn increases micro- 
vascular haemorrhage within the intima of an atherosclerotic plaque (Zamir 1992; Doyle
2007). Several studies have shown that macrophages could be involved in plaque rupture by 
producing angiogenic mediators such as acidic and basic fibroblast growth factors and 
vascular endothelial growth factor (VEGF) (Brogi 1993; Ramos 1998). The most common 
type of plaque rupture is fibrous cap rupture and is responsible for three quarters of all acute 
myocardial infarctions. Pro-inflammatory mediators such as interferon (IFN)-y, which 
inhibits collagen production by SMCs by inducing apoptosis and activating matrix 
metalloproteinase (MMP), also enhances plaque vulnerability (Galis 1994; Sukhova 1999; 
Herman 2001; Halvorsen 2008). Although plaque ruptures can heal by the formation of new 
fibrous tissue and collagen structures (Figure 1.2d), they may rupture again during 
subsequent progression (Burke 2000; Virmani 2000).
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Figure 1.2 Stages of atherosclerotic plaque development. The normal artery structure and 
modification of the cells occur during disease progression to thrombosis are shown, a, The normal 
artery consist of three different layers. The inner layer is the tunica intima, the middle layer named as 
tunica media and the outer layer known as the adventitia, b, The initial steps of atherosclerosis is the 
adhesion of leukocytes to the activated endothelial monolayer which recruited the migration of the 
bound leukocytes into the intima, differentiation of monocytes into macrophages under influence of M- 
CSF, and their excessive uptake of lipid leads to foam cells formation, c, Lesion progression involves 
the migration of SMCs from the media to the intima, the proliferation of resident intimai SMCs and 
media-derived SMCs, and augment the synthesis of extracellular matrix macromolecules such as 
collagen, elastin and proteoglycans. Plaque macrophages and SMCs can die in advancing lesions via 
apoptosis. The accumulation of extracellular lipid derived from dead and dying cells in the central 
region of a plaque known as necrotic core. The advanced plaques compose of cholesterol crystals 
and microvessels, d. Thrombosis, the ultimate complication of atherosclerosis is due to a physical 
disruption. The rupture of the plaque's fibrous cap, stimulate blood coagulation components to burst 
out and make contact with tissue factors in the plaque's interior, triggering the thrombus that extends 
into the vessel lumen, where it can obstruct blood flow. Adapted from Libby, 2011.
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1.2.1.4 Diversity of T-cells in atherosclerosis
T-cells play an important role in early and late atherosclerotic lesion (Lichtman 1996; 
Hansson 1997). T-cell subsets can be classified according to their fimctions and surface 
markers. They also express certain cell surface receptors such as receptors for antigen 
recognition (T-cell receptors (TCR), CD3 complex and CD4 or CDS coreceptors) (Chan AC 
1992; Skapenko 2005), co-stimulatory molecules (CD28, CD40L) (Chambers 1997; Yin D 
1999), and adhesion molecules (CD2, CD11/CD18), which participate in the signalling that 
regulates the adaptive immune response. T-cells cannot recognise and bind antigens directly. 
The antigen is recognised via molecular interaction between the TCR expressed on the 
surface of T-cells and a complex of peptide antigen with MHC molecules that are expressed 
on the surface of antigen presenting cells (APCs) (Nicholas R.J. Gascoigne 2001). T-cells are 
divided into two subsets: CD4^ T and CD8  ^T-cells according to their interaction with MHC 
molecules. CD4^ T-cells, known as T-helper (Th) cells, bind antigen in association with 
MHC II molecules (Nicholas R.J. Gascoigne 2001). Th cells play an important role in helping 
other cells of the immune system such as B cells, phagocytic cells and CD8  ^ T-cells to 
perform their immune fimctions. Meanwhile, CD8  ^ T-cells that recognised antigens loaded 
on MHC class I molecules are known as cytotoxic T lymphocytes (CTLs) (Nicholas R.J. 
Gascoigne 2001). These cells routinely fight against intracellular infections by killing target 
cells via releasing granzymes B and perforin (S. Pathak 2005). Naive T-cells differentiate 
further into distinct cell populations with various functions following antigen stimulation.
1.2.1.5 T-helper cells in atherosclerosis
CD4^ T-cells play an important role in human atherosclerotic plaque. It has been shown that 
transfer of CD4^ T-cells firom aged apoE' '^ mice into ApoE’^ VSCID mice increased the 
number of CD4^ T-cells in the lesions and accelerated lesion development as high as the 
levels of immunocompetent mice (Zhou 2000). Depletion of CD4^ T-cells using anti-CD4 
antibodies or genetic distruption of the gene encoding CD4 prevents C57BL/6 mice fed with 
high cholesterol diet from the formation of fatty streaks (Emerson 1996; Huber 2001). 
Studies on CD4’^ 7ApoE‘^‘ mice have revealed that mice lacking CD4 only develop small 
lesions, suggesting that CD4^ T-cells are important in atherosclerosis progression (Zhou, 
Robertson et a l 2005; Khallou-Laschet, Caligiuri et a l 2006). CD4^ T-cells differentiate into 
several different subsets induced by exposure to different cytokine patterns. In recent years, 
several other CD4^ T-cells have been described including T regulatory cells (Treg), Th9, T
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follicular helper (Tfh) and Thl7 cells (Figure 1.3). CD4^ T-cells subset have either pro- or 
anti-atherogenic role.
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Figure 1.3 I  helper cell differentiation. Following engagement with MHC-peptide presented by 
APCs via TCR, naive CD4  ^ I  cells differentiate into Thi, Th2, Th i7, Treg, and Tfh cells. These 
differentiation programs are regulated by cytokines secreted by innate immune cells, such as IL-12 
and IFNy, which are crucial for Thi differentiation, and IL-4, which is important for Th2 differentiation. 
TGF-p in the presence of IL-6 drives Th i7 cell differentiation, whereas TGF-p, retinoid acid (RA) and 
IL-2 induce Treg differentiation. Specific transcription factors that direct the differentiation program of 
each T helper cell subset have been determined; T-bet for Th1 cells, GATA-3 for Th2 cells, RORyt for 
Th i7 cells, and FoxpS for Treg cells. Although Thi and Th2 cells show more stable phenotypes, Treg 
cells and Th i7 cells can switch to other T helper cell under influence of certain cytokines. For 
example, Treg cells can switch into IL-17-producing cells under influence of IL-6 and IL-21. Treg cells 
also can become Tfh cells, and this requires B cells and CD40-CD40L engagement. T h i7 cells may 
also switch into IFNy-producing Thi cells or IL-4-producing Th2 cells under influence of IL-12 or IL-4 
respectively. Th2 cells may convert into IL-9-producing cells in response TGF-p, although is still 
unclear whether these Th9 cells truly represent a distinct lineage. Adapted from Zhou et a!., 2009.
i) T h i ceUs
Thi cells produce mainly IFNy, which activates macrophages to destroy phagocytosed 
pathogens (Heinzel FP 1989). The other cytokines secreted by Thi cells are IL-2 and TNFa. 
They also express CD40L and can assist B-cells to secrete IgG isotypes, which is also 
involved in complement activation and opsonisation (Kawamo 1996). Naïve CD4^ T-cells 
differentiate into Thi cells under the influence of IL-12 and IFNy, which are secreted by 
DCs, macrophages and other cells near the T-cells (Macatonia 1995). This induces signal
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transducer activator of transcription 4 (STAT-4) and STAT-1 signaling pathway, leading to 
the expression of transcription factor, T-bet (Szabo 2000; Mullen 2001). Alternatively, Thi 
cells can also induce the expression of Notch delta like ligands (NLL) 1 and 4, which are 
expressed on the surface of APCs. NLL 1 and 4 interact with Notch 3 receptor on the surface 
of CD4^ T-cells and lead to the expression of transcription factor, T-bet which enhances Thi 
responses (Amsen 2009).
The Thi key cytokine, IFNy, is dominantly present in the atherosclerosis plaques (Hansson 
1989; Frostegard, Ulfgren et a l 1999). IFNy accelerates atherosclerosis via its effect on 
macrophages and vascular cells, and activates macrophages, leading to secretion of nitric 
oxide (NO), pro-inflammatory cytokines, and pro-thrombotic and vasoactive mediators 
(Anna-Karin 2006). Additionally, IFNy suppresses ECs proliferation, VSMC proliferation 
and differentiation, and also reduces collagen production by these cells leading to a reduction 
in cell and collagen content of the fibrous cap, thus prompting plaque instability. Various 
studies using animal models have helped in the understanding of the role of Thi cells in the 
progression of atherosclerotic lesions. Mice lacking IFNy or its receptor display less plaque 
development, whereby IFNy administration in mice can exacerbate atherosclerosis severity 
(Gupta 1997; Whitmann 2000; Whitmann 2002). Injection of IL-12 in mice can also 
accelerate the development of atherosclerosis (Lee, Yen et a l 1999). Furthermore, IL-18 a 
cytokine with the ability to induce the secretion of IFNy in many cells including T-cells, also 
participates in this process. Studies in mice deficient of lL-18 showed the attenuation of 
lesion size (Elhage 2003), whereas injection of IL-18 in mice enhanced atherosclerosis 
development (Whitmann 2002). More recently, a study demonstrated that the deficiency of 
Thi transcription factor, T-bet' '^/Ldlr^" in mice led to significant reduction of plaque size 
(Buono, Binder et a l 2005).
ii) Th2 cells
Th2 cells mainly secrete lL-4, lL-5, lL-10 and IL-13 cytokine (Stetson 2004). IL-4 is a potent 
stimulator of IgE production by B cells (Nelms 1999), whereas lL-5 can enhance the 
production of IgA and IgM antibodies. Th2 cells play an important role in recruiting 
eosinophils to the site of inflammation, and help in clearing parasitic infection as well as 
allergic reactions (Stetson 2004). Naïve CD4^ T-cells differentiate into Th2 under the effect 
of lL-33 or by IL-4 (Rank 2009), which can activate the STAT-6 signalling cascade (Takeda 
1996). STAT-6 induces the expression of Th2 transcription factor, GATA-3 which is a
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powerful inducer for IL-4 and Th2 related cytokines (Zheng 1997; Zhou 2003). The 
transcription factor c-Maf is also associated with Th2 subsets and can induce IL-4 secretion 
(Ho 1998). Furthermore, Notch ligand jagged 1 and 2 are expressed on the surface of APCs 
following contact with parasites or allergens, and interact with Notch receptors 1 and 2 on the 
CD4^ T-cells enhancing the expression of GATA-3 and subsequently IL-4 production 
(Amsen 2009).
The role of Th2 cells in atherosclerosis is still unclear. The signature cytokine for Th2 cells, 
lL-4 is not always detected in human atherosclerotic plaques (Frostegard, Ulfgren et al. 
1999). However, studies carried out in apoE" '^ and Ldlr' '^ mice have revealed that IL-4 may 
promote atherosclerosis development (King 2002; Davenport and Tipping 2003). In contrast, 
studies in the BALB/c mice, which are prone to Th2 cell development and STAT-6 
suppression, showed similar characteristics with Thi cells by inducing the susceptibility to 
atherosclerosis development (Huber, Sakkinen et al. 2001). Other studies have also suggested 
that Th2 cells can play a protective role in atherosclerosis. For example, Ldlr"^ " mice lacking 
of T-bet showed a T-cell response prone to Th2 cells, as IL-5 secretion is increased and a 
change in the specific antibody isotypes is associated with reduced atherosclerosis 
development (Buono, Binder et al. 2005). It was demonstrated previously that engraftment of 
lL-5 deficient bone marrow in the same mouse strains can enhance the development of 
atherosclerosis but at the same time reduce the secretion of natural antibodies required for the 
protection against atherosclerosis (Binder, Hartvigsen et al. 2004). It has been suggested that 
IL-5 might play a protective role by stimulating B-1 cells to produce IgM antibodies (Horrko 
1999). Moreover, IL-33 acts as Th2 cells inducer and is also involved in the promotion of IL- 
5 production. Injection of lL-33 in apoE"^ " mice prevented the development of atherosclerosis 
in these mice (Miller, Xu et al. 2008).
iii) Treg cells
Treg cells play an important role in the maintenance of homeostasis of the immune system 
(Sakaguchi S 2008). Natural Treg cells develop in the thymus and are characterized by the 
expression of CD25 and the transcription factor foxhead/winged helix transcription factor 
(Foxp3) (Fontenot 2003; Hori 2003; O’Gorman 2009). They work in the peripheral tissues to 
prevent autoimmunity by inhibiting pathogenic lymphocytes and maintaining self tolerance 
(Bluestone 2003; Kronenberg 2005). During an active immune response in the periphery, 
naive CD4^CD25" or effector T-cells can become inducible Treg cells (iTreg) characterised
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by the phenotype CD4^CD25^oxp3^. This process occurs in the presence of TGF-p and IL- 
10, or under low doses of antigens (Roncarolo 2006; Carrier 2007; Carrier 2007). iTreg 
induced under the influence of lL-10 are called Trl cells (Roncarolo 2006), whereas TGF-p 
induced iTreg are called Th3 cells (Carrier 2007; Carrier 2007). These cells mediate 
suppression functions via secretion of lL-10 (Roncarolo 2006) and TGF-p (Carrier 2007; 
Carrier 2007). The transcription factor Foxp3 is important in mediating the inhibitory role of 
Treg cells on pathogenic effector T-cells. This was demonstrated by Gambineri and 
colleagues in a Foxp3 knock-out mice (Gambineri 2003; Khattri 2003). The expression of 
Foxp3 is regulated by TGF-P via smad3 in combination with nuclear factor activated T-cells 
(NFAT) and by the lL-2 receptor that induces STAT-5 activation (Burchill 2007; Tone 2008). 
Foxp3 suppress lL-2 transcription but induces the expression of genes required for Treg 
functions, such as CD25 and cytotoxic T lymphocyte associated antigen-4 (CTLA-4) (Wing
2008). The mechanisms by which Treg cells suppress immune responses are yet not 
completely clear. For instance, three general mechanisms of suppression have been proposed. 
The first mechanism implies that inhibition by Treg cells is through the secretion of 
inhibitory cytokines such as TGF-P, lL-10 or IL-35 (Collison 2007; Tang 2008; Shevach
2009). The second mechanism refers to contact-dependent inhibition which involves the 
interaction of CTLA-4 expressed by natural Treg cells with CD80 expressed by effector cells 
or CD80/CD86 on APCs (Pucetti 2007). The engagement of natural Treg cells by APCs 
induces indoleamine dioxygenase, which causes the downregulation of effector T-cell 
responses via tryptophan catabolism (Pucetti 2007). The third mechanism refers to a passive 
suppression by Treg cells. Effector T-cells produce lL-2 upon activation, which engages 
CD25 on the surface of Treg cells (Pandiyan 2007). lL-2 and CD25 engagement maintains 
and activates Treg cell genes such as Foxp3, which in turn down-regulates lL-2 secretion in a 
feedback loop (Pandiyan 2007). Activated Treg cells inhibit effector T-cells depriving them 
from an essential growth factor such as lL-2. It has been shown that Treg cells induce 
apoptosis of activated T-cells in vitro and in vivo by depriving them of lL-2 (Pandiyan 2007).
Treg cells play an important protective role in atherosclerosis development. A recent study 
showed that transfer of Treg cells in ApoE"^ "Rag2"^ " with 28' ‘^ splenocytes reduces 
atherosclerosis, whereas depletion of Treg cells using anti-CD25 antibodies in apoE’^ ' mice 
increases atherosclerosis (Ait-Oufella 2006). However, depletion of CD25^ cells in apoE"^ " 
mice lacking of TGF-p did not show any reduction of plaque size suggesting that this 
cytokine has atheroprotective effects (Ait-Oufella 2006). In addition, TGF-p have been
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shown to promote collagen synthesis by SMCs, which contributes to plaque stability (Li
2006). The studies also showed that TGF-P exerts its atheroprotective effects by dampening 
down Thi cell activity which is predominant in the plaques (Li 2006).
On the other hand, apoE' "^ mice that received oral anti-CD3 antibodies showed less plaque 
development and this result seems to be related to the induction of the CD4^AP^ latency 
associated peptide (LAP) Treg cells (Sasaki, Yamashita et ah 2009). CD4%AP^ Treg also 
suppress experimental autoimmune encephalitis in a TGF-p-dependent fashion (Chen, Yan et 
al 2008). iTreg cells producing IL-10, also known as Trl, can be induced by intranasal 
administration of anti-CD3 in mice (Wu 2008). One study have shown that adoptive transfer 
of ovalbumin-specific Trl cells together with cognate antigens into apoE' "^ mice increases IL- 
10 secretion and suppresses Thi cells lineage leading to a reduction of plaque development 
(Mallat, Gojova et a l 2003). The protective role of Trl derived-lL-10 has been further 
demonstrated in other studies at early and late stages of the development of the disease 
(Mallat, Besnard et a l 1999; Caligiuri, Rudling et ah 2003; Potteaux, Esposito et a l 2004).
iv) Th9 cells, T follicular helper (Tfh) cells and Th22
Th9 and Tfh cells are newly discovered CD4^ T-cell subsets in human and mice. Th9 cells 
secrete IL-9 and IL-10 and induce the secretion of TGF-p (Veldhoen 2008). Tfh cells reside 
in the germinal centres of lymphoid B-cell follicles to help B-cells in secreting antibodies and 
are characterized by the expression of transcription factors MAF and BCL-6 (King 2009). 
Th22 is characterized by the secretion of lL-22 in the absence of 1L-17A and IFNy. Th22 is 
enriched in cells expressing CCR4, CCR6 and CCRIO. Their roles in atherosclerosis are still 
unknown.
v) Thl7 cells
The Thi 7 cell lineage will be further discussed in section 1.3.
1.2.1.6Thl/Th2vsThl7
Thi cells act in a pro-atherogenic way via the high secretion of IFNy, IL-6 and IgG2a, 
increased expression of MHC class 11, as well as upregulation of chemokines and adhesion 
molecules on ECs which are involved in the recruitment of leukocytes into the aorta (Getz 
2005; Aukrust 2008). In contrast, the Th2 signature cytokine, IL-4 is less dominant in the 
atherosclerotic plaques and may act in a pro-atherogenic or anti-atherogenic way (George J
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2000; George J 2000). The cytokines secreted by Thi and Th2 cells have inhibitory effects 
upon the differentiation and maturation of one over to the other, which suggests that in the 
atherosclerotic lesion a cross regulation between these subtypes of T-cells may exist. In 
addition, IFNy and IL-12 suppress Th2 responses, whereas IL-4 and IL-10 inhibit Thi 
pathways and cytokine secretion (Weaver, Hatton et a l 2007). Therefore, many studies 
suggest that the Thl/Th2 imbalance plays a critical role in the development of atherosclerosis 
and plaque rupture. Recently, the view of immunological process in atherosclerosis changed 
again. The third subtype of CD4^ effector T-cells that is supposed to be implicated in 
atherosclerotic lesions is Thi 7 cells.
1.3 Thl7 cells
1.3.1 Background
Although the importance of the lL-17 family, especially IL-17A and 1L-17F, has been 
reported for several years (Rolls 2004), it was only recently that their role became clear after 
the discovery of lL-17 producing T-cells, known as Thl7 cells (Harrington 2005; Park 2005). 
Initially, Thi 7 cells were linked with the pro-inflammatory cytokine IL-23, because lL-23- 
deficient pl9 ‘^‘ mice contain few Thi 7 cells and are resistant to autoimmune diseases such as 
experimental autoimmune encephalitis (EAE) and collagen induced arthritis (CIA) (Langrish
2005). However, although lL-23 seems to participate in Thl7-mediated immune pathology 
(McGeachy and Cua 2007), this cytokine is not able to generate de novo lL-17 producing T- 
cells from naïve T-cells precursors (Langrish 2005).
13,2 Differentiation of Thi 7 cells
Early in 2006, three research groups demonstrated that TGF-P, in the presence of the pro- 
inflammatory cytokine lL-6, can induce the differentiation of naïve T-cells into Thi 7 cells 
(Bettelli, Carrier et a l 2006; Mangan 2006; Veldhoen 2006) (Figure 1.4). IL-23 is important 
for survival, expansion and pathological function of Thi 7 cells in vivo (Mangan 2006) 
(Figure 1.4). In addition, IL-21 is produced by Thi 7 cells upon stimulation by IL-6 and can 
act in an autocrine manner to promote Thi 7 cells differentiation along with TGF-p in the 
absence of lL-6 (McGeachy and Cua 2008) (Figure 1.4). On the other hand, IL-23 and IL-lp 
play a pivotal role in the differentiation of human Thi 7 cells (Chen, Tato et a l 2007; Wilson 
2007) (Figure 1.4). Recent studies also showed that low doses of TGF-p is required for 
human Thi 7 development (Manel 2008). The development of Thi7 cells is inhibited by IL-2
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and Thi or Th2 polarizing factors, such as IL-12, IFNy and IL-4 (Weaver, Harrington et al
2006) (Figure 1.4). Recently, lL-25 (Kleinschek, Owyang et a l 2007) and lL-27 (Fitzgerald, 
Ciric et al 2007) were also found to suppress Thi 7 development (Figure 1.4).
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Figure 1.4 Thi7 cells differentiation in mouse and man. (A) In mouse, naive T-cells differentiate 
into Th i7 cell in the presence of TGF-p and IL-6. In the absence of IL-6, IL-21 acts as autocrine 
manner to promote Th i7 cell differentiation along with TGF-p whereby TGF-p alone stimulates naive 
T-cells into Treg cells. IL-23 secreted by APCs maintains the survival of Th17 cell. Th17 cell 
development is suppressed by Thi and Th2 cytokies, IL-27, as well as IL-2 and retinoic acid. (B) In 
man, IL-23 and IL-1 drives Th i7 cell differentiations that express IL-23R and CCR6. IL-Ts effects 
may be increased under influence of IL-23 and/or lL-6. Th1 cell-promoting cytokines suppress T h i7 
cell differentiation. Adapted from McGeachy and Chua, 2008.
1.3.3 Characteristics of Thl7 cells
Thi 7 cells produce 1L-17A, 1L-17F, and lL-22 as hallmark cytokines (Bettelli, Carrier et al 
2006; McGeachy and Cua 2008). Thus far, six lL-17 family members (1L-17A, 1L-17B, IL- 
17C, 1L-17D, 1L-17E, 1L-17F) have been identified (Weaver 2007). Among them, 1L-17A 
and 1L-17F are produced by Thi 7 cells and the most characterised to date. Besides being 
produced by Thi 7 cells, 1L-17A and 1L-17F are also secreted by a various of cell types such 
as yô T cells, NKT cells, NK cells, neutrophils and eosinophils (Molet S 2001; Starnes T 
2001; Ferretti S 2003; Lockhart E 2006). 1L-17A and 1L-17F are 55% homologous (Weaver
2007) and can exist as 1L-17A and 1L-17F homodimers or 1L-17A/1L-17F heterodimers 
(Chang SH 2007; Liang SC 2007; Wright JF 2007). Both 1L-17A and 1L-17F are key
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cytokines for the recruitment, activation and migration of neutrophils in acute and chronic 
inflammatory conditions (Korn, Bettelli et a l 2009). The roles of 1L-17A in the 
atherosclerotic plaque development were extensively studied as described in section 1.3.4 
whereby 1L-17F has been detected in the atherosclerotic plaques (de Boer, van der Meer et a l
2009) but its role in the atherosclerosis development still need fiirther clarifications. In 
contrast, the biological fimctions of IL-17B, IL-17C, IL-17D, and 1L-17E is less known 
(Butcher 2011). IL-17E is expressed by mucosal epithelial cells, mast cells, basophils, Th2 
cells, and alveolar macrophages and stimulates the secretion of Th2 cytokines (Hurst 2002). 
1L-17E was detected in the human atherosclerotic plaque suggests its involvement in 
atherosclerosis development (de Boer, van der Meer et a l 2009). IL-17B and 1L-17C elicit 
TNFa and IL-lp secretion from the monocytic cell line THP-1 (Li 2000). As adenovirally 
delivered IL-17A, IL-17C, 1L-17E and IL-17F evoked bronchoalveolar lavage neutrophilia 
(Hurst 2002), and ectopic expression of IL-17B and IL-17C exacerbated collagen-induced 
arthritis (Yamaguchi 2007). However, the role of IL-17B, 1L-17C and 1L-17D in 
atherosclerosis is still unknown. IL-22 is one of the members of the IL-10 family that 
increases during chronic inflammatory responses and can induce acantosis and dermal 
inflammation (Zheng 2007). Thi 7 cells also secrete IL-21 which can act in self-amplifying 
loops to induce Thi 7 cells development (Kom 2007). Thi 7 cells also produce IL-26, which 
has similar roles but its precise role requires further investigation (Wilson 2007). Moreover, 
RAR-related orphan receptor gamma (RORyt) is a master regulator that directs the 
development of Thi 7 cells (Ivanov, McKenzie et a l 2006). The induction of RORyt depends 
on STAT-3, therefore STAT-3 and RORyt seem to co-operate in the production of IL-17 
(Yang, Pappu et a l 2008). STAT-3-null cells fail to express RORyt and secrete a reduced 
level of DL-17 whereas retroviral restoration of STAT-3 recovers the lL-17 defect (Mathur
2007). In addition, ectopic overexpression of STAT-3 in RORyt-deficient cells, and vice 
versa, fails to restore lL-17 secretion (Zhou 2007). The expression of chemokine receptor 
CCR6 have also been shown to additionally define human and mouse Thi 7 cells (Acosta- 
Rodriguez 2007; Hirota, Yoshitomi et a l 2007; Lim, Lee et a l 2008; Singh, Zhang et a l
2008). The chemokine receptor CCR6 is known to be expressed on activated T-helper cells 
but the role of CCR6  ^expressed by these cells is still poorly understood (Fitzhugh 2000). 
Recent studies on Thi 7 cells have begun to explain the role of this particular T-cell subsets in 
different pathophysiological scenarios (Acosta-Rodriguez 2007). Previous studies 
demonstrated that CCR6 is a specific marker to define functional antigen-specific Thi 7 cells
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in mice. IL-17 secreting T-helper cells from lymph nodes exclusively reside within the 
CCR6  ^T-helper cell fraction in naïve and immunised mice. Analysis of the cytokine profile 
secreted by sorted CCR6  ^T-helper cells clearly show that this T-helper cell fraction is the 
only source of IL-17 protein within the T-helper cell population (Potzl 2008). Studies in 
humans and mice have also revealed the existence of hybrid Thi 7 cells, which produce IL-17 
and IFNy at the same time (Steinman 2008). This Thl/Thl7 cells also express both Thl7- 
inducing transcription RORyt and Thi-inducing factor T-bet (Steinman 2008). These hybrid 
Thi 7 cells have been found in EAE lesions in mice (Ivanov, McKenzie et a l 2006). 
Recently, Kurschus et al showed that both in vitro and in vivo generated Thi 7 cells switch 
into Thl7/Thl, or even into Thi cells by using the IL-17F-Cre^^^^ Thi 7 reporter mouse line 
(Kurschus FC 2010). In human, Nistala et al demonstrated the conversion offhl7 into Thi 
plasticity driven by inflammatory environment in patients with autoimmune polyarthritis 
(Nistala K 2010). Likewise, Cosmi et a l have found an accumulation of CD4^CD161^ T- 
cells able to secrete IFNy (Thi), or both IFNy and IL-I7A (Thl7/Thl), but not IL-17A alone 
(Thi 7), in the synovial fluid of children with oligoarticular juvenile idiopathic arthritis 
(Cosmi L 2011). They also showed that the switch of Thi 7 into Thi could be blocked by IL- 
12 neutralisation (Cosmi L 2011). Therefore, IL-12 drived the transition of Thi 7 cells into 
Thi cells through the intermediate phenotype of Thl7/Thl cells (Cosmi L 2011) (Figure 1.5).
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Figure 1.5 Origin of Th17 cells and their differentiation into Thi cells. Human T h i7 cells develop 
from a naive precursor expressing RORC, T-bet, IL-23R, IL-1R, CD161, and CCR6, under influence 
of IL-ip and IL-23. The same precursor differentiates into Thi cells in the presence of IL-12. IL-12 
also drives the switch of Th17 cells into Th1 cells through the intermediate phenotype of Thi 7/Th 1 
cells. Adapted from Cosmi, L., 2011).
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Beside that, Cosmi et a l also demonstrated a novel subset of human circulating memory CD4 
T-cells that secrete both IL-17A and IL-4 (Cosmi L 2010). This unknown population of 
Thl7/Th2 cells was highly detected in the circulation of patients with allergic asthma than in 
healthy donors, suggesting a possible role of Thl7/Th2 cells in the pathogenesis of the 
disease (Cosmi L 2010). They also hypothesised that an IL-4-rich microenvironment could 
stimulate the conversion of allergen-specific Thi 7 cells into Thl7/Th2 cells (Cosmi L 2010).
1.3.4 Thl7 cells in atherosclerosis
Even though, the roles of IL-17 have been extensively studied in various inflammatory and 
autoimmune diseases, its role in the development of atherosclerosis remains controversial. 
Initially, the study in LDLR‘^ '/IL-6’^’ mice showed a decrease of IL-17 levels, and a modest 
reduction in atherosclerotic plaque development, suggesting the potential involvement of the 
Thi 7 cells in atherogenesis (Song L 2004). Most importantly, Eid and his colleagues 
demonstrated that IL-17 and IFNy are concomitantly present in clinical specimens of 
coronary atherosclerosis. This was confirmed after detecting the presence of IL-17/IFNy 
double producing T-cells within plaques and a synergistic effect of IL-17 and IFNy on the 
induction of pro-inflammatory cytokine and chemokine secretion in cultured human VSMC 
(Eid, Rao et a l 2009). Another study revealed that patients with acute coronary syndrome 
have a significant increase in peripheral Thi 7 cell number, Thi 7 related cytokines (IL-17, IL- 
6 and IL-23) and Thi 7 cells transcription factor, RORyt levels. Additionally, they also 
showed reduction in the numbers of Treg, Treg related cytokines (IL-10 and TGF-P) and 
FoxpB compared with patients of stable angina and controls (Cheng, Yu et a l 2008). In 
contrast to these studies, the loss of suppressor of cytokine signaling-3 (SOCS-3) in mouse T- 
cells increases both IL-17A and IL-10 secretion, inducing an anti-inflammatory macrophage 
phenotype which leads to reduced plaque size and vascular inflammation (Taleb, Romain et 
al 2009).
Interestingly, recent studies have shown additional, and in some cases more direct evidence, 
of a pro-atherogenic role of IL-17. Xie et a l showed that apoE'^" mice highly express Thl7- 
related cytokines (IL-17 and IL-6) and RORyt at mKNA levels and have low expression of 
Treg numbers, TGF-p 1 and Foxp3 mRNA levels in comparison to age-matched C57BL/6 
mice (Xie, Wang et a l 2009). Another recent study revealed that different IL-17A, IL-17F 
and IL-17E are expressed in human atherosclerotic plaques (de Boer, van der Meer et a l
2009). Furthermore, the anti-inflammatory cytokine IL-17E was detected in normal and
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atherosclerotic vessels and might play a role in controlling immune responses in the vessel 
wall (de Boer, van der Meer et a l 2009). Pejnovic and his group have shown that exacerbated 
atherosclerotic lesion formation correlated with the increase in Thi 7 cells, IL-23 producing 
vascular smooth muscle cells (VSMC) and macrophages, and also with thin fibrous cap 
lesions in IL-18’VApoE'^‘ mice (Pejnovic, Vratimos et a l 2009).
The most direct evidence of the pro-atherogenic role of IL-17 has been produced by van Es 
and his colleagues fi*om Leiden University, who carried out bone marrow chimera studies and 
transplanted irradiated LDLR-deficient recipient mice with IL-17R-deficient bone marrow 
(van Es T 2009). They found a 46% reduction of western-type diet-induced atherosclerotic 
lesions in the aortic root and plaque of recipient mice (van Es T 2009). Other studies have 
shown that blockade of IL-17A by administration of anti-IL-17A monoclonal antibodies in 
apoE'^" mice reduced atherosclerotic lesion development and decreased plaque vulnerability, 
cellular infiltration and tissue activation (Erbel, Chen et a l 2009). They suggested that IL-17 
is involved in atherogenesis by facilitating pro-inflammatory changes at various levels, such 
as cell adhesion, cell extravasation, cell activation, T-cell co-stimulation/proliferation and 
antigen presentation in the inflammatory process (Erbel, Chen et a l 2009). The main 
limitation is that the blockade of IL-17A will not prevent Thi 7 cell formation since other IL- 
17 producing cell types may also have effects aside fi*om IL-17A production (Weaver CT 
2007; Smith E 2008; Yang Y 2009).
In the Keynote Symposia (Advances in Molecular Mechanisms of Atherosclerosis, February
2010), Smith and his colleagues demonstrated that IL-17A^ T-cells are significantly increased 
in the aortas and surrounding adventitia, spleen, and lamina propia of aged apoE’^ ' mice in 
comparison to C57BL/6 mice. The IL-17A^ T-cells were characterized as CD45^CD3^ T- 
cells and were dominantly Thi 7 cells and yÔ T-cells (Smith, Prasad et a l 2010). Blockade of 
IL-17A by using adenovirus-produced soluble IL-17R in apoE'^" mice fed with western diet 
showed a significant reduction of atherosclerotic lesions which indicated that IL-17A- 
dependent pathway may influence the development and progression of atherosclerosis 
(Smith, Prasad et a l 2010). Recently, Liu et a l (2011) demonstrated that increased peripheral 
blood Thi 7 cells and Thl7-associated cytokines (IL-17, IL-6 and TNFa) are positively 
linked with the severity and progression of carotid artery. Therefore, they suggested that 
Thi7 cell frequencies and Thi 7 cells-associated cytokines may serve as quantitative indices 
for disease severity in diagnosis/prognosis of atherosclerosis (Liu 2012). In another study, the
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same group also showed that patients with unstable carotid artery plaque had high 
frequencies of Thi 7 cells in the peripheral blood, high plasma levels of Thl7-related 
cytokines such as IL-17, IL-6, IL-23 and TNFa, and high expression of Thi 7 cell 
transcription factor, RORyt compare to patients with negative to carotid artery plaque and 
stable carotid artery plaque (Liu, Wang et al. 2012). In contrast, patients with unstable carotid 
artery plaque had low frequencies of Treg cells, low plasma levels of Treg-related cytokines 
(TGF-p and IL-10) and low expression of Treg cells transcription factor, Foxp3 compare to 
patients with negative artery plaque and stable artey plaque (Liu, Wang et al. 2012). This 
finding suggests that Thi 7 cells may promote atherogenesis while Treg cells may have 
protective role against atherosclerotic plaque.
1.4 Hypothesis, aims and objectives of the study
Thi 7 cells differentiate from CD4^ T-cells under the influence of TGF-p and IL-6 whereas 
IL-23 maintains and expands these cells in vivo. However, there are no reports on the 
mechanism of Thi7 cell differentiation from CD4^ T-cells during atherogenesis, direct 
interaction of between oxLDL and Thi 7 cells, and the effect of Thi 7 cell differentiation on 
the atherosclerotic plaque development. We hypothesise that in the atherosclerotic plaques, 
oxLDL-treated DCs and SMCs secrete IL-6 and TGF-p, which drive Thi 7 cell differentiation 
in the plaque. OxLDL engagement with scavenger receptor or TLRs expressed on the surface 
of Thi 7 cells influence Thi 7 cell function, and Thi 7 cell induction in vivo exacerbates 
atherosclerotic plaque development.
Therefore, the aims and objectives of this study were:
1. To determine whether cytokines secreted by oxLDL-treated DCs influence the 
differentiation of Thl7 cells from CD4^ T-cell precursors. CD4^ T-cells were co­
cultured with oxLDL-treated DCs and the median fluorescence intensity (MFI) of 
Thi 7 cells was determined by flow cytometry.
2. To examine whether SMCs derived cytokines affect the differentiation of Thl7 
cells in vitro. Cytokines secreted by oxLDL-treated SMCs were measured by ELISA. 
CD4^ T-cells were cultured in the supernatant of oxLDL-treated SMCs in the 
presence of anti-CD3 and anti-CD28, the Thi 7 cells were determined by flow 
cytometry.
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3. To assess whether oxLDL can directly engage with Thl7 cells in vitro. Thi7 cells 
were induced in vitro under the influence of oxLDL and the expression levels of 
CD36, TLR-2 and TLR-4 were measured by flow cytometry. Thi7 cell transcription 
factor, STAT-3 was measured by ELISA.
4. To investigate the effect of Thl7 cells differentiation in vivo on atherosclerosis 
development in the apoE^ mice. To achieve this, female apoE'^" mice fed with HFD 
were intraperitoneally injected with PTx, PC61, and a combination of both. At 
termination, splenocytes were processed and the median fluorescence intensity (MFI) 
of Thi 7 cells determined by flow cytometry. Thl/Th2/Treg/Thl7 gene and protein 
were analysed by RT-PCR and CBA, respectively. The lipid profile such as total 
cholesterol, HDL-cholesterol and triglycerides would also be examined. Finally, the 
effect of Thi 7 cells on the atherosclerotic plaque development and stability, such as 
collagen content, would be analysed by morphometric analysis.
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CHAPTER 2 
GENERAL MATERIALS AND METHODS
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2.1 Materials
2.1.1 General reagents
General laboratory chemicals and reagents were purchased from Sigma Aldrich (UK) unless 
otherwise stated.
2.1.1.1 Health and safety
Usage of all reagents and handling were carried out according to the safety regulations 
stipulated by the suppliers of each product (e.g. COSHH regulations and local University 
regulations). Biological waste was disposed off according to the University of Surrey 
guidelines.
2.1.1.2 Instruments and software
All centrifugation was carried out using a Hareus Megafuge l.OR of Thermo Fisher Scientific 
Inc., UK, Beckman Optima XLIOO ultracentrifuge (Beckman Coulter Inc. USA) and Heraeus 
Pico 17 microcentrifuge (Thermo Fisher Scientific Inc, UK). Primary cells were incubated at 
37®C and 5% CO2 in a Hera Cell 240 incubator (Thermo Fischer Scientific Inc., UK). RNA 
and protein was estimated using Nano Drop (Thermo Fischer Scientific Inc., UK). DNA 
firagments were visualized under UV light and images were captured using a Syngene® Bio- 
Imaging System (USA). Densitometric analysis of the DNA Augments was carried out using 
Image Master Gene Snap software (Syngene, USA). Flow cytometry analysis was carried out 
using a BD FacsCanto (BD Pharmingen, USA). The analysis was performed using BD 
FacsDiva software (BD Pharmingen, USA). The absorbance of enzyme linked 
immunosorbent assay (ELISA) was determined using Bio-Tek ELxSOO plate reader from 
Bio-Tek Instruments, Inc., Ontario, Canada and supportive software (KC4 Programme, Bio- 
Tek Version 3.4, Bio-Tek Instruments, Inc., Ontario, Canada).
2.1.2 C57BL/6 apoE ' mice
ApoE''" (B6.129P2-Apoeft«/i7nc/J) mice used in the experiments were C57BL/6 background 
and were purchased from Charles Rivers (UK) and were bred at the Faculty of Health and 
Medical Sciences’ Experimental Biology unit (EBU), University of Surrey and housed under 
standard conditions. The author successfully attended a four days special course and passed 
the examination as a requirement to obtain an animal license and all the procedures carried 
out in this research work took full cognizance of the Animal Scientific Procedures Act 1986, 
British Home Office.
26
ApoE is an apoliprotein that acts as a ligand for the LDL receptor and chylomicron remnant 
receptor (Zhang SH 1992). ApoE deficiency can cause defective removal of chylomicron 
remnant receptors and intermediate density lipoprotein particles firom the circulation which 
can lead to hypercholesterolemia (Zhang SH 1992). ApoE"^ " mice develop similar 
atherosclerotic lesions to human plaques which progress fi*om lipid streaks to fibrofatty 
plaques and advanced lesions (Jawien J 2004). An advantage of the apoE*^ ‘ mouse (compared 
to other mouse models of atherosclerosis) is that this mouse spontaneously develops 
atherosclerosis without feeding them vrith a high fat diet (Breslow 1993; Nakashima Y 1994). 
A disadvantage of this model is that the lipoprotein profile is dominated by elevated VLDL 
which is different fi*om the human case, for which the profile is usually dominated by LDL 
(Jawien J 2004).
2.1.3 Cell culture
2.1.3.1 Cell culture reagents
All cell culture reagents were purchased from the Gibco Life Science Technology 
(Invitrogen, UK) unless otherwise stated. RPMI1640 media were cell culture certified and L- 
Glutamine fi*ee. The author used advanced RPMI 1640 media that is L-Glutamine free, 
containing 110 mg/L Sodium Pyruvate and non-essential amino acids (Invitrogen, UK). 
Disposable plasticware, such as syringes, needles and tubes were purchased from BD 
Plastipak (UK), Terumo Europe (Belgium) and Barloworld Scientific (UK), respectively.
2.1.3.2 General solutions
2.13.2.1 Composition of general buffers, solutions and reagents
The general buffers, solutions and reagents, as well as their composition were used as listed 
in Table 2.1.
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Table 2.1 General buffers, solutions and reagents
Name Composition
PBS Na2HP04 (O.OIM), KCl (0.0027M) and NaCl (0.137M), pH 7.4.
EDTA(0.5M)
0.5 M stock solution was made from 
ethelenediaminetetreacetic acid disodium dehydrate 
solid, adjusted to pH 7.5 adjusted with NaOH at RT.
TAB (50x)
121 g Tris base, 28.5 ml glacial acetic acid and 50 ml of 
0.5 M EDTA in 300 ml of DEPC treated water. The 
final volume was made up to 500 ml with DEPC-treated 
water. A working TAB (Ix) buffer was prepared by 
diluting 20 ml of stock solution in 980 ml of DEPC- 
treated water.
ELISA washing buffer 0.05% (v/v) Tween-20 in PBS.
Flow cytometry labelling 
(staining) buffer 1% (v/v) BSA, 0.05% (v/v) NaNs in PBS, pH 7.4.
Flow cytometry fixative 
buffer 2% (v/v) Formaldehyde in PBS.
Flow cytometry 
permeabilisation buffer
0.5% (w/v) Saponin, 1% (w/v) BSA, 0.05% NaNs in 
PBS
Flow cytometry washing 
buffer 0.5% (w/v) BSA in PBS.
RIPA buffer Ix PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS
2.2 General methodology
2.2.1 Isolation of low density lipoprotein (LDL)
LDL was isolated using iodixanol density gradient ultracentrifugation (Davies et al, 2008). 
Blood (30 ml) was obtained from healthy donors by qualified personnel and mixed with 3 ml 
sodium citrate solution (Sigma Aldrich, UK). Blood collection has prior approval from the 
University of Surrey Ethics Committee (Reference number: EC/2009/01/FHMS) and 
collected after informed consent was obtained. The plasma was harvested by centrifugation at 
450 X g for 45 minutes at 4°C. Then, 2 ml of the 60% Optiprep (Fresinius Kabi Norge,
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Norway) was mixed with 8 ml plasma in the new falcon tube to provide 12% of Optiprep 
(Fresinius Kabi Norge, Norway). In parallel, 6 ml of 6% Optiprep (Fresinius Kabi Norge, 
Norway) was added in a Beckman tube and the 12% of Optiprep was then carefully layered at 
the bottom of Beckman tube. Next, the tube was capped and centrifuged at 341000 X g for 4 
hours at 16°C using a Beckman NVT 65 rotor and a Beckman Optima XLIOO ultracentrifuge 
(Beckman Coulter Inc. USA). The yellow LDL band was carefully collected and transferred 
into a new falcon tube covered with aluminium foil to prevent from the direct light exposure. 
LDL was dialysed against PBS for 48 hours. The LDL was oxidised using CUSO4 for 24 
hours at room temperature. Next, the oxidized LDL was filtered through 0.2 pi filter and then 
dialysed against PBS for 24 hours. Finally, the concentration of oxLDL was determined using 
Nano drop® (Thermo Fischer Scientific Inc., UK) and was adjusted to 1 mg/ml.
2.2.2 CD4  ^T-cells isolation
2.2.2.1 Splenocytes isolation
Mouse spleens were gently teased apart to generate a single cell suspension in complete 
RPMI (Sigma Aldrich, UK) medium containing 10% FCS, 100 U/ml Penicillin, 100 mg/ml 
Streptomycin. The cells were transferred into a 50 ml tube with complete RPMI medium and 
were centrifuged for 10 minutes at 200 X g. Following centrifugation, the supernatant was 
discarded and the cells were resuspended in Ix M-lyse buffer (R&D system, UK) and were 
mixed well by vortexing. Then, the cells were incubated at room temperature for 10 minutes. 
The cells were washed by centrifugation in complete RPMI medium for 10 minutes at 200 X 
g. The supernatant was discarded and the cells were resuspended in 1 ml complete RPMI 
medium and the cells were counted using a haemocytometer as described in section 2.2.2.3.
2.2.2.2 Isolation of CD4  ^T-cells
Splenocytes were firstly incubated in tissue culture flasks (25 cm^) for 2 hours to deplete 
samples from adherent cells including monocytes/macrophages. Non-adherent cells were 
collected and placed into a 50 ml centrifuge tube and centrifuged for 10 minutes at 200 X g. 
The supernatant was discarded and the pellet resuspended in 1 ml complete RPMI medium 
and the cells were counted as described. A cocktail of monoclonal antibodies which included 
rat anti mouse CD8 (AbSerotec, UK), GDI lb (AbSerotec, UK), C D llc (AbSerotec, UK), 
CD 19 (AbSerotec, UK) and CD 16/32 (Pharmingen, USA) were added per 10  ^ cells and 
incubated for 30 minutes at 4°C. In parallel, BioMag beads (Qiagen, USA) were washed with 
complete RPMI medium 2-3 times to remove NaNs and finally were resuspended in 9 ml
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complete RPMI medium. The cells were centrifuged for 5 minutes at 200 X g to remove 
unbound antibodies and then resuspended in 1 ml of complete RPMI medium and mixed with 
the washed BioMag beads (Qiagen, USA) and incubated at 4®C for 30 minutes. The vessel 
was then applied to a magnetic separator for 10 minutes. Once separation was complete, the 
supernatant was carefully removed without disturbing the pellet and centrifuged for 5 minutes 
at 200 X g. The cell pellet was resuspended into 1 ml complete RPMI medium and the cells 
were counted.
2.2.23 Cell viability analysis and quantification
Trypan Blue, one of several stains recommended for use in dye exclusion procedures, was 
used for viable cell counting. The method is based on the principle that viable cells do not 
take up certain dyes, whereas non-viable cells do. Such staining also facilitates the 
visualisation of cell morphology. The cells were prepared in 1ml of RPMI 1640 medium. 
Trypan Blue solution was prepared by mixing the Trypan Blue with PBS at a 1:1 ratio. A 
small number of cells (dilution factor =10) was added to the Trypan Blue solution and then 
transferred to both chambers of a haemocytometer for counting. The concentration of cells, 
total cells and cell viability per ml were calculated as follows:
Cells per ml = the average of counts per square x dilution factor x 10"^
Total cells = cells per m ix the original volume of cell suspension from which the cell sample 
was removed
2.23 Polymerase Chain Reaction (FCR)
2.23.1 Total RNA extraction
Total RNA was isolated using Ultraspec™ RNA isolation system (Biotecx, USA). The cells 
were homogenized with 1 ml of Ultraspec™ RNA reagent by passing the cell lysate several 
times through a pipette. Following homogenization, the homogenate were stored for 5 
minutes at 4®C to permit the complete dissociation of the nucleoprotein complexes. Next, 0.2 
ml of chloroform was added, mixed vigorously and kept on ice for 5 minutes. The 
homogenate was centrifuged at 12000 X g for 15 minutes using Heraeus Pico 17 
microcentrifuge (Thermo Fisher Scientific Inc, UK). Following centrifugation, the 
homogenate formed two phases: the lower organic phase and the upper aqueous phase. The 
aqueous phase containing the RNA was carefully collected and transferred into a new tube
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and 50 pi of RNA tack® resin was added into isopropanol. The samples were centrifuged at 
12000 X g for 1 minute and the supernatant discarded. The pellet was washed twice with 
75% ethanol by vortexing and subsequent centrifugation for 1 minute at 12000 X g. The 
RNA pellets were dissolved in 50 pi of RNase free water and were centrifuged at 12000 X g 
for 1 minute. The supernatant were carefully transferred into new tube. The concentration and 
purity of RNA were measured using Nano Drop® (Thermo Fisher Scientific Inc, UK). The 
A260:A280 ratio of 1.7 to 1.9 was obtained indicating a low-level of protein contamination and 
high quality of RNA isolated for all the samples. The integrity of RNA preparation was 
examined by agarose gel eletrophoresis to ensure that clear 28S and 18S rRNA bands were 
demonstrated.
2.2.S.2 cDNA synthesis
A cDNA synthesis kit (Bioline, USA) was used following the manufacturer’s instructions. 
Total RNA (1 pg) was mixed with 1 pi oligo (dT)ig, 1 pi of 10 mM dNTP and RNase free 
water in a total of 10 pi in a tube before the mix was briefly centrifuged and incubated at 
60®C for 10 minutes. The mixture was incubated on ice for 2 minutes. Then, 4 pi of RT 
buffer, 1 pi of RNAse inhibitor, 0.25 pi of reverse transcriptase (200/pl) and RNase free 
water up to a final volume of 10 pi was added. Samples were then incubated at 37°C for one 
hour and finally the reaction was terminated at 70°C for 15 minutes. The success of cDNA 
synthesis was confirmed by the presence of the 110 bp GAPDH gene using PCR before 
subsequent analyses were carried out.
2 .233  Polymerase Chain Reaction (PCR)
The PCR mixture was carried out by adding 10 pi of PCR Master Mix (Promega,UK), 1 pi of 
20 pM of forward primer, 1 pi of 20 pM of reverse primer of each gene, 2 pi of cDNA (2 pg) 
and 6 pi of RNAse free water. The PCR was performed using Unocycler (VWR, UK). The 
reaction was initiated at 95°C for 5 minutes. This was followed by 40 cycles of dénaturation 
at 95®C for 1 minute, annealing at 55®C for 1 minute and elongation at 72®C for 1 minute. The 
reaction was terminated at 72°C for 5 minutes.
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2.2.4 DNA agarose gel electrophoresis
2.2.4.1 Preparation of agarose gel
1.5% agarose gels were prepared by mixing 1.5 g agarose with 100 ml of TAB (Ix) in a 250 
ml flask bottle. The bottle was heated in the microwave oven for about 2 minutes to dissolve 
the agarose powder. The bottle was then cooled down under flowing tap water while swirling 
to decrease the temperature of the solution to about 60°C. Then, 4 pi of Gel Red® (Biotium, 
UK) was added in the solution. The solution was mixed thoroughly and poured into a gel 
caster and was allowed to solidify at room temperature for 20 minutes.
2.2.4.2 Agarose gel electrophoresis
Ten microliters of the PCR products were mixed with 2 pi of 6x loading buffer (New 
England Biolabs, UK) and were electrophoresed in a 1.5% agarose gel containing 0.5 pg/ml 
Gel Red® (Biotium, UK) at 100 V for 30 minutes. The DNA fi^agments were then visualized 
under UV light and the image was captured using Syngene® Bio-Imaging System (USA). 
Densitometric analysis of the DNA Augments was carried out using the Image Master Gene 
Snap software (Syngene, USA).
2.2 4.3 Densitometric analysis of PCR products
The densitometric analysis steps were carried out following the equipment/software 
instructions. The analysis was performed manually and involved several steps namely, lanes 
creation, background subtraction, band detection and molecular weight calibration. The lanes 
creation mode is utilized to define the positions and areas occupied by the lanes of the gel on 
the gel image. When the positions and shapes of these lanes were recognized, the process of 
band detection in each lane that represents a single PCR product was carried out.
Background subtraction was performed on the gel image to eliminate the background 
intensity of the gel material on the image. Thus, the background was removed from the lanes 
to ensure that the calculated band volumes represented the volume of material in the band, 
rather than the volume of all materials that include the gel material at that position.
The bands of DNA fragments were detected by selecting each band in each lane. In this 
study, each band represents the expression of a single cytokine gene as well as the GAPDH 
band. Finally, the molecular weight calibration was carried out using 100 bp DNA marker as 
a standard. The software is able to interpolate and extrapolate contour lines of known 
molecular weight horizontally across the gel. Once the horizontal contours have been
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determined, the software uses a curve-fitting algorithm to determine the relationship of 
molecular size to position along the lane for all points in all the lanes. From this, the 
molecular size of each band in each lane is measured. An analysis report containing the 
molecular size and raw volumes of every band in each lane was derived fi*om the sofiware. 
The gene expression of each cytokine in every sample was then normalized as a ratio over 
GAPDH intensity reading.
2.2.5 Flow cytometry analysis
2.2.5.1 Cell surface and intracellular staining
In order to determine the percentage of Thl7 cell, cell surface and intracellular staining were 
carried out using flow cytometry analysis. The Thl7 cell-related markers were selected and 
the protocol started with the surface staining of cells expressing the markers of CD4 and 
CD25, CD4 alone or CD4 and CCR6, followed by intracellular staining with RORyt, IL-17A 
and IL-17F (Table 2.2). After counting, 1 x 10  ^cells were suspended in 100 pi of staining 
buffer (1% BSA, 0.05% NaNg in PBS) and were incubated with mouse SeroBlock FcR 
(AbSerotec, UK) for 10 minutes and then were added with AbSerotec antibodies (Table 2.2). 
The cells were mixed by vortexing and incubated at 4°C for 30 minutes. The cells were 
washed using 2 ml of washing buffer (0.5% BSA in PBS) by centrifugation for 5 minutes at 
200 X g. Then, the cells were fixed with fixation buffer (2% formaldehyde in PBS) by 
incubating at room temperature in the dark for 20 minutes. Next, the cells were washed with 
permeabilisation buffer (0.5% Saponin (Riedel-de Haen, UK), 1% BSA, 0.05% NaNg in 
PBS) twice by centrifugation for 5 minutes at 200 X g followed by incubation in 
permeabilisation buffer at room temperature in the dark for 15 minutes. Subsequently, the 
cells were blocked by using blocking buffer (5% mouse serum in permeabilisation buffer). 
After 15 minutes incubation at 4°C, the cells were centrifuged and resuspended in 
permeabilisation buffer. Then, the cells were incubated for 30 minutes at room temperature 
after staining with RORyt-RPE (eBioscience, UK), IL-17A-Alexa 647 (eBioscience, UK) and 
IL-17F-Alexa 488 (eBioscience, UK). Finally, the cells were centrifuged and were added 
with 300 pi staining buffer (1% BSA, 0.05% NaNg in PBS) before being analysed by flow 
cytometry with a BD FACS Canto (BD Biosciences, UK) and BD FACS Diva Software v5.1. 
Events (1x10^) were recorded and analysed.
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Table 2.2 The antibodies and isotypes used for the analysis of Th17 cells by using flow cytometry
Antibodies Company mg/ml For 1 X10^ Isotypes
Mouse Seroblock AbSerotec 1.0 1.0 pi -
Rat-anti-mouse
PerCP
CD4 BioLegend 0.2 2.0 pi Rat IgG2a-PerCP
Rat-anti-mouse
RPE
CD25 AbSerotec 0.1 5.0 pi RatlgGl-RPE
Rat-anti-mouse
RPE
CCR6 R&D system 0.1 5.0 pi RatlgGl-RPE
Rat-anti-mouse
RPE
RORyt eBioscience 0.2 2.0 pi Rat IgG2a-RPE
Rat-anti-mouse IL-17A- 
Alexa 647
eBioscience 0.5 2.0 pi Rat IgG2a-Alexa 
647
Rat-anti-mouse 
Alexa 488
IL-17F- eBioscience 0.5 2.0 pi Rat IgG2a-Alexa 
488
Isotypes Company mg/ml For 1 X 10^ Isotypes
Rat XgG2a-PerCP BD Bioscience 0.2 2.0 pi -
RatlgGl-RPE AbSerotec 0.1 5.0 pi -
Rat JgG2a-RPE AbSerotec 0.1 4.0 pi -
Rat XgG2a-Alexa 647 eBioscience 0.5 2.0 pi -
Rat IgG2a-Alexa 488 eBioscience 0.5 2.0 pi -
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2.2.5.2 Gating strategies for the analysis of Thl7 cells
CD4^ T-cells are important mediators of the cellular immune response. For many years, it 
was thought that CD4^ T-cells existed as a dichotomy of lineages known as Thl and Th2 
cells based on cytokine expression patterns. Recently, a unique subset of T helper cells that 
could differentiate into IL-17-secreting T cells in vitro and in vivo independently of Thl and 
Th2 development was discovered and named as Thl 7 cells. In addition of IL-17A secretion 
as a hallmark, Thl 7 cells also express another member of IL-17 cytokine family, IL-17F. 
Some studies determined Thl 7 cells frequency by measuring the frequency of CD4^L-17^ 
using flow cytometry (Horlock 2009). However, due to of ability of other subset of CD4^ T- 
cells express IL-17 A, we have designed three combinations of fluorochrome labelled 
antibodies based on Thl 7 cell related markers such as CD4, RORyt, CCR6, IL-17A and IL- 
17F were applied. Nevertheless, there are possible limitations for each combination due to 
ability of other T-cell subsets especially Treg cells to express Thl 7 cell related markers that 
we have selected.
i) Combination 1 (CD4+/CD25/IL-17A+/IL-17F+)
The CD4^CD25"IL-17A^IL-17F^ was selected to discriminate the subpopulation of 
CD4^CD25^oxp3^ Treg cells that has capacity to produce IL-17. Voo et al. showed that 3% 
of CD4^CD25^oxp3^ Treg cells in peripheral bloods and 25% of CD4^CD25^oxp3^ Treg 
cells in tonsils have capacity to produce IL-17 upon activation (Voo, Wang et at. 2009). 
Ayyob et at. also found that up to 20% of human memory Foxp3^ Treg cells able to secrete 
IL-17 ex vivo (Ayyoub 2009).
Limitation
The CD4^CD25TL-17A^L-17F^ gating strategy may include both naive and memory Thl 7 
cells because a large fraction of CD4^CD25‘ T-cells are naive T-cells that express high levels 
of CD45RB (CD45RB^'^), and the remaining CD4^CD25" peripheral cells express 
intermediate or low levels of CD45RB (CD45RB^°^) (Read 2000; Annacker 2001).
The combination of CD4^CD251L-17A’^ L-17F^ was used for staining of total splenocytes 
and CD4^ T-cells.
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Figure 2.1 The control tubes for CD4*/CD25 /IL-17A*/IL-17F* combination. Tube A. Unstained 
cells Tube B. lgG2a PercP/lgG1 RPE/lgG2a Alexa 647/lgG2a Alexa 488 Tube C. Rat lgG2a 
PercP/CD25 RPE/IL-17A Alexa 647/IL-17F Alexa 488 Tube D. CD4 PercP/Rat IgGI RPE/IL-17A 
Alexa 647/IL-17F Alexa 488 Tube E. CD4 PercP/CD25 RPE/Rat lgG2a Alexa 647/IL-17F Alexa 488 
Tube F. CD4 PerCP/CD25 RPE/IL-17A Alexa 647/Rat lgG2a Alexa 488.
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Figure 2.2 The gating strategies for CD4*CD25 IL-17A*IL-17F* Initially, the total splenocytes gated 
using FSC-A vs SSC-A. Lymphocytes were selected and named as P1 based on the unstained cells 
and isotypes control in Figure 2.1. Next, the PI population was applied on dot plot of CD4 PercP-A vs 
CD25 PE-A. The population of CD4^CD25‘ (P2) was gated based on tube A, B, C, D, E and F in 
Figure 2.1. P2 then was applied as histogram to determine the median fluorescence intensity (MFI) 
for IL-17A and IL-17F respectively. P3 represented MFI for IL-17A  ^ expression on CD4’^CD25' 
expressing cells while P4 represented MFI for IL-17F  ^expression on CD4’^CD25'expressing cells.
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Figure 2.3 The control tubes for CD4*/CD25 /IL-17A*/iL-17F* combination Tube A. Unstained cells 
Tube B. lgG2a PercP/lgG1 RPE/lgG2a Alexa 647/lgG2a Alexa 488 Tube C. Rat lgG2a PercP/CD26 
RPE/IL-17A Alexa 647/IL-17F Alexa 488 Tube D. CD4 PercP/Rat lgG1 RPE/IL-17A Alexa 647/IL-17F 
Alexa 488 Tube E. CD4 PercP/CD25 RPE/Rat lgG2a Alexa 647/IL-17F Alexa 488 Tube F. CD4 
PerCP/CD25 RPE/IL-17A Alexa 647/Rat lgG2a Alexa 488.
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Figure 2.4 The gating strategies for CD4*CD25 IL-17A*IL-17F*. Initially, the CD4  ^ T-cells gated 
using FSC-A vs SSC-A. CD4"’ T-cells were selected and named as P1 based on the unstained cells 
and isotypes control in Figure 2.3. Next, the P1 population was applied on dot plot of CD4 PercP-A vs 
CD25 PE-A. The population of CD4^CD25‘ (P2) was gated based on tube A, B, C, D, E and F in 
Figure 2.3. P2 then was applied as histogram to determine the median fluorescence intensity (MFI) 
for IL-17A and IL-17F respectively. P3 represented MFI for IL-17A"^  expression on CD4'"CD25‘ 
expressing cells while P4 represented MFI for IL-17F^ expression on CD4^CD25‘ expressing cells.
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ii) Combination 2 (CD4/RORyt/LL-17A /ÏL-17F")
The CD4^RORyt^IL-17A^IL-17F^ gating strategy was selected to represent Thl 7 cells 
because RORyt is Thl 7 transcription factor (Ivanov, McKenzie et al. 2006), whereby IL-17A 
and IL-17F are the main cytokines secrete by Thl7 cells (Bettelli, Carrier et al. 2006; 
McGeachy and Cua 2008). RORyt deficiency results in attenuate Thl 7 activity and severely 
reduced expression of IL-17 (Ivanov, McKenzie et al. 2006).
Limitation
The gating strategy may include the population of Treg cells which able to secrete IL-17 and 
express RORyt as previously described (Ayyoub 2009; Voo, Wang et al. 2009).
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Figure 2.5 The control tubes for CD4TRORyt*/IL-17A*/iL-17F* combination. Tube A. Unstained 
cells Tube B. lgG2a PercP/lgG2a RPE/lgG2a Alexa 647/lgG2a Alexa 488. Tube C. Rat lgG2a 
PercP/RORyt^  RPE/IL-17A Alexa 647/IL-17F Alexa 488 Tube D. CD4 PercP/Rat lgG2a RPE/IL-17A 
Alexa 647/IL-17F Alexa 488 Tube E. CD4 PercP/ROR< RPE/Rat lgG2a Alexa 647/1L-17F Alexa 488 
Tube F. CD4 PercP/RORyt^  RPE/IL-17A Alexa 647/Rat lgG2a Alexa 488.
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Figure 2.6 The gating strategies for CD4*/RORyt*/iL-17A*/iL-17F*. Initially, the total splenocytes 
gated using FSC-A vs SSC-A. Lymphocytes were selected and named as P1 based on the unstained 
cells and isotypes control in Figure 2.5. Next, the P1 population was applied on dot plot of CD4 PercP- 
A vs RORyt* PE-A. The population of CD4* RORyt* (P2) was gated based on tube A, B, C, D, E and F 
in Figure 2.5. P2 then was applied as histogram to determine the median fluorescence intensity (MFI) 
for IL-17A and IL-17F respectively. P3 represented MFI for IL-17A* expression on CD4*R0Ryt* 
expressing cells while P4 represented MFI for 1L-17F* expression on CD4*RORyt* expressing cells.
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Figure 2.7 The control tubes for CD4*/RORyt*/IL-17A*/IL-17F* combination. Tube A. Unstained 
cells Tube B. lgG2a PercP/lgG2a RPE/lgG2a Alexa 647/lgG2a Alexa 488 Tube C. Rat lgG2a 
PercP/RORyt* RPE/1L-17A Alexa 647/1L-17F Alexa 488 Tube D. CD4 PercP/Rat lgG2a RPE/1L-17A 
Alexa 647/1L-17F Alexa 488 Tube E. CD4 PercP/RORyt* RPE/Rat lgG2a Alexa 647/IL-17F Alexa 488 
Tube F. CD4 PercP/RORyt* RPE/1L-17A Alexa 647/Rat lgG2a Alexa 488.
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Figure 2.8 The gating strategies for CD4*/RORyt*/IL-17A*/iL-17F*. Initially, the CD4* T-cells gated 
using FSC-A vs SSC-A. CD4* T-cells were selected and named as P1 based on the unstained cells 
and isotypes control in Figure 2.7. Next, the P1 population was applied on dot plot of CD4 PercP-A vs 
RORyt* PE-A. The population of CD4* RORyt* (P2) was gated based on tube A, B, C, D, E and F In 
Figure 2.7. P2 was then applied as histogram to determine the median fluorescence intensity (MFI) 
for IL-17A and IL-17F respectively. P3 represented MFI for IL-17A* expression on CD4*R0Ryt* 
expressing cells while P4 represented MFI for 1L-17F* expression on CD4*R0Ryt* expressing cells.
iii) Combination 3 (CD4/CCR6/IL-17A /IL-17F^)
The CD4^CCR6^IL-17A^IL-17F^ gating strategy was selected to determine population of 
Thl 7 cells because CCR6 is the best surface marker to define Thl 7 cells (Potzl 2008), 
whereby IL-17A and IL-17F are the main cytokine produce by Thl 7 cells (Bettelli, Carrier et 
al. 2006; McGeachy and Cua 2008). In addition, the CD4^CCR6^ T-cells expressed high 
levels of the mRNA for RORyt, the transcription factor for Thl 7 cell differentiation (Ivanov, 
McKenzie et al. 2006).
Limitation
The chemokine receptor CCR6 is not only expressed by Thl 7 cells but also on a distinct 
subset of mouse Treg cells (Kleinneweitfeld 2005). Therefore, there is possibility that this 
gating strategy may include the population of Treg cells which can produce IL-17 (Ayyoub 
2009; Voo, Wang et al. 2009).
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Figure 2.9 The control tubes for CD4*/CCR6*/IL-17A*/IL-17F* combination. Tube A. Unstained 
cells Tube B. lgG2a PercP/lgGI RPE/lgG2a Alexa 647/lgG2a Alexa 488 Tube C. Rat lgG2a 
PercP/CCR6* RPE/IL-17A Alexa 647/IL-17F Alexa 488 Tube D. CD4 PercP/Rat lgG1 RPE/IL-17A 
Alexa 647/IL-17F Alexa 488 Tube E. CD4 PercP/CCR6* RPE/Rat lgG2a Alexa 647/IL-17F Alexa 488 
Tube F. CD4 PercP/CCR6* RPE/IL-17A Alexa 647/Rat lgG2a Alexa 488.
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Figure 2.10 The staining strategies for CD4*/CCR6*/IL-17A*/IL-17F*. Firstly, CD4"^  T-cells gated 
using FSC-A vs SSC-A. CD4  ^T-cells were selected and named as P1 based on the unstained cells 
and isotypes control in Figure 2.9. Next, the P1 population was applied on dot plot of CD4 PercP-A vs 
CCR6 PE-A. The population of CD4"^  CCR6"^  (P2) was gated based on tube A, B, C, D, E and F in 
Figure 2.9. The P2 was then applied in dop plot of IL-17F FITC-A vs IL-17A APC-A. P2 then was 
applied as histogram to determine the median fluorescence intensity (MFI) for IL-17A and IL-17F 
respectively. P3 represented MFI for IL-17A  ^expression on CD4*CCR6^ expressing cells while P4 
represented MFI for IL-17F^  ^expression on CD4^CCR6* expressing cells.
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2.2.6 Enzyme linked immunosorbent assays (ELISA)
Measurement of cytokine secretion levels from the supernatant of cell cultures was carried 
out using:
• Mouse IL-6 ELISA ready set go (eBioscience, UK; Cat No: 88-064)
• Human/mouse TGF-pl ELISA ready set go (eBioscience, UK; Cat No: 88-7344-88)
• Mouse IL-17A ELISA ready set go (eBioscience, UK; Cat No: 88-7371-22)
• Mouse IL-17F ELISA ready set go (eBioscience, UK; Cat No: 88-7472-22)
• Mouse IL-23 ELISA ready set go (eBioscience, UK; Cat No: 88-7234-22)
All kits contained: capture antibody, detection antibody, standard, ELISA coating buffer 
powder, 5x assay diluent, detection enzyme, Tetramethylbenzidine (TMB) substrate solution, 
certificate of analysis and 96 well plates.
The protocol was performed according to manufacturer’s instructions. One packet of ELISA 
coating powder was reconstituted in one liter of distilled water. The mixture was mixed well 
until dissolved and then was filtered through a 0.22 pm filter. Forty-eight microliter of each 
capture antibody was diluted in 12 ml of coating buffer for each plate and 100 pi per well 
was immediately added to each 96 well plates. The plates were sealed and incubated 
overnight at 4°C.
After aspirating the wells to remove the liquid, the plates were washed 5 times using 300 pi 
of washing buffer (0.05% Tween-20 in PBS) per well. The assay diluent was diluted 1:5 in 
distilled water and the plates were immediately blocked with 200 pi per wells of Ix assay 
diluent. The plates were sealed and incubated at room temperature for 1 hour. The standard 
solutions (500 pg/ml) for IL-6 and IL-17A were prepared by adding 5 pi of standard solution 
into 10 ml of Ix assay diluent. The top standard for TGF-p (8 ng/ml) was prepared by adding 
20 pi of standard solution into 2.5 ml of Ix assay diluent. The standard solution for IL-17F (2 
ng/ml) was prepared by adding 10 pi of standard solution into 5 ml of Ix assay diluent. The 
top standard of IL-23 (4 ng/ml) was prepared by adding 20 pi of standard solution into 5 ml 
of Ix assay diluent. One hundred pi of standard per well were added in duplicate. Two fold 
serial dilutions of the top standards were prepared to make a standard curve. One hundred pi 
of sample were added to each well in duplicate and incubated overnight at 4°C. On the other 
hand, to activate latent TGF-p 1 to an immunoreactive form, 100 pi of sample was mixed with
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20 pi of 1 N HCL and incubated 10 minutes at room temperature. Then, the mixture were 
neutralised with 20 pi of 1 N NaOH and incubated overnight at 4®C.
Plates were washed 5 times with 300 pi of wash buffer per well, 100 pi of detection antibody 
which was prepared by adding 48 pi of antibody solution into 12 ml of Ix assay diluent were 
added per well and incubated at room temperature for 1 hour. The plates were washed 5 times 
with 300 pl/well of wash buffer and 100 pi of Avidin-HRP diluted in Ix assay diluent (48 pi 
of enzyme solution into 12 ml of Ix assay diluent) were added per well and incubated at 
room temperature for 30 minutes. The wells were aspirated and washed 7 times using 
washing buffer. In this washing step, the wells were soaked in washing buffer for 2 minutes 
prior to aspiration. Then, 100 pi per well of TMB substrate solution were added and the 
plates were incubated for 15 minutes at room temperature for colour development. The 
reaction was stopped by adding 50 pi of 1 M H2SO4 to each well. The plates were read at 450 
nm wavelength using Bio-Tek ELx800 plate reader (Bio-Tek Instruments, Inc., Ontario, 
Canada).
2.3 Statistical analysis
Statistical analysis in this study was performed to compare treatment groups with controls 
using GraphPad Prism software (version 5.02, GraphPad Software Inc., La Jolla, CA, USA). 
For in vitro studies, each experiment was repeated at least three times. Values herein were 
expressed as mean + SD. A one-way ANOVA was performed followed by a Bonferroni 
multiple comparison post-hoc test, to determine which groups were significantly different. In 
all cases, statistical significance was attained if the 2-tailed probability was: *p < 0.05 or **p 
< 0.01 or ***p < 0.001.
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CHAPTERS
EFFECT OF OXIDISED LOW DENSITY LIPOPROTEIN-TREATED DENDRITIC
CELLS ON TH17 CELLS
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3.1 Dendritic Cells (DCs)
3.1.1 Introduction
The role of dendritic cells (DCs) in the initiation of immune responses was originally 
described by Steinman and Cohen (Steinman 1973). DCs were shown to be potent APCs that 
can link innate and adaptive immune responses (Banchereau J 2000; Steinman 2007). 
Immature DCs were activated by endogenous or exogenous antigens to become mature DCs, 
which secreted cytokines that activated T and B immune responses (Banchereau J 2000; 
Schlichting 2005; Merad 2009; Novak 2010). DCs have also been shown to be involved in 
various autoimmune diseases (Steinman 2007; Khan 2009; Burchell 2010) and cardiac 
pathologies such as atherosclerosis (Niessner 2010), endothelial dysfunction and heart 
transplantation (Kofler 2008).
3.1.2 DCs and atherosclerosis
DCs play an important role in the development of atherosclerosis (Niessner 2010). DCs were 
found to accumulate in small amounts within healthy arteries and other organs such kidney, 
lung and intestines (Zhang 2010). DCs also have been found in the adventitia and intima of 
large arteries such as aorta, coronary and carotid (Bobryshev 1995). In contrast, DCs were 
not detected in normal veins and they only reside in the diseased veins after injury of the 
vessels (Cherian 1999). It is thought that the vascular resident DCs are “immature DCs” that 
act as sentinels to screen any potential harmful antigens that appear in vascular tissues (Wick 
1997; Waltner-Romen 1998).
The evidence that DCs accumulate within atherosclerotic lesions was first reported by 
Bobryshev (1995), when it was revealed that a greater number of DCs accumulated in the 
intima of atherosclerotic-prone areas than in the atherosclerotic resistant areas of non­
diseased aorta (Lord 1999). DCs are present in healthy arteries, pre-atherosclerotic arteries 
and within atherosclerotic lesions (Bobryshev 1998). Vascular and blood-derived DCs have 
been also shown to contribute to the development of atherosclerotic lesions via neo-vessel 
formation and inflammation (Bobryshev 1998; Bobryshev 2000). This finding was supported 
by Kawahara et al (2007) who found that the expression of vascular DCs in human 
atherosclerotic plaques may be associated with the occurrence of ischemic stroke. They also 
found a close correlation between the mean signal intensity of DCs derived from 
atherosclerotic plaques and the symptoms of patients with significant carotid plaques. In 
addition, vascular DCs were shown to be involved in plaque destabilisation that can lead to
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myocardial infarction and stroke (Zhang 2010) and the number of DCs tremendously 
increased at the shoulder region of arteries where plaques are more prone to rupture (Yilmaz 
2004).
Activated myeloid DCs located within human coronary and carotid plaques express high 
levels of T-cell-attracting chemokines, CCL19 and CCL21, which facilitate the interaction 
with T-cells and lead to plaque destabilisation (Niessner 2007). The accumulation of DCs and 
natural killer (NK) cells in rupture prone areas in human atherosclerotic plaque suggests that 
DCs may influence the functional activity of NK cells that contribute to plaque 
destabilisation (Bobryshev 2005). The activation of vascular DCs with antigens such as virus, 
bacteria or auto-antigens facilitate the activation of T-cells and NK cells, and also initiate the 
inflammatory response in the artery walls (Niessner 2010).
3.1.3 Recruitment of DCs into the vessel wall
Immature dendritic 
cells (DCs)
1 P-selectin
1 E-selectin
• oxLDL
T VCAM-1
1 VLA-4
• PTX
SRs
— TLRs
#  Mature DCs
Endothelial cells (EC)
Thl cells
Th2 cells
Thl7 cells
Figure 3.1 Recruitment of DCs into atheroscierotic plaques and differentiation of T-cell 
subsets. The activation of ECs by oxLDL induced the expression of E- and P-selectin, VCAM-1 which 
facilitate the migration of DCs into atherosclerotic plaques. The uptake of oxLDL by DCs leads to their 
maturation. Mature DCs present peptides to naïve T-cells driving their differentiation into Th1, Th2, 
Treg and Th17 cells.
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OxLDL activates ECs that leads to change of its biological characteristics by reducing the 
intracellular concentration of nitric oxide (NO) (Szmitko 2003). NO generated following the 
conversion of the amino acid L-arginine to NO and L-citrulline by the enzyme NO synthase 
which acts as key endothelium-derived relaxing factor that plays an important role in the 
regulation of vascular tone and vasomotor function (Moncada 1993). In addition, NO also 
acts as a protector’s againts vascular injury, inflammation, and thrombosis (Szmitko 2003). 
NO also suppresses leukocyte adhesion to endothelium, sustains vascular smooth muscle 
cells in non-proliferative state and restricts platelet aggregation (de Graaf 1992; Cornwell 
1994; Gautier 1995). Angiotensin II, a vasoconstrictor associated with hypertension and 
opposes with NO action, elicits the secretion of reactive oxygen species (ROS), increase the 
expression of proinflammatory cytokines such as IL-6 and MCP-1, and upregulates vascular 
cell adhesion molecule-1 (VCAM-1) on the ECs (Figure 3.1) (Griendling 1997; Kranzhofer, 
Schmidt et al 1999; Tummala 1999). In addition, platelets covering ruptured lesions may 
facilitate the adhesion of DCs to injured vessels (Langer 2007). DCs roll and adhere to the 
vessel wall helped by the expression of E-and P-selectins on ECs (D’Amico 1998). Then, 
DCs bind to VCAM-1-expressing ECs through very late antigen-4 (VLA-4) and respond to 
locally produced chemokines by migrating into the arterial tissues (Hansson and Libby 2006). 
In addition to those mentioned above, fractalkine receptor on DCs, CX3CR1 may be another 
important chemokine that contributes to the accumulation of DCs in the atherosclerotic 
plaque by binding with its ligands, CX3CRL1 express on SMCs (Liu 2008).
3.1.4 Maturation of DCs by oxLDL
Following the migration into the subendothelial space, DCs have the capacity to capture 
oxLDL via LOX-1, CD36 and CD205, which act as scavenger receptors (Figure 3.1). After 
undergoing proteolytic processing via the endocytosis pathway, fragments of oxLDL, apoB- 
100, bind to nascent MHC class II molecules and transported to the cell surface (Hansson and 
Libby 2006). A recent study showed that mildly activated oxLDL induced DCs maturation 
and increased DCs-induced T-cell activation and proliferation (Alderman 2002). However, 
high concentrations of oxLDL can also suppress DCs function due to the commencement of 
apoptotic pathways (Alderman 2002). Following maturation, DCs express CD la receptor, 
which is partially responsible for triggering the accumulation of mature DCs in the 
atherosclerotic plaques and also for priming naïve T-cells within the plaques to induce 
oxLDL-speciftc T-cells (Bobryshev 2005).
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3.1.5 Maturation of DCs by PTx and a combination of oxLDL and PTx
PTx is an established microbial component that have immunoadjuvant effects and the ability 
to induce experimental autoimmune encephalomyelitis (EAE) (Munoz 1984). PTx has also 
been widely utilized to induce autoimmune disease in other animal model such as orchitis 
(Kohno 1983), uveitis (Fujimoto 2006) and inflammatory myopathy (Hart 1987). Plenty of 
evidences showed that PTx induces maturation of DCs that leads to the expansion of effector 
T-cells (Wakatsuki 2003) and differentiation of Thl and Th2 cells (Hofstetter 2002; Hou 
2003). PTx induces DCs maturation via TLR-4 (Kerfoot 2004; Wang 2006). Previous studies 
also showed that PTx was capable of inducing IL-17-producing cells fi*om unfiactionated 
CD4^ T-cells that were co-cultured with BMDC (Chen, Howard et al 2007). Furthermore, 
PTx has the capability to evoke an IL-6-independent Treg response in co-culture of naïve 
CD4^ T-cells and BMDC and favours the induction of Thl 7 cells under the influence of IL-6 
(Chen, Howard et al 2007). A combination of oxLDL and PTx was used to boost the 
maturation of DCs and induced more secretion of IL-6 and TGF-p.
3.1.6 Engagement of mature DCs with T-cells induce T-cell differentiation
Engagement between mature DCs and naïve T-cells in the plaque leads to T-cell 
differentiation (Figure 3.1). Activation of DCs by oxLDL also leads to secretion of a wide 
array of cytokines such as IL-6, IL-10, TNFa and IL-12 (Nickel 2009). IL-I2 secreted by 
mature DCs influence the differentiation naïve lymphocytes into Thl type cells. IL-12 also 
induces the expression of CCL5 receptor on T-cells which facilitates the migration of T-cells 
into atherosclerotic plaques (Zhang 2006). Most of the oxLDL-reactive CD4^ T-cells belong 
to the Thl phenotype which have been demonstrated to accelerate atherosclerosis 
development (Stemme, Faber et a l  1995).
The current study used mitomycin C (MMC) to treat oxLDL-treated DCs. MMC is an 
alkylating agent utilized in cancer therapy that strongly binds to distinct DNA regions, cross 
linking double helical strands, to suppress DNA and RNA synthesis, and leads to the 
suppression of cell proliferation (Temess 2008). MMC also blocks cell division by creating 
intrachromatid cross-links in chromosomes (Cooke 1973). In addition, the treatment of DCs 
with MMC stably converts stimulatory into inhibitory cells (Jiga 2007). They also conclude 
that allogenic MMC-DCs specifically inhibit the T-cell response in vivo and suggest the 
downregulation of CD80, CD86, and ICAM-1 as a potential mechanism of this effect (Jiga
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2007). In agreement with that, MMC did not inhibit but reduced the expression of MHC class 
II and CD80/CD86 on treated DCs which required for naïve T-cells activation (Temess
2008). Huang et a l also demonstrated based on their in vitro and in vivo experiments that 
MMC-DCs are tolerogenic DCs-like cells, and the mechanisms of the induction of 
immunosuppression are multifactorial, including induction of apoptosis of allogeneic T cells, 
Treg cells expansion, reduced Thl-type secretion such as IL-2 and IL-12, and increased 
secretion of Trl-type cytokine, IL-10 (Huang 2010).
Since T-cell differentiation during atherogenesis depends on the presence and persistence of 
factors such as oxLDL and cytokines in their environment (Kapsenberg 2003); our 
hypotheses is that oxLDL may serve as a potential antigen that may induce IL-6 and TGF-p 
expression by DCs which in turn may drive Thl 7 cell differentiation during atherosclerosis 
development. The suppression of oxLDL-treated DCs with MMC treatment may stop or 
decrease their IL-6 and TGF-p secretion, and the presence of exogenous IL-6 and TGF-p 
may affect Thl 7 cell differentiation.
3.2 Aim
This study is aimed at investigating the potential mechanism involved in Thl 7 cell 
differentiation by using oxLDL-treated DCs.
3.3 Objectives
Hence the objectives of this research are as follows:
1. To assess the level of maturation markers expressed by oxLDL-treated DCs by flow 
cytometry analysis and to measure IL-6 and TGF-p secreted by them by ELISA.
2. To determine the population of Thl 7 cells generated following co-culturing oxLDL- 
treated DCs with CD4^ T-cells by flow cytometry analysis.
3. To determine the number of differentiated Thl 7 cells following co-culturing MMC- 
treated oxLDL-treated DCs with CD4^ T-cells by flow cytometry analysis.
4. To determine the number of Thl 7 cells when co-cultured with either oxLDL-treated 
DCs or MMC-treated oxLDL-treated DCs with CD4^ T-cells under the influence of 
exogenous IL-6 and TGF-p by flow cytometry analysis.
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3.4 Materials and methods
3.4.1 Animais
Six week old of female apoE' '^ mice (strain B6.129P2-ApoetmlUnc/J) bred in-house, were 
used. Splenocytes, femur and tibia were collected at termination for further analysis.
3.4.2 Isolation of CD4  ^T-cells
CD4^ T-cells isolation was carried out as described in Chapter 2 section 2.2.2.2.
3.4.3 Generation of bone marrow-derived dendritic cells (BMDC)
The bone marrow was extracted from the femur and the tibia of female apoE’^ ' mice by 
flushing through the bones with 10 ml RPMI 1640 (Invitrogen, UK) using a syringe and 25- 
gauge needle. After the collection, the cells were washed twice with complete RPMI medium 
by centrifiigation (Heraeus Megafuge l.OR, Thermo Fisher Scientific Inc, UK) at 200 X g for 
5 minutes. The contaminant erythrocytes were eliminated by resuspending the pellet in Ix M- 
lyse buffer (R&D Systems, UK). The cells were vortexed and incubated at room temperature 
for 10 minutes, until red cell lysis was complete. The cells were washed twice with complete 
RPMI medium by centrifugation at 200 X g for 5 minutes. The supernatant was discarded and 
the cells were resuspended in 1 ml complete RPMI medium, prior to cell counting using a 
haemocytometer.
The cells were negatively selected after incubation with 1 pg of cocktail of each monoclonal 
antibody per 10^  cells, which included rat anti mouse CD4 (AbSerotec), CDS (AbSerotec, 
UK) and CD 19 (AbSerotec, UK) for 30 minutes at 4°C. At the same time, BioMag beads 
(Qiagen, USA) were washed with complete RPMI medium 2-3 times to remove sodium azide 
(NaNs) and finally were resuspended in 9 ml complete RPMI medium. The cells were 
centrifuged for 5 minutes at 200 X g to remove unbound antibodies and were resuspended in 
1 ml complete RPMI medium, prior to its mixing with the washed BioMag beads (Qiagen, 
USA) and incubated at 4°C for 30 minutes. The vessel was then applied to a magnetic 
separator for 10 minutes. Once separation was complete, the supernatant was carefully 
removed without disturbing the pellet and was centrifuged for 5 minutes at 200 X g. The cell 
pellet was resuspended in 1 ml of complete advanced RPMI medium and the cells were 
counted as described in Chapter 2 section 2.2.2.3.
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Bone marrow derived cells were cultured at a concentration of 1x10* cells/well in 24-well 
plates for 7 days, with advanced RPMI 1640 and supplements (Table 3.1). Cultures were fed 
with fresh media every 2 days and on day 7 the cells were further purified (enriched) by 
density gradient, using Histopaque®-1077 (Sigma Aldrich, UK) at 1:2 ratio of Histopaque to 
cells, in order to eliminate contaminants such as ECs, epithelial cells and dead cells. After 7 
days in culture, the cells were gently detached from the plates using a 1 ml syringe plunge 
and passed to a 50 ml tube for washing by centrifugation at 200 X g for 5 minutes. The cells 
were then resuspended to a final volume of 10.5 ml with complete RPMI 1640 and slowly 
added to 4 ml of Histopaque®-1077, previously brought to room temperature (RT), then 
centrifuged at 200 X g for 30 minutes at RT. The inter-phase layer, containing the 
mononuclear cells, was collected and washed twice with PBS at 4°C by centrifugation at 200 
X g for 5 minutes. The cell pellet was resuspended into 1 ml complete advanced RPMI 
medium (Invitrogen, UK) and the cells were counted as described in Chapter 2 section 
2.2.2.3.
The cell concentration was adjusted to 3-5x10^ cells/ml with complete advanced RPMI 1640 
and supplements (50 pM 2-pME, 25 mM HEPES) and cytokines (10 ng/ml rmGM-CSF and 2 
ng/ml rmIL-4) and plated 1 ml/well in 24-well plates (NUNC, Thermo Fisher Scientific Inc., 
UK). The cells were cultured for another 2 days in the incubator at 37°C, 5% CO2 (Heraeus, 
HERA Cell 240, Thermo Fisher Scientific Inc, UK).
3.4.4 In vitro cell culture
BMDC were cultured in complete RPMI medium in the presence of 100 pg/ml oxLDL, 1 
pg/ml Pertussis Toxin (PTx) (Sigma Aldrich, UK) or a combination of oxLDL and PTx for 
24 hours. After collection, the cells were stained for flow cytometry analysis and the 
supernatant were stored for subsequent IL-6 and TGF-P analysis. Another experiment was set 
up in parallel where cells were stimulated with MMC (25 pg/ml) (Sigma Aldrich, UK) for 45 
minutes at 37°C, and then collected after extensive washing. CD4^ T-cells (1x10*) were 
cultured with BMDC (1x10^) or BMDC treated MMC in a 24-well plate for 3 days. In some 
studies, IL-6 (20 ng/ml) (Peprotech, UK) and TGF-P (2 ng/ml) (Peprotech, UK) were added 
to the culture. At day 3, the cells were stimulated with phorbol 12-myristate-13-acetate 
(PMA) (50 ng/ml, Fluka, UK) and ionomycin (800 ng/ml. Sigma Aldrich, UK) for 5 hours in 
the presence of 2 pM of monensin (eBioscience, UK).
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Table 3.1 Recipe for RPMI advanced medium and its supplements
Properties Volume Final concentration
RPMI 1640 Basic cell culture medium 500 ml Ix
100% PCS A rich source of nutrients required 
for cell growth. It derived from the 
pregnant cow. Blood without any 
cells, platelets or clotting factors
25 ml 5%
lOOx Pen/Strep/Glu 
(PSG)
Antibiotics to prevent bacterial cell 
culture contamination
5 ml 100 U/ml, 100 pg/ml, 
2mM
IM HEPES Buffering agent with nutritional 
benefits to medium but not to cells. 
It was added when the cell culture 
need extended periods of 
manipulation outside of the CO2 
incubator.
25 mM
50 mM
2-p Mercaptoethanol
Ethylene glycol hybrid used to 
reduce disulfide bonds. It acts as 
biological anti-oxidant by 
scavenging hydroxyl radical. The 
hydroxyl group confers solubility 
in water and lower instability.
50 pM
10 pg/ml GMCSF Bioreactive protein participated in 
growth development such as in 
granulocyte and macrophage 
progenitor cells, stimulation and 
initiation of myeloblasts and 
monoblasts differentiation, 
chemotaxis of eosinophils.
10 ng/ml
2 pg/ml IL-4 Bioreactive protein, which induces 
the proliferation and differentiation 
of activated B cells, up-regulated 
MHC class n  and IgE receptors.
2 ng/ml
3.4.5 Measurement of cytokine by ELISA
IL-6 and TGF-p were detected using the supernatant of cultured BMDC stimulated with 100 
pg oxLDL, 1 pg PTx or the combination of oxLDL and PTx after 24 hours. The supernatant 
was collected by centrifugation and stored at -20®C until further analysis. Levels of IL-6 and 
TGF-P were detected using commercially available ELISA kits (eBioscience, UK) following 
manufacturer’s recommendations as described in Chapter 2 section 2.2.6.
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3.4.6 Detection of DCs maturation markers by flow cytometry analysis
The staining protocol involved the direct staining of cells surface markers such as CD 11c 
(RPE), CDllb (APC), CD40 (FITC), CD86 (FITC) and MHC II (FITC) using a cocktail of 
anti-mouse fluorescently labelled monoclonal antibodies (AbSerotec, UK and eBioscience, 
UK). After counting, 1x10* cells were suspended in 100 pi in staining buffer (PBS with 1% 
(w/v) BSA and 0.05% (w/v) NaNg) and were incubated with mouse SeroBlock FcR 
(AbSerotec, UK) for 10 minutes and then with AbSerotec antibodies (Table 3.2). The cells 
were mixed by vortexing and incubated at 4°C for 30 minutes. The cells were washed using 2 
ml washing buffer (0.5% BSA (w/v) in PBS) by centrifugation for 5 minutes at 200 X g. 
Then, the supernatant was discarded and 300 pi of staining buffer was added. The samples 
were analysed by flow cytometry using a BD FACS Canto (BD Biosciences, UK) and BD 
FACS Diva Software v5.1. Events (2x10"^ ) were recorded and analysed.
Table 3.2 The antibodies and isotypes control for detection of DCs maturation markers.
Antibodies Company Cat. No. [mg/ml] WD lO** cells Isotype
Mouse Seroblock 
FcR
AbSerotec BUF041B 1.0 mg/ml Neat 1
Hamster anti-mouse 
CDllc-RPE
AbSerotec MCA1369PE 0.1 mg/ml Neat 10 Hamster
IgG-RPE
Rat anti-mouse 
CDl Ib-Alexa 647
AbSerotec MCA74A647 0.5 mg/ml Neat 10 Rat IgG2b- 
Alexa 647
Rat anti-mouse 
CD40-FITC
AbSerotec MCA1143F 0.1 mg/ml Neat 10 Rat IgG2a- 
FITC
Rat anti-mouse 
CD86-FITC
AbSerotec MCA1587F 0.1 mg/ml Neat 10 Rat IgG2a- 
FITC
Mouse anti-mouse 
MHC n-FITC
AbSerotec MCA1501F 0.1 mg/ml Neat 10 Mouse
IgM-FITC
Isotypes Company Cat. No. f mg/ml] WD 10* ceUs Isotype
Hamster IgG-RPE AbSerotec MCA2356PE 0.1 mg/ml Neat 10 -
Rat IgG2b-Alexa 
647
AbSerotec MCA1125A647 0.05 mg/ml Neat 10
■
RatIgG2a-FITC AbSerotec MCA1212F 0.1 mg/ml Neat 10 -
Mouse IgM-FITC AbSerotec MCA692F 0.1 mg/ml Neat 10 -
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3.4.6.1 Gating strategy
In mice, all DCs express the integrin CDl Ic and DC subsets are further defined based on the 
expression of the myeloid marker, CDllb (Hammad 2008). The expression levels of DCs 
maturation markers, CD40, CD86 and MHC class II were determined on CDllb^CDllc^ 
cells by flow cytometry analysis, 24 hours after treatment with oxLDL, PTx and a 
combination of oxLDL and PTx. Figure 3.2, 3.3, 3.4, 3.5, 3.6 and 3.7 showed the gating 
strategies for the determination of maturation markers on CDl Ib^CDllc^ DCs.
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Figure 3.2 The control tubes for the combination of CD11b*CD11c*CD40*. Tube A. Unstained 
Tube B. IgG RPE/lgG2b Alexa 647/lgG2a FITC Tube C. IgG RPE/CD11 b Alexa-647/CD40 FITC Tube 
D. CD11c RPE/lgG2b Alexa-647/CD40 FITC Tube E. CDl 1c RPE/CD11 b Alexa-647/lgG2a FITC
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Figure 3.3 The gating strategy for determination of maturation markers of DCs, CD40. Initially, 
the population of DCs was gated based on FSC-A vs SSC-A. DCs was selected and named as P1 
based on the unstained cells and isotypes control in Figure 3.2. Next, the P1 population was applied 
on dot plot of C D llb  APC-A vs CDl 1c PE-A. The population of CDIIc’^CDIIb’  ^ (P2) was gated 
based on tube A, B, C, D and E in Figure 3.2. The P2 was then applied in histogram of CD40 FITC-A. 
P3 represented MFI for CDl Ic^CDI Ib ’  ^expressing CD40.
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Figure 3.4 The control tubes for the combination of CD11b*CD11c*CD86*. Tube A. Unstained 
Tube B. IgG RPE/lgG2b Alexa 647/lgG2a FITC Tube C. IgG RPE/CD11 b Alexa-647/CD86 FITC Tube 
D. CD11c RPE/lgG2b Alexa-647/CD86 FITC Tube E. CDl 1c RPE/CD11 b Alexa-647/lgG2a FITC
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Figure 3.5 The gating strategy for determination of maturation markers of DCs, CD86. initially, 
the population of DCs was gated based on FSC-A vs SSC-A. DCs was selected and named as P1 
based on the unstained cells and isotypes control in Figure 3.4. Next, the P1 population was applied 
on dot plot of CD11b APC-A vs CD11c PE-A. The population of CD11c*CD11b’  ^ (P2) was gated 
based on tube A, B, C, D and E in Figure 3.4. The P2 was then applied in histogram of CD86 FITC-A. 
P3 represented MFI for CD11c'"CD11b’  ^expressing CD86.
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Figure 3.6 The control tubes for the combination of CD11b*CD11c*MHCir. Tube A. Unstained 
Tube B. IgG RPE/lgG2b Alexa 647/lgM FITC Tube 0. IgG RPE/CDIIb Alexa-647/CD86 FITC Tube 
D. CDl 1c RPE/lgG2b Alexa-647/CD86 FITC Tube E. CDl 1c RPE/CD11b Alexa-647/lgM FITC
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Figure 3.7 The gating strategy for determination of maturation markers of DCs, CD86. Initially, 
the population of DCs was gated based on FSC-A vs SSC-A. DCs was selected and named as FT 
based on the unstained cells and isotypes control in Figure 3.4. Next, the P1 population was applied 
on dot plot of CD11b APC-A vs CD11c PE-A. The population of CD11c^CD11b^ (P2) was gated 
based on tube A, B, C, D and E in Figure 3.6. The P2 was then applied in histogram of MHC II FITC- 
A. P3 represented MFI for CD11c^CD11b  ^expressing MHC II.
3.4.7 Detection of Thl7 cells by flow cytometry analysis
The staining protocol involved first the staining of cells for surface markers such as CD4 
(PercP) and CD25 (RPE), followed by intracellular labelling of RORyt (RPE), IL-17A (Alexa 
Fluor 647) and IL-17F (Alexa Fluor 488) cytokines using a cocktail of anti-mouse 
fluorescently labelled monoclonal antibodies (Cambridge Bioscience, UK, AbSerotec, UK 
and eBioscience, UK). Samples were analysed by flow cytometry with a BD FACS Canto 
(BD Biosciences, UK) and BD FACS Diva Software v5.1. Events 100,000 were recorded and 
analysed per sample. The staining protocol and gating strategy for CD4^CD25TL-17A^IL- 
17F  ^ and CD4^RORyt^IL-17A^IL-17F^ were performed as described in Chapter 2 section 
2.2.5.
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3.5 Results
3.5.1 OxLDL and PTx induce the expression of DCs maturation markers and pro/anti­
inflammatory cytokines
DCs are APCs with potent capacity to initiate immune responses. The uptake of atherogenic 
stimuli such as oxLDL by DCs is mediated by scavenger receptors, whereas PTx engages 
DCs mainly through TLR-4 expressed on their surface. Any of these two processes induce 
the maturation of DCs and the secretion of pro-inflammatory cytokines. Maturation markers 
of DCs such as CD40, CD86 and MHC II can then be analysed using flow cytometry 
analysis. Quantifying the secretion of pro-inflammatory cytokines using ELISA analysis can 
also monitor the effects.
Figure 3.8 shows CDllc^Cllb^ DCs expressing CD40^. OxLDL, PTx and combination of 
PTx and oxLDL treatment on DCs significantly increased the expression levels of CD40 
compared to untreated DCs (p<0.001). The expression levels of CD40 were significantly 
higher on oxLDL-treated DCs and combination of PTx-oxLDL-treated DCs compared to 
PTx-treated DCs (p<0.001). OxLDL (p<0.01), PTx (p<0.01) and combination of PTx and 
oxLDL (p<0.001) treatment on DCs also significantly increased the expression levels of 
CD86 compared to untreated DCs (Figure 3.9). Figure 3.10 shows oxLDL (p<0.001) and 
combination of PTx and oxLDL (p<0.01) treatment on DCs significantly increased the 
expression levels of MHC class II. The expression levels of MHC class II on oxLDL-treated 
DCs significantly higher compared to PTx-treated DCs (p<0.001) and PTx-oxLDL-treated 
DCs (p<0.05) respectively.
Levels of IL-6 and TGF-P secreted by DCs were detected after 24 hours treatment with 
oxLDL, PTx or the combination of both (Figure 3.11). PTx and the combination of oxLDL 
and PTx-treated DCs significantly increased the secretion of IL-6 compared to untreated DCs 
(p<0.001). OxLDL-treated DCs also significantly increased the secretion of IL-6 (p<0.001) in 
contrast with the low levels of IL-6 induced by the treatment with PTx and combination of 
both treatments on DCs (p<0.001). Similarly, treatment with oxLDL or with the combination 
of PTx and oxLDL on DCs significantly induced the secretion TGF-P compared to untreated 
DCs (p<0.01). In addition, PTx-treated DCs significantly increased the secretion of TGF-p 
compared to untreated DCs (p<0.001) and this effect was also significantly higher than that 
of oxLDL alone or when the combination of both were used (p<0.001).
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Figure 3.8 The effect of oxLDL, PTx and a combination of both on DCs-expressing CD40.
BMDC were cultured In the presence of oxLDL, PTx or in a combination of both for 24 hours. Cells 
were then directly stained with DCs surface marker, CD40 (FITC) for flow cytometry analysis. 
Representative dot plots for the analysis are shown: A. Untreated DCs B. OxLDL-treated DCs C. PTx- 
treated DCs D. PTx-oxLDL-treated DCs Graph shows MFI of CD11b*CD11c^ expressing CD40 (E). 
Values represent the mean + SD. The experiment was performed three times. (***P < 0.001).
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Figure 3.9 The effect of oxLDL, PTx and a combination of both on DCs-expressing CD86.
BMDC were cultured in the presence of oxLDL, PTx or in a combination of both for 24 hours. Cells 
were then directly stained with DCs surface marker, CD86 (FITC) for flow cytometry analysis. 
Representative dot plots for the analysis are shown; A. Untreated DCs B. OxLDL-treated DCs C. PTx- 
treated DCs D. PTx-oxLDL-treated DCs Graph shows MFI of CD11b*CD11c^ expressing CD86 (E). 
Values represent the mean + SD. The experiment was performed three times. (**P < 0.01; ***P < 
0 .001).
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Figure 3.10 The effect of oxLDL, PTx and a combination of both on DCs-expressing MHC II.
BMDC were cultured in the presence of oxLDL, PTx or In a combination of both for 24 hours. Cells 
were then directly stained with DCs surface marker, MHC II (FITC) for flow cytometry analysis. 
Representative dot plots for the analysis are shown: A. Untreated DCs B. OxLDL-treated DCs C. PTx- 
treated DCs D. PTx-oxLDL-treated DCs Graph shows MFI of CD11b^CD11c* expressing MHC II (E). 
Values represent the mean + SD. The experiment was performed three times. {*P < 0.05; **P < 0.01; 
***P< 0.001).
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Figure 3.11 The effect of oxLDL, PTx and a combination of both on IL-6 and TGF-p secretion by 
DCs. Levels of IL-6 (A) and TGF-p (B) were detected in the supernatant of oxLDL, PTx and 
combination of oxLDL and PTx-treated DCs after 24 hours by using ELISA analysis. Panel A show 
the standard curve for IL-6 range from 4 pg/ml to 500 pg/ml and graph represents the concentration of 
IL-6 in the supernatant after 24 hours. Panel B show the TGF-p standard curve range from 60 pg/ml 
to 8 ng/ml and graph represents the TGF-p levels after 24 hours.The values represent the mean + 
SD. The experiment was performed three times in duplicate (**P < 0.01; ***P < 0.0001).
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3.5.2 OxLDL and PTx-treated DCs stimulate Thl7 cell differentiation in vitro
Many reports have shown the regulatoiy role of DCs in Th cell differentiation (Banchereau 
1998; Rissoan 1999). In the current study, we used oxLDL as an antigen together with PTx to 
convert immature DCs into mature cells. Mature DCs were then co-cultured with CD4^ T- 
cells in four different conditions to assess the differentiation of Thl7 cells using flow 
cytometry.
3.5.2.1 CD4  ^T-cells co-culture with oxLDL and PTx-treated DCs
IL-6 and TGF-p are key factors for the differentiation of Thl7 cells in vitro. In order to 
determine the effect of IL-6 and TGF-P secreted by mature DCs on the stimulation of Thl7 
cells, CD4^ T-cells were co-cultured with untreated DCs as controls, oxLDL-treated DCs, 
PTx-treated DCs and a combination of both oxLDL and PTx-treated DCs for 3 days. Thl7 
cells were determined based on the MFI of IL-17A^ and IL-17F^ expression on both 
CD4^CD25' expressing cells and CD4^0Ryt^ expressing cells using flow cytometry 
analysis.
a) OxLDL, PTx and a combination of oxLDL and PTx-treated DCs did not increased 
IL-17A^ and IL-17F^ expression on CD4 CD25  ^expressing cells
Figure 3.12E shows that oxLDL, PTx and combination of oxLDL and PTx-treated DCs did 
not significantly increased IL-17A^ expression on CD4^CD25‘ expressing cells after co- 
cultured with CD4^ compared to control.
An increase of IL-17F^ expression on CD4^CD25" expressing cells was also observed in all 
treated DCs compared to the control, but this was not statistically significant (Figure 3.12F).
b) OxLDL, PTx and combination of botb-treated DCs did not increased IL-17A^ and 
IL-17F^ expression on CD4'*KORyt^  expressing cells
An increased of IL-17A^ expression on CD4^0Ryt^ expressing cells was observed when 
CD4^ T-cells co-cultured with oxLDL, PTx and combination of PTx and oxLDL-treated DCs 
but this was not statistically different (Figure 3.13E).
No significant increased of IL-17F^ expression on CD4^0Ryt^ expressing cells was also 
observed when CD4^ T-cells co-cultured with oxLDL, PTx and combination with oxLDL 
and PTx-treated DCs compared to control (Figure 3.13F).
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Figure 3.12 Effect of oxLDL, PTx and a combination of both on Th17 cell differentiation. CD4* 
T-cells were co-cultured with oxLDL, PTx and combination of both treated BMDC for 3 days. At day 3, 
the cells were re-stimulated with PMA and ionomycin for 5 hours in the presence of monensin. The 
MFI of (L-17A  ^ and IL-17F^ expression on CD4^CD25‘ expressing cells were determined by flow 
cytometry analysis and representative dot plots and histogram of MFI are shown: A. CD4  ^T-cells co- 
cultured with untreated DCs B. CD4  ^T-cells co-cultured with oxLDL-treated DCs C. CD4* T-cells co- 
cultured with PTx-treated DCs D. CD4* T-cells co-cultured with PTx-oxLDL-treated DCs. The MFI for 
IL-17A^ expression on CD4*CD25' expressing cells (E) and IL-17F* expression on CD4"^ CD25 
expressing cells (F) were represented as a bar graph. Values are represent as the mean + SD. (n=3).
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Figure 3.13 Effect of oxLDL, PTx and a combination of both on Th17 ceil differentiation. CD4* 
T-cells were co-cultured with oxLDL, PTx and combination of both treated BMDC for 3 days. At day 3, 
the cells were re-stimulated with PMA and ionomycin for 5 hours in the presence of monensin. The 
MFI of IL-17A* and IL-17F* expression on CD4*R0Ryf^  expressing cells were determined by flow 
cytometry analysis and representative dot plots and histogram of MFI are shown: A. CD4  ^T-cells co- 
cultured with untreated DCs B. CD4  ^T-cells co-cultured with oxLDL-treated DCs C. CD4  ^T-cells co- 
cultured with PTx-treated DCs D. CD4  ^T-cells co-cultured with PTx-oxLDL-treated DCs. The MFI for 
IL-17A* expression on CD4*R0Ryt* expressing cells (E) and IL-17F* expression on CD4*R0Ryt* 
expressing cells (F) were represented as a bar graph. Values are represent as the mean + SD. (n=3).
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3.S.2.2 CD4  ^T-cell co-cultured with oxLDL and PTx-treated DC with addition of IL-6 
and TGF-P
Human atherosclerotic plaques are composed of blood-home inflammatory and immune 
cells, such as macrophages and T-cells, as wells as vascular EC, SMCs, extracellular matrix, 
lipids and acellular lipid-rich debris. These cells may secrete IL-6 and TGF-p as signs of 
activation. In order to determine the effect of IL-6 and TGF-P secreted by oxLDL-loaded 
DCs and other cell sources during atherogenesis on the differentiation of Thl7 cells, purified 
CD4^ T-cells were co-cultured with non-treated DCs as a control, oxLDL-loaded DCs, PTx- 
loaded DCs and combination of oxLDL and PTx-loaded DCs in the presence of exogenous 
IL-6 and TGF-p for 3 days. Flow cytometry analysis was carried out to determine the 
differentiation of Thl7 cells following all the treatments based on MFI of IL-17A^ and IL- 
17F  ^expression on both CD4^CD25" expressing cells and CD4^0Ryt^ expressing cells.
a) OxLDL, PTx and combination of oxLDL and PTx-treated DCs did not increased IL- 
17A  ^and BL-17F  ^expression on CD4 CD25 expressing cells
As shown in Figure 3.14E, the expression of IL-17A^ on CD4^CD25" expressing cells did not 
significantly increased after co-culture of CD4^ T-cells with oxLDL, PTx and combination of 
PTx and oxLDL-treated DCs under influence of exogenous IL-6 and TGF-P compared to 
control.
CD4^ T-cells co-cultured with oxLDL, PTx and combination of PTx and oxLDL-treated DCs 
in the presence of IL-6 and TGF-P also did not increased the expression of IL-17F^ on 
CD4^CD25' expressing cells when compared to control (Figure 3.14F).
b) OxLDL, PTx and combination of PTx and oxLDL-treated DCs did not Increased the 
expression of IL-17A‘*' and IL-17F^ on CD4^0Ryt^ expressing cells
The expression of IL-17A^ on CD4‘^ 0Ryt^ expressing cells did not significantly increased 
when CD4^ T-cells were co-cultured with oxLDL, PTx and combination of PTx and oxLDL- 
treated DCs in the presence of IL-6 and TGF-P compared to control (Figure 3.15E). 
Similarly, all the treatments also did not significantly increase the expression of IL-17F^ on 
CD4^0Ryt^ expressing cells compared to control (Figure 3.15F).
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Figure 3.14 Effect of oxLDL, PTx and a combination of both on Th17 cell differentiation. CD4"^  
T-cells were co-cultured with oxLDL, PTx and combination of both treated BMDC for 3 days in the 
presence of exogenous IL-6 and TGF-p. At day 3, the cells were re-stimulated with PMA and 
ionomycin for 5 hours in the presence of monensin. The MFI of IL-IZA"" and IL-17F* expression on 
CD4^CD25' expressing cells were determined by flow cytometry analysis and representative dot plots 
and histogram of MFI are shown; A. CD4  ^T-cells co-cultured with untreated DCs B. CD4* T-cells co­
cultured with oxLDL-treated DCs C. CD4  ^T-cells co-cultured with PTx-treated DCs D. CD4"^  T-cells 
co-cultured with PTx-oxLDL-treated DCs. The MFI for IL-17A^ expression on CD4^CD25 expressing 
cells (E) and IL-17F* expression on CD4^CD25‘ expressing cells (F) were represented as a bar graph. 
Values are represent as the mean + SD. (n=3).
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Figure 3.15 Effect o f oxLDL, PTx and a combination of both on Th17 cell differentiation. CD4  ^
T-cells were co-cultured with oxLDL, PTx and combination of both treated BMDC for 3 days in the 
presence of exogenous IL-6 and TGF-p. At day 3, the cells were re-stimulated with PMA and 
ionomycin for 5 hours In the presence of monensin. The MFI of IL-17A^ and IL-17F* expression on 
CD4*R0Ryt^  expressing cells were determined by flow cytometry analysis and representative dot 
plots and histogram of MFI are shown: A. CD4* T-cells co-cultured with untreated DCs B. CD4* T- 
cells co-cultured with oxLDL-treated DCs C. CD4* T-cells co-cultured with PTx-treated DCs D. CD4* 
T-cells co-cultured with PTx-oxLDL-treated DCs. The MFI for IL-17A* expression on CD4^R0Ryt^  
expressing cells (E) and IL-17F* expression on CD4*R0Ryt* expressing cells (F) were represented as 
a bar graph. Values are represent as the mean + SD. (n=3).
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3.S.2.3 CD4  ^ T-cells co-cultured with oxLDL and PTx-treated DCs which had 
previously been inactivated with Mitomycin C (MMC)
The activation of DCs by oxLDL elicited IL-6 and TGF-p, which may guarantee optimal 
support for Thl7 cell differentiation in vitro. Therefore, inhibition of DCs protein synthesis 
may consequently suppress cell proliferation. In order to determine the effect of possible 
inhibition of IL-6 and TGF-p secreted by mature DCs on the differentiation of Thl7 cells, we 
incubated oxLDL and PTx-treated DCs for 24 hours with MMC for 45 min, then washed 
thoroughly and subsequently cultured with CD4^ T-cells for 3 days. Flow cytometry analysis 
was carried out to determine the Thl7 cell differentiation following all the treatments based 
on MFI of IL-17A^ and IL-17F^ expression on both CD4^CD25* expressing ceUs and 
CD4^0Ryt^ expressing cells.
a) No significant changes of IL-17A^ and IL-17F^ expression on CD4 CD25 expressing 
cells
Flow cytometry analysis showed no significant increased of IL-17A^ and IL-17F^ expression 
on CD4^CD25" expressing cells when CD4^ T-cells co-cultured with oxLDL, PTx and 
combination of both-treated DCs which previously treated with MMC compared to control 
(Figure 3.16E and 3.16F).
b) No changes of IL-17A'^  and IL-ITF*” expression on CD4'*RORyt^  expressing cells
No changes of IL-17A^ and IL-17F^ expression on CD4^0Ryt^ expressing when CD4^ T- 
cells co-cultured with MMC inactivated DCs treated with oxLDL, and combination of 
oxLDL and PTx compared to control (Figure 3.17E and 3.17F).
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Figure 3.16 Effect of oxLDL, PTx and a combination of both on Th17 celi differentiation. OxLDL, 
PTx and combination of both treated BMDC for 24 hours were inactivated with MMC, then were 
washed extensively and were co-cultured with CD4  ^T-cells for 3 days. At day 3, the cells were re­
stimulated with PMA and ionomycin for 5 hours in the presence of monensin. The MFI of IL-17A^ and 
IL-17F^ expression on CD4^CD25‘ expressing cells were determined by flow cytometry analysis and 
representative dot plots and histogram of MFI are shown: A. CD4‘" T-cells co-cultured with untreated 
DCs B. CD4  ^T-cells co-cultured with oxLDL-treated DCs C. CD4  ^T-cells co-cultured with PTx-treated 
DCs D. CD4"^  T-cells co-cultured with PTx-oxLDL-treated DCs. The MFI for IL-17A  ^ expression on 
CD4*CD25 expressing cells (E) and IL-17F^ expression on CD4*CD25 expressing cells (F) were 
represented as a bar graph. Values are represent as the mean + SD. (n=3).
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Figure 3.17 Effect of oxLDL, PTx and a combination of both on Th17 ceil differentiation. OxLDL, 
PTx and combination of both treated BMDC for 24 hours were inactivated with MMC, then were 
washed extensively and were co-cultured with CD4  ^T-cells for 3 days. At day 3, the cells were re- 
stimulated with PMA and ionomycin for 5 hours in the presence of monensin. The MFI of IL-17A^ and 
IL-17F^ expression on CD4^R0Ryt* expressing cells were determined by flow cytometry analysis and 
representative dot plots and histogram of MFI are shown: A. CD4"' T-cells co-cultured with untreated 
DCs B. CD4  ^T-cells co-cultured with oxLDL-treated DCs C. CD4* T-cells co-cultured with PTx-treated 
DCs D. CD4"^  T-cells co-cultured with PTx-oxLDL-treated DCs. The MFI for IL-17A"^  expression on 
CD4"^R0Ryt* expressing cells (E) and IL-17F* expression on CD4*RORyt"^  expressing cells (F) were 
represented as a bar graph. Values are represent as the mean + SD. (n=3).
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3.S.2.4 CD 4^ T -cells c o -c u ltu re d  w ith  oxL D L  a n d  P T x -tre a te d  D C s w h ich  h a d  
p rev io u s ly  been  in ac tiv a ted  b y  M M C  a n d  a d d itio n  o f  DL-6 a n d  T G F -p
The abrogation of IL-6 and TGF-p secretion by mature DCs may affect Thl7 cells induction 
in vitro. However, the presence of these cytokines from other cellular sources in the 
atherosclerotic plaque may overturn this effect and drive Thl7 cell differentiation. In order to 
determine the effect of exogenous IL-6 and TGF-p secreted by other cellular sources on the 
differentiation of Thl7 cells in vitro, DCs treated with oxLDL, PTx or with the combination 
of both for 24 hours were incubated with MMC for 45 min, then washed thoroughly and 
subsequently cultured with CD4^ T-cells for 3 days in the presence of exogenous IL-6 and 
TGF-p. Thl7 cells population was determined based on MFI of IL-17A^ and IL-17F^ 
expression on both CD4^CD25" expressing cells and CD4^0Ryt^ expressing cells by using 
flow cytometry analysis.
a) N o changes o f  IL -17A ^ a n d  IL -17F ^ ex p ressio n  on  C D 4 C D 25 ex p ress in g  cells
The inactivation of oxLDL, PTx and combination of oxLDL and PTx-treated DCs with MMC 
followed by co-cultured with CD4^ T-cells with the addition of external sources of IL-6 and 
TGF-p did not significantly increased the expression of IL-17 A^ and IL-17F^ on CD4^CD25‘ 
expressing cells compared to control (Figure 3.18E and 3.18F).
b ) N o changes o f  IL -17A ^ a n d  IL -IT F ^  ex p ressio n  o n  CD4'lRORyt'^ ex p ress in g  cells
Figure 3.19E and 3.19F show the inactivation of oxLDL-, PTx- and combination of oxLDL 
and PTx-treated DCs with MMC followed by co-culturing with CD4^ T-cells under influence 
of external sources of IL-6 and TGF-P did not significantly increased the expression of IL- 
17A^ and IL-17F^ on CD4^0Ryt^ expressing cells compared to control.
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Figure 3.18 Effect of oxLDL, PTx and a combination of both on Th17 ceii differentiation. OxLDL, 
PTx and combination of both treated BMDC for 24 hours were inactivated with MMC, then were 
washed extensively and were cultured with CD4* T-cells for 3 days in the presence of exogenous IL-6 
and TGF-p. At day 3, the cells were re-stimulated with PMA and Ionomycin for 5 hours in the 
presence of monensin. The MFI of IL-17A  ^and IL-17F'" expression on CD4"^CD25' expressing cells 
were determined by flow cytometry analysis and representative dot plots and histogram of MFI are 
shown: A. CD4* T-cells co-cultured with untreated DCs B. CD4^ T-cells co-cultured with oxLDL- 
treated DCs C. CD4* T-cells co-cultured with PTx-treated DCs D. CD4^ T-cells co-cultured with PTx- 
oxLDL-treated DCs. The MFI for IL-17A  ^expression on CD4^CD25' expressing cells (E) and IL-17F^ 
expression on CD4*CD25' expressing cells (F) were represented as a bar graph. Values are 
represent as the mean + SD. (n=3).
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Figure 3.19 Effect of oxLDL, PTx and a combination of both on Th17 cell differentiation. OxLDL, 
PTx and combination of both treated BMDC for 24 hours were Inactivated with MMC, then were 
washed extensively and were co-cultured with CD4* T-cells for 3 days in the presence of exogenous 
IL-6 and TGF-p. At day 3, the cells were re-stimulated with PMA and ionomycin for 5 hours in the 
presence of monensin. The MFI of IL-17A* and IL-17F* expression on CD4*R0Ryt* expressing cells 
were determined by flow cytometry analysis and representative dot plots and histogram of MFI are 
shown: A. CD4^ T-cells co-cultured with untreated DCs B. CD4^ T-cells co-cultured with oxLDL- 
treated DCs C. CD4* T-cells co-cultured with PTx-treated DCs D. CD4* T-cells co-cultured with PTx- 
oxLDL-treated DCs. The MFI for IL-17A* expression on CD4*R0Ryt^ expressing cells (E) and IL-17F^ 
expression on CD4^R0Ryt^ expressing cells (F) were represented as a bar graph. Values are 
represent as the mean + SD. (n=3).
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3.5.3 T h e  effect o f  exogenous IL -6  a n d  T G F -P , M M C  in h ib itio n  a n d  b o th  on th e  
d iffe re n tia tio n  o f  T h l7  cells in vitro
The atherogenic stimuli, oxLDL plays a key role in the development of atherosclerosis. In the 
atherosclerotic plaque, oxLDL induces maturation of DCs which stimulate the differentiation 
of naïve CD4^ T cells into Thl7 cells. Therefore, we investigated the effect of exogenous IL- 
6 and TGF-P, MMC inhibition and both on the differentiation of Thl7 cells when CD4^ T 
cells co-cultured in all conditions of oxLDL-treated DCs.
The results showed that the addition of exogenous IL-6 and TGF-p when CD4^ T-cells co- 
cultured with oxLDL-treated DCs increased IL-17A^ expression on CD4^CD25" expressing 
cells compared to without these exogenous cytokines, but it was not statistically significant. 
The expression of IL-17A^ on CD4^CD25’ expressing cells derived from this condition 
higher compared with MMC-oxLDL-treated DCs with or without exogenous IL-6 and TGF-p 
but not statistically significant. Likewise, CD4^ T-cells co-cultured with oxLDL-treated DCs 
increased IL-17F^ expression on CD4^CD25" expressing cells and frirther upward trend after 
the addition of the exogenous IL-6 and TGF-p, but not statistically significant. In contrast, 
the expression of IL-17F^ on CD4^CD25" expressing cells decreased following co-cultured of 
CD4^ T-cells with MMC-oxLDL-treated DCs and further reduced when addition of 
exogenous IL-6 and TGF-p, but did not show any significant different.
The expression of IL-17A^ expression on CD4^0Ryt^ expressing cells noted to be 
significantly higher when CD4^ T-cells co-cultured with oxLDL-treated DCs under influence 
of exogenous IL-6 and TGF-p compared when CD4^ T-cells co-cultured with MMC oxLDL- 
treated DCs with or without exogenous IL-6 and TGF-P (p<0.05). On the other hand, the 
exogenous IL-6 and TGF-p did not have any effect on IL-17F^ expression on CD4^ RORyt*^  
expressing cells in all conditions.
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Figure 3.20 The effect of exogenous IL-6 and TGF-p, MMC inhibition and both on the 
differentiation of Th17 cells in vitro. CD4* T-cells were co-cultured with oxLDL-treated DCs with or 
without exogenous IL-6 and TGF-p or CD4^ T-cells were co-cultured with MMC inactivated oxLDL- 
treated DCs with or without exogenous IL-6 and TGF-p. The graphs represent MFI for: A. CD4*CD25‘ 
IL-17A* expressing cells B. CD4*CD25 IL-17F^ expressing cells C. CD4^RORyt^lL-17A^ expressing 
cells D. CD4'"RORyt^lL-17F^ expressing cells. Values are represent as the mean + SD. (n=3) (*P< 
0.05).
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3.6 Discussion
Thl7 cells have been identified as a new subset of T helper cells involved in the pathogenesis 
of atherosclerosis (Cheng, Yu et ah 2008). To date, the differentiation of murine Thl7 cells 
by DCs is well documented through the various findings of in vitro and in vivo studies. 
However, there are no reports on how Thl7 cells are differentiated fi*om naïve precursors in 
the atherosclerotic plaques. The current study focused on the source of IL-6 and TGF-P in the 
atherosclerotic plaques, as these two key cytokines are involved in mouse Thl7 cell 
differentiation (Bettelli, Carrier et al 2006; Mangan 2006; Veldhoen 2006).
DCs play a central role in orchestrating the innate and adaptive immune responses, and the 
maturation of DCs is a critical step for their fimction in immune responses. DCs were 
generated by culturing bone marrow for 6 to 8 days under influence of GM-CSF and IL-4. 
GM-CSF has been shown to act by inducing DCs progenitor expansion as well as promoting 
differentiation and survival of DCs (Markowicz 1990). IL-4 plays a role in suppressing 
macrophage colony formation in addition to its role in promoting DCs growth and maturation 
from monocytes (Romani 1994). Treatment with GM-CSF and IL-4 leads to the formation of 
immature DCs phenotype which display inefficient antigen presentation (Zou 2002). DCs 
was defined by the expression of both CD 11b and CDllc (Hammad 2008). CDllb^CDllc^ 
DCs also known as myeloid DCs (Zamani 2007). Multiple elements in the plaque may affect 
DCs maturation and their pro-inflammatory roles. Maturation boosts their capability to 
present antigens to T-cells efficiently and is mediated by up-regulation of co-stimulatory 
molecules such as CD86 and CD40. Co-stimulation by the ligands CD80/CD86 and its 
receptors CD28 on T-cells is required for T-cell stimulation (Carreno 2002). In the current 
study, an atherogenic stimulus, oxLDL was used as antigen to convert the immature DCs to 
mature DCs, and subsequently to activate CD4^ T-cells differentiation into Thl7 cells. In 
addition, PTx was used as a surrogate (positive control) indicator for triggering DCs 
maturation.
Our study showed that oxLDL and the combination of both oxLDL and PTx induced the 
maturation of DCs, accompanied by an increased phenotypical expression of co-stimulatory 
and maturation markers such as CD86 (B7-2), CD40 and MHC class II. These changes are 
associated with the ability of DCs to become fully competent to activate T-cells. Several 
studies have demonstrated that oxLDL causes similar effects on DCs, including a higher 
expression of co-stimulatory molecules and increased capability of T-cells stimulation
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(Perrin-Cocon 2001; Alderman 2002). Both studies showed an increase in DCs function 
through DC-induced T-cell proliferation or through an increased secretion of IL-2 in the 
presence of oxLDL. Interestingly, Coûtant et al (2004) showed that the maturation of DCs 
induced by oxLDL but can be inhibited by native LDL and lipid emulsions. High 
concentrations (50-100 pg/ml) of oxLDL, but not LDL, lead to up-regulation of CD83, 
CCR7, HLA-DR and CD86 levels (Zaguri, Verbovetski et al 2007). The upregulation of 
maturation markers expressed by DCs can initiate the activation of adaptive immune 
responses.
Recently, T-cell activation in atherosclerotic plaques has been attributed to DCs due to the 
presence of a large number of them within atherosclerotic plaques that can physically engage 
T-cells, required for stimulation and activation of T-cells (Inaba 1986). Cytokines produced 
by DCs can trigger T-cell differentiation. For example, Thl cells can be induced by DC- 
derived IL-12 production upon recognition of CpG via TLR-9 or detection of LPS via TLR-4 
(Gi 2009). In addition, IFNa produced by plasmacytoid DCs after capturing viral DNA via 
TLR-7 can induce the conversion of naïve CD4^ T-cells into Thl cells (Ito 2002; Trinchieri 
2003). Here, we demonstrated that oxLDL, PTx and combination of both treated DCs 
induced the secretion of IL-6 and TGF-p. IL-6 is an important factor that can switch immune 
responses ranging from the induction ofFoxp3^ Treg to pathogenic Thl 7 cells in vivo (Korn, 
Mitsdoerffer et a l 2008). Accumulative evidences have shown that single naïve T-cells can 
differentiate into both of Treg cells and Thl 7 cells (Zhou 2008). TGF-p is required to induce 
the expression of both Foxp3 and RORyt, the master transcription factor for Treg and Thl 7 
cells respectively (Manel 2008). However, TGF-p alone enhances the function of Foxp3 but 
suppress the function of RORyt (Manel 2008). Only when additional signaling of pro- 
inflammatory cytokines such as IL-6 or IL-21 is available, then the TGF-P-mediated 
fimctional inhibition of RORyt removed, and Thl 7 cells are induced (Korn, Mitsdoerffer et 
al 2008). Our results are also consistent with these previous studies showing that DCs are 
capable of producing IL-6 and TGF-p themselves (Veldhoen 2006). IL-23 and IL-ip were 
not measured in the supernatant of oxLDL and PTx-treated DCs because these two cytokines 
are only involved in human Thl 7 cell differentiation and not applicable in mouse Thl 7 cells 
which was our main focus (Acosta-Rodriguez 2007; Chen, Tato et al 2007). IL-23 is not 
crucial for murine Thl 7 cell differentiation, but only required to amplify or stabilise Thl 7 
cells phenotype (Aggarwal S 2003). On the other hand, IL-lp and TNFa were also found to
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amplify the Thl 7 response induced by TGF-p and IL-6 (Bettelli, Carrier et ah 2006; Mangan 
2006; Veldhoen 2006).
Different results were observed on the effect of PTx on expression of DCs maturation 
markers and cytokine secretion. PTx did not significantly increase DCs maturation markers, 
and the combination of oxLDL and PTx seem to halt the expression of the DCs surface 
markers rather than synergizing it. In addition, PTx-treated DCs significantly increased IL-6 
and TGF-p secretion but the secretion of these cytokines when treated together with oxLDL 
was not increased further. This showed that PTx and oxLDL could not work in concert in 
boosting the maturation of DCs and its cytokine secretion. The variation between oxLDL and 
PTx in terms of the nature of their antigenicity such as absorbability and binding power may 
affect these results.
To assess the synthesis of IL-6 and TGF-p by DCs treated with oxLDL, PTx or the 
combination of both and their effect on Thl 7 cell differentiation from CD4^ T-cells, we co- 
cultured treated DCs with CD4^ T-cells for 3 days based on previous study by Chen, Howard 
et al (2007). Our results showed that oxLDL, PTx and combination of both oxLDL and PTx- 
treated DCs co-cultured with CD4^ T-cells increased the expression of IL-17A^ and IL-17 A  ^
on CD4^CD25‘ expressing cells compared to the control, but did not statistically different. 
Likewise, we also observed an increase of IL-17A^ and IL-17F^ expression on CD4^0Ryt^ 
expressing cells after co-cultured of CD4^ T-cells with oxLDL, PTx and combination of 
both-treated DCs but did not showed any significant different. On the other hand, CD4^ T- 
cells co-cultured with oxLDL, PTx and combination of both-treated DCs which previously 
treated with MMC, failed to show significant increase of IL-17A^ and IL-17F^ expression on 
both CD4^CD25" expressing cells and CD4^0Ryt^ expressing cells. Furthermore, the 
addition of exogenous IL-6 and TGF-p in co-culture experiment of CD4^ T-cells with 
oxLDL, PTx and combination of both increased of IL-17A^ and IL-17F^ expression on both 
CD4^CD25‘ expressing cells and CD4^0Ryt^ expressing cells but also did not statistically 
significant. The addition of exogenous IL-6 and TGF-p in co-culture experiment of CD4^ T 
cells with oxLDL, PTx and combination of both-treated DCs which previously treated with 
MMC also did not significantly increased of IL-17A^ and IL-17F^ expression on both 
CD4^CD25" expressing cells and CD4’^ 0Ryt^ expressing cells. These results raised the 
possibility that IL-6 secreted by treated DCs or exogenous IL-6 may not enough to induce 
differentiation of CD4^ T-cells into Thl 7 cells. This speculation was supported by the finding
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from Bhattacarya et a l (2011) who showed that naïve CD4^ T cells co-cultured with control- 
spleen derived DCs, GM-CSF-spleen derived DCs and BMDC without exogenous antigen 
did not increased Thl 7 cells population. Their RT-PCR results also clearly showed that 
BMDC produce far less IL-6 compared to spleen derived DCs. Besides that, our results also 
showed that the concentration level of TGF-p detected following oxLDL, PTx and 
combination of both-treated DCs was higher compared to IL-6 level. This condition may lead 
to the differentiation of high number of Treg cells rather than Thl 7 cells. In support our 
speculation, Zhou et al (2008) showed that at low concentration, TGF-P would synergise 
with IL-6 or IL-21, favouring Thl 7 cell differentiation, whereas high concentration of TGF-p 
would suppress IL-23R expression and favour Treg cells. The possible differentiation of Treg 
cells in the culture may inhibit the differentiation of Thl 7 cells. However, the effect of 
exogenous IL-6 and TGF-p, MMC inhibition and both were fiirther explored on oxLDL- 
treated DCs. The results showed that the addition of exogenous IL-6 and TGF-p when CD4^ 
T-cells co-cultured with oxLDL-treated DCs significantly increased the expression of IL- 
17A^ on CD4^0Ryt^ expressing cells compared when CD4^ T-cells co-cultured with 
oxLDL-treated DCs which previously were inactivated with MMC with or without 
exogenous IL-6 and TGF-p. The results may suggest that the addition of high concentration 
of IL-6 than TGF-p in the culture set up may alter the concentration of these cytokine which 
in favor of Thl 7 cell differentiation. Furthermore, in agreement with our finding that MMC 
treatment on oxLDL-treated DCs reduce Thl 7 cells, a previous finding showed CD4^ T-cells 
co-cultured with LPS stimulated MMC-treated BMDC under influence of Thl 7 cells 
polarization cytokines significantly reduced CD 4^-17^ cells but increased CD4‘lFNy‘^  cells 
(Bouguermouh, Fortin et al 2009). Furthermore, the low expression of MHC class II and co­
stimulator, CD80/86 on MMC treated mature DCs as previously showed by Temess et a l  
(2008) may responsible for the reduction of Thl 7 cells.
There were several limitations of our study. The level of IL-6 secreted by PTx and a 
combination of PTx and oxLDL-treated DCs were above the linear range of standard curve 
which indicated their concentration in the samples is too high. There was no indication 
provided demonstrating that MMC treatment indeed blocked IL-6 and TGF-p secretion by 
DCs because these cytokine levels were not measured by ELISA in 3-days supernatants. 
Linkage between low levels of MHC class II and co-stimulatoiy molecules could not be 
explored as the expressions of maturation markers on MMC-oxLDL-treated DCs were not
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measured. Larger number of events acquired for DCs maturation markers determination and 
Thl 7 cells are needed in order to obtain reproducible results.
In conclusions, our data suggested that oxLDL induced the maturation of DCs by increasing 
the expression of maturation markers, which were required for T-cells activation. The higher 
level of TGF-p secretion than IL-6 following oxLDL-treated DCs did not favor Thl 7 cell 
differentiation from CD4^ T-cells. The combination of exogenous IL-6 and TGF-p and the 
same said cytokines secreted by oxLDL-treated DCs increased the population of Thl 7 cells 
but MMC treatment on oxLDL-treated DCs reduced Thl 7 cells. The subsequent chapter 
demonstrates the role of other intra-plaque cells on the differentiation of Thl 7 cells.
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C H A P T E R  4
S M O O T H  M U S C L E  C E L L -D E R IV E D  C Y T O K IN E S  D R IV E  T H 1 7  C E L L S
D IF F E R E N T IA T IO N  IN  VITRO
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4.1 S m ooth  m uscle  cells (SM C s) in  a th e ro sc le ro s is
4.1.1 S M C s re s id in g  reg ions
SMCs are involved in the atherosclerotic lesion formation, where they migrate into the 
neointima and secrete a wide range of proteins that, among other things, stabilise the fibrous 
cap of the plaque (Lusis 2000; Geng 2002; Owens 2004). A study found that SMCs are 
abundant at sites prone to atherosclerosis development but less are prominent in the regions 
that are resistant to atherosclerosis (Stary HC 1995). The majority of plaque residing SMCs 
are located within the medial layer of the artery vessels. A significant number of these can 
also be found in the intima regions (Doran 2008). Within the intima, SMCs contribute to 
intima thickening, which can be either eccentric or diffuse. Eccentric intima thickening occur 
in the regions where advanced atherosclerotic plaques are observed (Stary 1992; Stary 2000). 
On the other hand, diffiise intima thickening occurs throughout vasculature especially in 
older people probably as part of the normal aging process. Both types of thickening contain 
exclusively SMCs and the proteoglycans that they secrete (Stary 1992).
4.1.2 P h en o ty p ic  fe a tu re s  o f  S M C s w ith in  a th e ro sc le ro tic  p laq u es
Intima SMCs are significantly different from medial SMCs because they have unique 
atherogenic properties that make them a fertile ground for triggering atherosclerotic plaque 
development (Mosse 1985). Human medial SMCs contain mainly “contractile SMC” that 
express high levels of smooth muscle cell myosin heavy chain (SM-MHC) or smooth muscle 
cell a-actin (SM-aA), whereas intima SMCs are populated by “synthetic SMC”. Synthetic 
SMCs express low levels of SM-MHC or SM-aA but have a higher proliferative index and 
thus have greater synthetic capacity for extracellular matrix, proteases and cytokines 
(Campbell 1994; Worth 2001; Owens 2004). In vitro studies have shown that rat and mouse 
SMCs can switch between the contractile and synthetic phenotypic states in response to 
various atherogenic stimuli, including extracellular matrix components (Thyberg 1994), 
cytokines such as TGF-P (Hautmann 1997; Li 1997), shear stress (Reusch 1996), reactive 
oxygen species (Su 2001), and lipids (Pidkovka 2007). Synthetic SMCs migrate and 
proliferate more promptly and are able to synthesize up to 25 to 46 times more collagen than 
contractile SMCs (Ang 1990; Owens 2004). In addition, they also express a greater amount 
of VLDL, LDL and scavenger receptors that facilitate the uptake of lipids and the formation 
of foam cells (Campbell 1994; Rong 2003). Therefore, the conversion into synthetic SMCs 
increases their pathogenic roles.
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4.1.3 P a th o g en ic  ro les o f  SM C s in  a th e ro sc le ro s is
4 .1 3 .1  R e te n tio n  o f  m onocy tes a n d  m ac ro p h ag e s
SMCs play important roles in retaining monocytes and macrophages within atherosclerotic 
lesions. The expression of adhesion molecules, VCAM-1 and ICAM-1 on SMCs mediates the 
migration of monocytes from the blood stream into the intima where they differentiate into 
macrophages (Doran 2008). VCAM-1 has been shown to be expressed in the intima by SMCs 
within atherosclerotic coronaries, aorta and carotid arteries both in mice and in humans but 
has not been detected in healthy medial SMCs (O’Brien 1993; Jang 1994). In addition, 
detection of VCAM-1 on SMCs within lesion-prone areas of the aorta apoE'^ * mice and the 
expression of VCAM-1 in the medial SMCs before the mononuclear cell infiltration suggests 
that these events occur in early atherosclerosis stages (Braun 1999). ICAM-1 is also 
expressed by SMCs in the intima of the lesion but it is upregulated before mononuclear 
infiltration. Conversely, ICAM-1 expression is not found in the healthy aorta (Endres 1997).
The interaction between fractalkine ligand (CX3CL1) expressed by SMCs and its receptor 
CX3CR1, which is highly expressed by human monocytes following stimulation by oxidized 
lipids, leads to the accumulation of SMCs and monocytes within the vessel wall under 
hyperlipidémie conditions (Barlic 2006). SMCs in healthy arteries do not express fractalkine, 
but this is significantly increased in SMCs that can be found in atherosclerotic lesions (Barlic 
2007).
4.1.4 L ip id  u p ta k e  b y  SM C s
SMCs from human, rat and rabbits express various lipoprotein uptake receptors, such as LDL 
receptor (Ruan 2006), VLDL receptor (Takahashi 2005), CD36 (Matsumoto 2000; Lim 2006) 
scavenger receptor type I and II (Bickel 1992; Matsumoto 2000), and CXCL16/SR-PS0X 
(Wagsater 2004). SMCs derived from rabbits fed a western diet have high levels of scavenger 
receptor (Li 1995). The LDL receptor on SMCs can mediate the uptake of unmodified LDL 
(Ruan 2006), acytylated LDL (Pitas 1990), enzymatically modified LDL (Klouche 2000) and 
chylomicron remnants (Botham 2005). The scavenger receptor CXCL16/SR-PSOX, which is 
detected in atherosclerotic plaques but not in healthy blood vessels, is also linked to the 
uptake of oxLDL by human SMCs (Gronholdt 1998).
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4.1.5 Expression of MHC class H by SMCs
Several studies have shown that SMCs derived from atherosclerotic plaques can express the 
MHC class II antigen, HLA-DR and HLA-DQ (Jonasson 1985; Hansson 1986), which are not 
present in healthy blood vessels but can be induced by the treatment of cultured SMCs with 
IFNy, a pro-athrogenic cytokine secreted by activated T-cells (Hansson 1988; Jonasson 
1988). In post transplant graft atherosclerosis, administration of IFNy induces the expression 
of MHC class I by the graft SMCs (Tellides 2000). In addition, IL-18 has also been shown to 
increase the number of SMCs expressing MHC class II in atherosclerotic lesions of apoE"^ " 
mice (Whitman 2002). IL-18 acts in synergy with IL-12 to induce IFNy production by NK 
cells, T-cells, macrophages and also in SMCs (Gerdes 2002). Therefore, the administration of 
IL-18 in IFNy-null mice did not alter the MHC class II expression (Whitman 2002).
4.1.6 Tbl7 cells and SMCs
The newly discovered IL-17-producing cells, Thl 7 cells, play an important role in various 
immune diseases such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis 
and seem to contribute in atherosclerosis development as well (Weaver, Hatton et a l 2007). 
At the cellular level, tiie Thl 7 related cytokine, IL-17 has been shown to induce a pro- 
inflammatory phenotype of vascular smooth muscle cells (VSMC) by eliciting the release of 
the pro-mflammatory mediators IL-6, CXCL8/10 and CRP involving p38 mitogen activated 
protein kinase (p38MAPK) signalling (Hashmi 2006; Patel DN 2007). In atherosclerotic 
plaques, Thl 7 cell driven cytokines, IL-6 and TGF-P were also secreted by other cell sources 
such as macrophages, DCs, ECs, SMCs and T-cells (Huber 1999; Hansson and Libby 2006). 
The current study hypothesises that IL-6 and TGF-P secreted by oxLDL-treated SMCs in 
atherosclerotic plaques stimulate the differentiation of Thl 7 cells following the engagement 
of CD4^ T-cells with oxLDL-treated DCs, as previously discussed in Chapter 3.
4.2 Aim
To study the effect of intra-plaque source of IL-6 and TGF-p secreted by oxLDL-treated 
SMCs on the differentiation of Thl 7 cells.
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4.3 Objectives
The objectives of research work as described in this chapter are as follows:
1. To determine specific marker of SMCs generated from the aorta of apoE'^’ mice by 
immuno-staining.
2. To assess the cytokine profile secreted by oxLDL-treated SMCs using ELISA.
3. To determine the differentiation of Thl 7 cell by either co-culturing of oxLDL-treated 
SMCs with CD4^ T-cells, or by culturing CD4^ T-cells in the oxLDL-treated SMCs 
supernatant with the presence of anti-CD3 and anti-CD28. We also used the above 
mentioned cultures supplemented with exogenous IL-6 and TGF-p to determine their 
influence on Thl 7 cell differentiation.
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4.4 Materials and methods
4.4.1 A n im als
Six week old of female apoE' '^ mice (strain B6.129P2-Apoetml bred in-house, were 
used. The abdominal aorta and splenocytes were collected at termination for further analysis.
4.4.2 Iso la tio n  o f  SM C s
The aorta was dissected beginning from the aortic arch to the abdominal aorta, and immersed 
in complete RPMI medium. The fats and connecting tissues were removed with fine forceps 
under a stereoscopic microscope. Next, the clean aorta was transferred to a new dish 
containing complete RPMI medium. The aorta was cut into small pieces (approximately 2-3 
mm in size), and subsequently attached to a new dish without medium and placed in the CO2 
incubator for 30 minutes. Finally, 10% FBS in DMEM (Invitrogen, UK) was added gently 
and the cells were placed and left in the incubator for about 10 days/until confluent.
4.4.2.1 P a ssag in g  th e  S M C s
The SMCs were split when they were at approximately 90% confluent. The medium was 
discarded and the cells were washed with sterile Ix PBS. Next, Ix trypsin (Sigma Aldrich, 
UK) was added to the dish, mixed thoroughly and then discarded. The dish was placed in the 
incubator for 5 minutes. Three hundred pi of trypsin inhibitor (Sigma Aldrich, UK) was 
added into the dish to inactivate any remaining trypsin activity. Finally, 1 ml of DMEM 
containing 10% FBS was added and the cells were transferred into the new dish. The dish 
was placed in the incubator to allow the SMCs to grow.
4.4.2.2 C h a ra c te r is a tio n  o f  th e  SM C s
SMCs were cultured on the cover glass in a 24-well plate for one day to allow the cells to 
attach to the cover glass. The cells were washed twice with PBS and then fixed by adding 2 
ml cold methanol per well and incubated at -20°C for 5 minutes. The cells were then washed 
with PBS for 5 minutes. After blocking with 100 pi of blocking buffer (5% mouse serum in 
PBS) for 30 minutes at room temperature, the cells were washed for 5 minutes with PBS. 
Next, 100 pi of 1:200 dilution of mouse SMC-a-actin (Sigma Aldrich, UK) and goat platelet 
endothelial cell adhesion molecule 1 (PECAM-1) (Santa Cruz, UK) were added to the wells 
and incubated overnight at 4°C. After four consecutive washes with PBS, the cells were 
incubated with Alexa 568 anti-mouse and FITC anti-goat IgG antibodies (1:300) at room
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temperature for 40 minutes. The cells were then washed four times with PBS, and 100 pi of 
20 pM of DRAQ5™ (Biostatus, UK) were added. DRAQ5™ is a usefiil agent for the in vitro 
DNA labelling of live or fixed cells. The cells were washed again four times with PBS. A 
drop of FluorSave was added onto the slide and a coverslip was carefully removed from the 
well using forceps and placed on top of the slide. The slide was allowed to dry and then 
sealed with nail varnish around the edges. The slide was viewed using a Zeiss LSM 510 
confocal microscope controlled by LSM 510 Meta software (Carl Zeiss, USA).
4 .4 3  Iso la tio n  o f  n a ïv e  CD 4^ T-cells
CD4^ T-cells isolation was carried out as described in Chapter 2 section 2.2.2.
4.4.4 In vitro cell c u ltu re  1
The SMCs were cultured in the DMEM containing 10% FBS and were treated with 100 
pg/ml of oxLDL for 6, 12 and 24 hours. The supernatant at 24 hours was collected and used 
for further study.
CD4^ T-cells were added in supernatant of non-treated SMC, oxLDL-treated SMCs and 
oxLDL treated SMCs in the presence of anti-CD3 (4 pg/ml) and anti-CD28 (2 pg/ml) with or 
without addition of lL-6 (20 ng/ml) (Peprotech, UK) and TGF-p (2 ng/ml) (Peprotech, UK) 
for 3 days based on previous study by Korn et al (2007). At day 3, the cells were stimulated 
with phorbol 12-myristate-13-acetate (PMA) (50 ng/ml, Fluka, UK) and ionomycin (800 
ng/ml. Sigma Aldrich, UK) for 5 hours in the presence of 2 pM of monensin (eBioscience, 
UK).
4.4.5 In vitro cell c u ltu re  2
The SMCs were cultured in DMEM containing 10% FBS, and were treated with 100 pg/ml 
oxLDL for 24 hours. Then, CD4^ T-cells were co-cultured with untreated SMCs, oxLDL 
treated SMCs and oxLDL treated SMCs supplemented with lL-6 (20 ng/ml) (Peprotech, UK) 
and TGF-p (2 ng/ml) (Peprotech, UK) for 3 days based on previous study by Korn et al 
(2007). At day 3, the cells were stimulated with phorbol 12-myristate-13-acetate (PMA) (50 
ng/ml, Fluka, UK) and ionomycin (800 ng/ml. Sigma Aldrich, UK) for 5 hours in the 
presence of 2 pM monensin (eBioscience, UK).
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4.4.6 C y to k in e  d e te rm in a tio n
The supernatants from the untreated and oxLDL-treated SMCs collected at 6, 12 and 24 
hours were analysed for the synthesis of lL-6, TGF-p and lL-23 using commercial ELISA 
kits (eBioscience, UK) following manufacturer’s recommendations as described in Chapter 2 
section 2.2.6.
4.4.7 D etection  o f  T h l7  cells b y  flow  cy to m e try  ana ly sis
The staining protocol involved first the staining of cell surface markers, such as CD4 (PerCP) 
and CCR6 (RPE), followed by intracellular labelling of RORyt (RPE), 1L-17A (Alexa Fluor 
647) and IL-17F (Alexa Fluor 488) cytokines using a cocktail of anti-mouse fluorescently 
labelled monoclonal antibodies (Cambridge Bioscience, UK, R&D system, UK and 
eBioscience, UK). Samples were analysed by flow cytometry with a BD FACS Canto (BD 
Biosciences, UK) and BD FACS Diva Software v5.1. Events (100,000) were recorded and 
analysed. The staining protocol and gating strategy for combination two and three were 
employed as described in Chapter 2 section 2.2.5.
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4.5 Results
43.1 Characterisation of SMCs
Immunofluorescence demonstrated the specific expression of SMC-a actin, but did not 
exhibit PECAM-1 (Figure 4,1).
Figure 4.1 Overlay Image of Immunofluorescence of SMCs. Aortic SMCs were isolated and 
cultured as described in section 4.4.2., then fixed and stained with mouse SMC-a-actin and goat 
PECAM-1 antibodies. Cells were then stained with secondary antibodies Alexa 568 anti-mouse and 
FITC anti-goat IgG antibodies together with DRAQ-5™. The images were visualised using a Zeiss 
LSM 510 confocal microscope. (A-D) goat isotype control, (E-H) mouse isotype control, (I) SMCs 
stained with goat PECAM-1, (J) SMCs stained with DRAQ5 nuclear dye, (K) SMCs stained with 
mouse SMC a-actin, (L) Merged image showed SMCs expressing SMC a-actin and nuclear dye.
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4.5.2 O x L D L  h igh ly  induces th e  secre tio n  o f  EL-6, T G F -p  a n d  IL -23  by  S M C s a f te r  24 
h o u rs
LDL is a risk factor in the development of atherosclerosis and oxidative modifications of 
LDL increase its atherogenicity. The development of atherosclerosis most likely involves 
oxLDL-mediated SMCs proliferation, which is capable of inducing the production of various 
cytokines in the lesion. The effect of oxLDL treatment on Thl7 cell differentiation related 
cytokines secreted by SMCs was studied.
Figure 4.2 shows the concentration of IL-6 measured in the supernatant of oxLDL-treated 
SMCs. The highest concentration of IL-6 was detected after 24 hours of treatment of SMCs 
(p<0.001). The concentration of secreted TGF-p also significantly increased in the 
supernatant after 24 hours of treatment with oxLDL compared to untreated cells (p<0.001), 
after 12 hours (p<0.05) and 6 hours (p<0.01) (Figure 4.2). Levels of secreted lL-23 
significantly increased after 24 hours of treatment with oxLDL compared to untreated SMCs 
(p<0.01), 12 hours (p<0.05) and 6 hours (p<0.01) treatment (Figure 4.2).
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Figure 4.2 The effect of oxLDL-treated SMCs on cytokine secretion. The supernatant from 
untreated and oxLDL-treated SMCs collected at 6, 12 and 24 hours for detection of IL-6 (A), TGF-p 
(B) and IL-23 (0) using ELISA. Panel A show the standard curve for IL-6 range from 4 pg/ml to 500 
pg/ml and graph represents the concentration of IL-6 in the supernatant at 6, 12 and 24 hours. Panel 
B show the TGF-p standard curve range from 60 pg/ml to 8 ng/ml and graph represents the TGF-p 
levels at different time points. Panel 0  show the standard curve for IL-23 range from 30 pg/ml to 4 
ng/ml and graph shows the level of IL-23 at 6 ,12 and 24 hours. The values represent the mean + SD. 
The experiment was performed three times in duplicate (*P < 0.05; **P < 0.01 ; ***P < 0.001).
I l l
4.5.3 IL -6  a n d  T G F -P  secre ted  b o th  b y  o x L D L -trea ted  S M C s a n d  exogenous IL -6  a n d  
T G F -P  d id  n o t in d u ce  th e  exp ression  o f  IL -1 7 A  a n d  IL -1 7 F  on  C D 4 C C R 6^ ex p ressin g  
cells a n d  C D 4 ^ 0 R y t^  ex p ress in g  cells
The results described above show that SMCs are capable of producing the cytokines IL-6 and 
TGF-p, which play important roles in the differentiation of CD4^ T-cells into Thl7 cells. 
Further investigation was carried out to study the effect o f the cytokines secreted by oxLDL- 
treated SMCs on Thl7 differentiation by culturing the CD4^ T-cells with conditioned 
supernatant in the presence of anti-CD3 and anti-CD28. In addition, a parallel setup was 
constructed in which exogenous IL-6 and TGF-p was added to determine their influence on 
Thl7 cell differentiation. The MFI of IL-17A^ and IL-17F+ expression on CD4^CCR6^ 
expressing cells and CD4^R0Ryt^ expressing cells were measured using flow cytometry.
Figure 4.3D and 4.3E show there were no increased of IL-17A and IL-17 expression on 
CD4^CCR6^ expressing cells when CD4^ T-cells cultured in the oxLDL-treated SMCs 
supernatant with or without exogenous IL-6 and TGF-p compared to CD4^ T-cells cultured 
in untreated SMCs medium.
Likewise, there were also no increased of IL-17A and IL-17F on CD4^R0Ryt^ expressing 
cells when CD4^ T-cells were cultured in the supernatant of oxLDL-treated SMCs with or 
without exogenous IL-6 and TGF-p compared to the control (Figure 4.4D and 4.4E).
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Figure 4.3 The effect of cytokines secreted by oxLDL-treated SMCs and addition of exogenous 
cytokines on the differentiation of Th17 cells. CD4* T-cells were cultured in the supernatant of 
oxLDL-treated SMCs for 24 hours in the presence of anti-CD3 and anti-CD28 either with exogenous 
IL-6 and TGF-p or without them for 3 days. The MFI of IL-17A"^  and IL-17F"^  expression on 
CD4^CCR6* expressing cells were measured using flow cytometry analysis. The gating was applied 
based on control in Figure 2.9. Representative dot plots and histogram for MFI of IL-17A  ^and IL-17F^ 
expression on CD4^CCR6"  ^expressing cells are shown: A. CD4"^  T-cells cultured In untreated SMCs 
supernatant B. CD4"^  T-cells cultured in oxLDL-treated SMCs supernatant C. CD4"^  T-cells cultured in 
the oxLDL-treated SMCs supernatant in the presence of exogenous IL-6 and TGF-p. Graph shows 
the MFI of IL-17A* expression on CD4^CCR6* expressing cells (D) and IL-17F^ expression on 
CD4^CCR6* expressing cells (E) respectively. Values represent the mean + SD. Each experiment 
was performed three times. (*P < 0.05).
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Figure 4.4 Effect of cytokines secreted by oxLDL-treated SMCs and addition of exogenously 
cytokines on the differentiation of Th17 cells. CD4^ T-cells were in the supernatant of oxLDL- 
treated SMCs for 24 hours in the presence of anti-CD3 and anti-CD28 either with exogenous IL-6 and 
TGF-p or without them for 3 days. The MFI of IL-17A  ^ and IL-17F* expression on CD4^RORyt^ 
expressing cells were measured using flow cytometry analysis. Representative dot plots and 
histogram for MFI of IL-17A  ^and IL-17F^ expression on CD4^RORyt^ expressing cells are shown: A. 
CD4^ T-cells cultured in untreated SMCs supernatant B. CD4^ T-cells cultured in oxLDL-treated 
SMCs supernatant C. CD4* T-cells cultured in the oxLDL-treated SMCs supernatant in the presence 
of exogenous IL-6 and TGF-p. The MFI of IL-17A"^  expression on CD4*R0Ryt^ expressing cells (D) 
and IL-17F* expression on CD4*R0Ryt* expressing cells (E) for each treatments are shown in the 
graphs. Values represent the mean + SD. The experiment was performed three times.
114
4.5.4 C o -c u ltu re  o f  CD4^ T-cells w ith  o x L D L -trea ted  SM C s w ith  exogenous IL -6  a n d  
T G F -P  in c rease  th e  exp ression  o f  IL -17A  a n d  IL -1 7 F  o n  C D 4 C C R 6^ ex p ress in g  cells 
a n d  C D 4‘^ O R y t^  ex p ress in g  cells
VSMC plays an important role in keeping the atheroma stable and protected by the secretion 
of matrix proteins and forming a fibrous cap covering the lipid core (Pryshchep 2006). ECs 
are known to act as APCs controlling the fimctional activity of T-cells, but little is known 
about the interaction between VSMC and plaque-infiltrating T-cells (Pryshchep 2006). 
Therefore, it was necessary to study the effect of oxLDL-treated SMCs with or without the 
addition of exogenous IL-6 and TGF-P on the differentiation of Thl7 cells. The MFI of IL- 
17A^ and IL-17F^ expression on CD4^CCR6^ expressing cells and CD4^0Ryt^ expressing 
cells were measured using flow cytometry.
The results demonstrated that CD4^ T-cells co-cultured with oxLDL-treated SMCs with the 
exogenous IL-6 and TGF-P significantly increased the expression of IL-I7A and IL-17F on 
CD4^CCR6^ expressing cells compared to when CD4^ T-cells co-cultured with oxLDL- 
treated SMCs (p<0.05) and untreated SMCs (P<0.01) (Figure 4.5D and 4.5E).
On the other hand, there were no changes of IL-17A expression on CD4^0Ryt^ expressing 
cells when CD4^ T-cells were co-cultured with oxLDL-treated SMCs with or without the 
exogenous IL-6 and TGF-p compare to control (Figure 4.6D). However, CD4^ T-cells co- 
cultured with oxLDL-treated SMCs with the exogenous IL-6 and TGF-p significantly 
increased the expression of IL-17F on CD4^0Ryt^ expressing cells compared to when CD4^ 
T-cells co-cultured with oxLDL-treated SMCs (p<0.05) and untreated SMCs (P<0.01). 
(Figure 4.6E).
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Figure 4.5 Effect of cytokines secreted by oxLDL-treated SMCs and exogenous cytokines on 
Th17 cell differentiation. CD4  ^T-cells were co-cultured with oxLDL-treated SMCs with or without 
exogenous IL-6 and TGF-p for 3 days. The MFI of IL-17A* and IL-17F* expression on CD4"’CCR6  ^
expressing cells were determined by flow cytometry analysis. Representative dot plots and histogram 
for MFI of IL-17A  ^and IL-17F^ expression on CD4^CCR6* expressing cells are shown: A. CD4  ^T- 
cells co-cultured with untreated SMC B. CD4  ^T-cells co-cultured with oxLDL-treated SMCs C. CD4  ^
T-cells co-cultured with oxLDL-treated SMCs in the presence of exogenous IL-6 and TGF-p. Graph 
shows MFI for IL-17 expression on CD4^CCR6  ^ expressing cells (D) and IL-17F^ expression on 
CD4"^ CCR6  ^expressing cells (E) respectively. Values represent the mean + SD. Each experiment 
was performed three times. (*P < 0.05).
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Figure 4.6 The effect of cytokines secreted by oxLDL-treated SMCs and exogenous cytokines 
on Th17 cell differentiation. CD4"^  T-cells were co-cultured with oxLDL-treated SMCs with or without 
exogenous IL-6 and TGF-p for 3 days. The MFI of IL-17A^ and IL-17F^ expression on CD4^R0Ryt^  
expressing cells were determined by flow cytometry analysis. Representative dot plots and histogram 
for MFI of IL-17A^ and IL-17F^ expression on CD4"^ RORyt^  expressing cells are shown.: A. CD4"^  T- 
cells cultured in untreated SMCs supernatant B. CD4* T-cells cultured in oxLDL-treated SMCs 
supernatant C. CD4  ^ T-cells cultured in the oxLDL-treated SMCs supernatant in the presence of 
exogenous IL-6 and TGF-p. The MFI for IL-17A* expression on CD4"^ RORyt^  expressing cells (D) and 
IL-17F  ^expression on CD4*R0Ryt^  expressing cells (E) for each treatments are shown in the graphs. 
Values represent the mean + SD. The experiment was performed three times.
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4.6 Discussion
Human atherosclerotic plaques are composed of blood-bome inflammatory and immune 
cells, especially macrophages and T-cells, as well as vascular ECs, SMCs, ECM, lipids and 
acellular lipid rich debris (Jonasson 1986). As previously discussed in Chapter 3, other intra­
plaque sources of IL-6 and TGF-p have also been found to influence Thl7 cell differentiation 
following the engagement of CD4^ T-cells with oxLDL-treated DCs. Therefore, the possible 
role of intra-plaque cells, namely SMCs, on Thl7 cell differentiation in atherosclerotic 
plaques was investigated for the first time.
In the present study, an explant method for the isolation of SMCs from murine aortas (Ray 
2001) was used, resulting in the growth of SMCs in ‘spindle shaped’ patterns as previously 
described (Kobayashi 2005). SMCs were obtained using this methodology that had been 
passaged up to three times. The phenotype of the SMCs was confirmed via fluorescence 
microscopy using double staining for PECAM-1, a specific marker for EC; and mouse SMC- 
a-actin antibody, a specific marker for SMCs. The result showed a clear expression of SMC- 
a-actin, which characterised the differentiation of SMCs. SMC a-actin is the most abundant 
protein in differentiated SMCs, accounting for about 40% of the total cellular protein 
and~70% of the total actin (Owen 1995). SMC-a actin is also the most widely used SMCs 
marker because of the commercial availability of a number of very high-afflnity and highly 
selective antibodies for this protein (Skalli 1986), and was the first recognised protein 
expressed during differentiation of the SMCs during development (Frid 1992; Hungerford 
1996). The isolated SMCs were then used in subsequent studies.
OxLDL is known to be involved in atherogenesis via the induction of the synthesis of foam 
cells and in the initiation of inflammatory responses (Heinecke 1991; Brown 2000). OxLDL 
is captured by SMCs via scavenger receptors such as CD36 leading to the proliferation and 
secretion of various cytokines involved in the development of atherosclerosis. The effect of 
oxLDL on the synthesis of SMC-derived cytokines showed that oxLDL was capable of 
inducing the secretion of IL-6, TGF-p and IL-23 by SMCs after 6 hours in culture which was 
significantly increased after 24 hours. These three cytokines were selected because they were 
known to be involved in Thl7 cell differentiation from naïve precursors (Bettelli, Carrier et 
a l 2006). It has been shown that SMC-secreted cytokines and adhesion molecules, such as 
IL-8, IL-6 and VCAM-1, may regulate monocyte and macrophage adhesion and other 
processes in atherosclerosis (Orr 2010). SMCs can also produce a wider range of cytokines
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including: platelet derived growth factor (PDGF), TGF-P, macrophage inhibitory factor 
(MIF), IFNy, and monocyte chemoattractant protein one (MCP-1) (Doran 2008). All these 
cytokines can also be produced by other cells within the lesion, which raised the possibility 
that IL-6 and TGF-p may influence the differentiation of CD4^ T-cells to become Thl7 cells 
within atherosclerotic plaques. It appears that the combination of IL-6 and TGF-P may be 
required for the differentiation of murine Thl7 cells fi-om naïve precursors (Bettelli, Carrier 
et al. 2006; Mangan 2006; Veldhoen 2006). The secretion of IL-23 by oxLDL-treated SMCs 
is consistent with previous studies that revealed that VSMC within the arterial walls are the 
main producers of IL-23 especially under high cholesterol diet regimes (Pejnovic, Vratimos 
et a l 2009). Even though IL-23 is not directly involved in Thl7 cell differentiation from 
naïve T-cells, it can still serve as an activator of memory CD4^ T-cells to produce IL-17 and 
low levels of IFNy, and also to increase their proliferation (Aggarwal 2003). Therefore, IL-23 
plays an important role in maintaining Thl7 cells (Korn, Oukka et a l 2007). Hence, oxLDL 
can stimulate SMCs to produce IL-6 and TGF-P, which may in turn influence the 
commitment of naïve T-cells to differentiate into Thl7, and also the secretion of IL-23 to 
sustain the fimctional roles of Thl7 cells.
The potential role of the above-mentioned cytokines secreted by oxLDL-treated SMCs under 
conditions that mimic in vivo stimulation by APCs was investigated. The results showed that 
CD4^ T-cells cultured in the supernatant of oxLDL-treated SMCs with or without exogenous 
IL-6 and TGF-p did not increased the expression of IL-17A and IL-17F on CD4^CCR6^ 
expressing cells and CD4^R0Ryt^ expressing cells. These results raised possibility that other 
inhibitory factors may present in the culture, which influence the differentiation of CD4^ T- 
cells into Thl7 cells in the experiment set up. In support of our speculation, 3 days 
stimulation of CD4^ T-cells with anti-CD3 and anti-CD28 in the supemantant of oxLDL- 
treated SMCs may augment the secretion of IFNy and IL-2 by activated CD4^ T-cells. 
Jenkins et a l showed that CD28 signalling induced IFNy and IL-2 secretion in activated 
CD4^ T-cells (Jenkins 1991). In agreement with this observation, Bougermouth et at. 
demonstrated that the increase of IFNy and IL-2-secreting CD4^ T-cells was inversely 
correlated with the frequency of IL-17 producing cells. Neutralisation of IFNy partially 
rendered CD28-mediated Thl7 cell suppression. However, the combination of anti-IL-2 and 
anti-IFNy mabs revoked the effect of CD28 engagement (Bouguermouh, Fortin et a l 2009).
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T-cells are abundant within atherosclerotic plaques and co-localise together with HLA-DR- 
bearing SMCs and macrophages, suggesting the occurrence of antigen-specific immune 
responses in atherosclerosis development (Hansson 1989). Most of the T-cells in the plaque 
are CD4^ T helper cells that react with antigens in the context of MHC class II proteins. 
These observations prompted a study on the effects of the interactions between CD4^ T-cells 
and oxLDL-treated SMCs on the differentiation of Thl7 cells. The results showed that CD4^ 
T-cells co-cultured with oxLDL-treated SMCs with exogenous IL-6 and TGF-p increased IL- 
17A expression on CD4^CCR6^ expressing cells and IL-17F expression on both CD4^CCR6^ 
expressing cells and CD4’^ 0R y t expressing cells. These findings may due to CD4^ T-cells 
that we purified for this experiment does not only contained naive CD4^ T-cells but also 
memory CD4^ T-cells. Therefore, even though SMCs may only express MHC class II but not 
co-stimulatory molecules which only required for fully activation of naive CD4^ T-cells 
(Murray 1995), the increased expression of EL-17A and IL-17F on respective cells may be 
derived fi-om memory CD4^ T-cells which not require co-stimulator for their activation under 
influence of IL-6 and TGF-p. In regards of the role of co-stimulators especially B7-1 and B7- 
2, Bouguermouh et a l (2009) showed that B7-1 and B7-2 act as negative regulators of human 
Thl7 cells development. Furthermore, other co-stimulatory molecules may override the 
absence of B7 co-stimulation for T-cell activation and differentiation into Thl7 cells (Butte 
2007).
However, there were several limitations noted in our finding for this chapter. The lack of 
positive control for PECAM-1 did not prove whether this antibody work. However, our 
personal communication with Ahmed fi-om Emmanuel Dupont group who used the same 
antibody has confirmed that it worked well for ECs staining. Even though, we have shown 
that oxLDL-treated SMCs able to secrete IL-6, TGF-p and EL-23 for 6, 12 and 24 hours 
compared to untreated SMCs, these results may only applicable for the cytokine secreted for 
24 hours because we only compared with supernatant fi-om untreated SMCs for 24 hours. The 
oxLDL-treated SMCs supernatant for 6 and 12 hours need to be compared with the 
supernatant firom untreated SMCs for 6 and 12 hours respectively. In addition, the IL-6 
cytokine levels detected in the oxLDL-treated SMCs at respective time exceeds the range of 
IL-6 standard curve which indicated the analyte concentration in the samples is too high. In 
contrast, the levels of TGF-p detected in the oxLDL-treated supernatant at respective time 
was below the detection range which is fi-om 60 pg/ml to 8 ng/ml. Likewise, the levels of IL- 
23 detected in the oxLDL-treated supernatant at 6 and 12 hours also below the detection limit
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of 30 pg/ml to 4 ng/ml. However, the levels of IL-23 detected in the supernatant for 24 hours 
of oxLDL-treated SMCs remain in the range of detection limit. Furthermore, the 
determination of MHC class II expression, B7-1 and B7-2, and other co-stimulatory 
molecules such as ICOS ligand (ICOSL) expression on oxLDL-treated SMCs also require in 
order to demonstrate the role of SMCs as APCs.
In conclusion, the possible presence of inhibitory cytokines in the supernatant of oxLDL- 
treated SMCs may hinder the differentiation of Thl7 cells. The possible engagement of CD4^ 
T-cells with oxLDL-treated SMCs via MHC or other co-stimulatory molecules which may 
override the absence of B7 co-stimulation on SMCs may lead to differentiation of Thl7 cells 
under influence of IL-6 and TGF-p.
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CHAPTERS
STUDY OF THE DIRECT EFFECT OF OXIDISED LOW DENSITY LIPOPROTEIN
ONTH17 CELLS
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5.1 Introduction
Thl7 cells are a distinct lineage of T-cells regulated by the transcription factors RORa, 
RORyt and STAT-3 (Bettelli, Carrier et al. 2006; Zhou 2007; Yang, Jia et al 2008). 
Differentiation of Thl7 cells from naïve T-cells require stimulation by TGF-P, IL-6 and IL- 
21, which can act in both autocrine and/or paracrine fashion (Veldhoen 2006; Bettelli, Kom 
et a l 2007). IL-23 plays an importance role in the survival of Thl7 cells (Aggarwal 2003; 
Harrington, Mangan et a l 2006). Thl7 cells mainly secrete IL-17A, IL-17F, IL-21 and IL-22 
(Kom, Anderson et a l 2007; McGeachy and Cua 2008). IL-6, IL-21 and IL-23 activate Janus 
kinases, which in turn preferentially activate STAT-3 (Chen, Laurence et al. 2007) as it is 
known that in vitro differentiation of Thl7 cells is impaired in STAT-3-deficient mice 
(Laurence, Tato et al. 2007; Yang, Panopoulos et al. 2007). The expression of Thl7 cell 
transcription factor, RORyt is also impaired in T-cells lacking STAT-3 (Chen, Laurence et a l 
2007). Furthermore, STAT-3 can be a direct regulator to IL-17 and IL-21 by directly binding 
to the II 17a/f {Chen, Laurence et al. 2006) and IL-21 promoters respectively (Wei, Laurence 
et a l 2007). Moreover, IL-6, IL-21 and IL-23 can enhance the expression of IL-23R and this 
process seem to be also dependent on the activation of STAT-3 (Chen, Tato et al. 2007; Zhou 
2007). Thus, STAT-3 appears to be an important transcription factor for Thl7 cells 
differentiation based on four mechanisms: directly engaging and modulating H17a, III 7 f and 
1121 loci, as well as controlling the expression of RORyt and IL-23R (Chen, Laurence et a l 
2007).
OxLDL is a key antigen in the initiation of atherosclerosis development. In the intima, 
oxLDL is recognised and internalised by macrophages and DCs via SRA-1/2, MACROS, 
CD36, Lectin-type oxidised low density lipoprotein-1 (LOX-1), SR-Bl, PSOX and Lectin- 
type C (CD205) (Pluddemann 2007; Nickel 2009). In addition, there is evidence showing that 
oxLDL binds to TLR-4-CD14 complexes and induces inflammatory responses (Xu 2001; 
Miller 2003). Following proteolytic processing via the endocytic pathway, peptide Augments 
of oxLDL, such as apoB, bind to MHC class II molecules, and are transported to the cell 
surface (Hansson and Libby 2006), where they are recognised by the TCR of naïve or 
memory CD4^ T-cells leading to the differentiation of Thl, Th2, Treg and Thl7 cells.
TLRs are primarily expressed on innate immune cells, such as DCs and macrophages 
(Kadowaki 2001; Visintin 2001). Each TLR can recognise one or more PAMPs derived from 
all known infectious agents to form homo or heterodimers that can detect a wide range of
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microbes (Davila and Kolls). From all TLR-4 ligands, LPS has been found to induce IL-17 in 
vitro (Happel 2003). Thl 7 cells can be also elicited in vivo following vaccination with several 
Freund’s-based antigen solutions, cholera toxin, and the TLR-4 ligand monophosphoryl lipid 
A/trehalose dicorynomycolate emulsion (Khader, Gaffen et a l 2009). Moreover, McAleer 
and Vella reported that TLR-4 activation increases the number of Thl 7 cells in the lamina 
propria (LP) through the expansion of pre-existing Thl 7 cells (McAleer, Liu et a l 2010). 
Recent studies have demonstrated that CD4 and CDS T-cells express functional TLRs 
(Davila and Kolls 2010; Komai-Koma 2004; Asproites 2008). The TLRs expression profile is 
different on each T-cell subset and depending on which TLR is activated can lead to distinct 
responses by each subset (Davila and Kolls 2010). For example, the engagement of TLR-3 or 
TLR-1/-2 on murine CDS T-cells has been demonstrated to increase the secretion of various 
effector molecules, such as IFNy, IL-2 and granzyme B (Asproites 2008). TLR-3, TLR-4 or 
TLR-9 ligation on CD4 T-helper cells can induce T-cell responses by regulating the 
expression of IL-2R, whereby TLR-l/-2-ligation on CDS T-cells can enhance its cytolytic 
activity (Komai-Koma 2004). In addition, TLR-9 stimulation on CD4 T-helper cells enhances 
T-cell survival via modulation of the expression of anti-apoptotic proteins, such as Bcl-2, bcl- 
xl and A1 (Davila and Kolls 2010).
CD36 is a member of the scavenger receptor family of leukocyte antigens (Lubick 2006). It is 
believed that its expression is only restricted to monocytes and ECs, and that it serves as 
receptor for oxLDL, apoptotic cells, thrombospondin-1 and Plasmodium falciparum- 
parasitised erythrocytes (Greenwalt 1990; Sarrias 2004; Hoebe 2005). The effect of CD36 is 
restricted by TLR-2 functions by enhancing the expression of TLR-2/TLR-6 ligand, but not 
TLR-2/TLR-1 (Hoebe 2005). Recently, yô T-cells have also been found to express CD36 at 
the RNA and protein levels. CD36 is expressed by resting yô T-cells while the surface levels 
increase following PMA/ionomycin treatment (Lubick 2006). A few non-yô T-cells also 
expressed CD36, but this fraction was irregular between samples, and it is uncertain at this 
time whether they were NK cells, a small subset of ap  T-cells, or B-cells (Lubick 2006).
The expression of TLRs different types of CD4^ T-cell subsets and possibility of small 
fraction of ap  T-cells which include CD4^ T-cells expressed CD36 suggests that oxLDL 
could directly interact with CD4^ T helper cell types. Incubation of CD4^ T-cells from 
healthy control subjects with oxLDL resulted in a non-significant reduction of CD4^CD25" T- 
cell numbers (Meier 2009). On the other hand, the percentage of CD4^CD25^ Treg cells was
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significantly decreased by incubation with the oxLDL (Meier 2009). Therefore, our 
hypothesis is that certain types of TLRs such as TLR-2, TLR-4, and CD36 may be express by 
Thl 7 cells, and they may mediate a direct interaction of these cells with oxLDL. This 
interaction may regulate Thl 7 cells functions such as secretion of IL-17A and IL-17F which 
may exacerbate or attenuate the atherosclerosis development. Beside that, excessive 
internalisation of oxLDL by Thl 7 cells via TLRs and CD36 also may lead to formation of 
foam cells derived Thl 7 cells. Then, the accumulation of foam cells derived Thl 7 cells and 
other cells derived foam cells will accelerate the formation of lipid streaks.
5.2 Aim
To study the direct interaction of oxLDL with Thl 7 cells.
5.3 Objectives
1. To determine the expression level of TLR-2, TLR-4 and CD36 on murine Thl 7 cells 
using flow cytometry analysis.
2. To determine the effect of oxLDL on the Thl 7 transcription factor, STAT-3 using an 
ELISA.
3. To assess Thl7 functionality based on the secretion of IL-17A and IL-17F using an 
ELISA.
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5.4 Materials and methods
5.4.1 Animals
Female 6 week old of apoE’^‘ mice (strain B6.129P2-ApoetmlUnc/J), bred in-house, were 
used. Splenocytes were collected at termination and processed as described in Chapter 2 
section 2.2.2.1 prior to subsequent experimental procedures.
5.4.2 Isolation of CD4^ T-cells
Isolation o f CD4^ T-cells was carried out as described in Chapter 2 section 2.2.2.
5.4.3 In vitro cell culture
Each experiment was set up into five different conditions namely; purified CD4^ T-cells only, 
CD4^ T-cells treated with oxLDL, CD4^ T-cells treated with oxLDL and addition of IL-6 (20 
ng/ml) (Peprotech, UK) and TGF-p (2 ng/ml) (Peprotech, UK), CD4^ T-cells activated with 
anti-CD3 (1 pg/ml) (eBioscience, UK) and CD28 (2 pg/ml) (eBioscience, UK) and treated 
with oxLDL, and finally CD4^ T-cells activated with anti-CD3 (1 pg/ml) (eBioscience, UK) 
and CD28 (2 pg/ml) (eBioscience, UK) and treated with oxLDL together with IL-6 (20 
ng/ml) (Peprotech, UK) and TGF-p (2 ng/ml) (Peprotech, UK). The concentration of oxLDL 
used for this experiment was 100 pg/ml. The cells were cultured in the 24-well plates for 5 
days because the development of polarized Thl 7-cell subset takes up to 5 days in vivo 
(Acosta-Rodriguez 2007). Betelli et al. (2006) also showed that IL-6 and TGF-p induce the 
differentiation of Thl 7 cells fi*om naïve T-cells in vitro for 3-5 days.
These five different culture conditions were labelled and named as listed below and the 
abbreviated names in the brackets will be henceforth used in the whole thesis.
1. Purified CD4^ T-cells only (untreated CD4^
2. CD4^ T-cells treated with oxLDL (treated CD4^
3. CD4^ T-cells treated with oxLDL and addition of IL-6 (20 ng/ml) and TGF-P (2 
ng/ml) (cytokine treated CD4^
4. CD4^ T-cells activated with anti-CD3 (1 pg/ml) and CD28 (2 pg/ml) and treated with 
oxLDL (TCR treated CD4^
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5. CD4^ T-cells activated with anti-CD3 (1 pg/ml) and CD28 (2 pg/ml) and treated with 
oxLDL together with IL-6 (20 ng/ml) and TGF-p (2 ng/ml) (treated Thl 7 cell induced 
culture)
5.4.4 Cytokine determination
At day 5, the supernatants from the experiment were collected by centrifugation and stored at 
-80°C until required. Levels of IL-17A and IL-17F were detected by ELISA kits 
(eBioscience, UK) following the manufacturer’s recommendations as described in Chapter 2 
section 2.2.6.
5.4.5 Flow cytometry analysis of TLR-2, TLR-4 and CD36
The staining protocol involved direct staining of cell surface markers such as CD4 (PerCP), 
CCR6 (RPE), TLR-2 (Alexa Fluor 647), TLR-4 (Alexa Fluor 488) and CD36 (FITC) using a 
cocktail of anti-mouse fluorescently labelled monoclonal antibodies (Cambridge Bioscience, 
UK and eBioscience, UK). After counting, 1 x 10^  cells were suspended in 100 pi in staining 
buffer (PBS with 1% (w/v) BSA and 0.05% (w/v) NaNg) and were incubated with mouse 
SeroBlock FcR (AbSerotec, UK) for 10 minutes and followed with the addition of other 
antibodies. The cells were mixed by vortexing and incubated at 4°C for 30 minutes. The cells 
were washed using 2 ml of washing buffer (0.5% BSA (w/v) in PBS) by centrifugation for 5 
minutes at 200 X g. Then, the supernatant was discarded and 300 pi of staining buffer was 
added. The samples were analysed by flow cytometry with BD FACS Canto (BD 
Biosciences, UK) and BD FACS Diva Software v5.1. Events (20,000) were recorded and 
analysed.
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5.4.5.1 Gating strategy
The gating strategies used for the combination of CD4/CCR6/TLR-2/TLR-4 and 
CD4/CCR6/CD36. CD4 and CCR6 surface marker were used to represent Thl 7 cells as 
CCR6 is the best marker to define Thl 7 cells (Potzl 2008). However, there is possibility that 
CD^CCR6^ may represent Treg cells, as a small fraction of mouse Treg cells also can express 
CCR6 marker (Kleinneweitfeld 2005).
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Figure 5.1 The control tubes for CD4*/CCR6*/TL-2*/TLR-4* combination. Tube A. Unstained cells 
Tube B. lgG2a PercP/lgGI RPE/lgG2a Alexa 6477lgG2a Alexa 488 Tube 0. Rat lgG2a PercP/CCR6 
RPE/TLR-2 Alexa 647/TLR-4 Alexa 488 Tube D. CD4 PercP/Rat lgG1 RPE/TLR-2 Alexa 647/TLR-4 
Alexa 488 Tube E. CD4 PercP/CCR6 RPE/Rat lgG2a Alexa 647/TLR-4 Alexa 488 Tube F. CD4 
PercP/CCR6 RPE/TLR-2 Alexa 647/Rat lgG2a Alexa 488.
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Figure 5.2 Gating strategies for CD4/CCR6/TLR-2/TLR-4. Initially, the CD4"^  T-cells gated using 
FSC-A vs SSC-A. CD4  ^T-cells were selected and named as P1 based on the unstained cells and 
isotypes control in Figure 5.1. Next, the Pi population was applied on dot plot of CD4 PercP-A vs 
CCR6 PE-A. The population of CD4"‘CCR6  ^ (P2) was gated based on tube A, B, 0, D, E and F in 
Figure 5.1. The P2 then applied in histogram to determine the MFI. P3 represented MFI for 
CD4^CCR6^LR-2^ while P4 represented MFI for CD4^CCR6^TLR-4\
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Figure 5.3 The control tubes for CD4*/CCR6*/CD36* combination. Tube A. Unstained cells Tube 
B. lgG2a PercP/lgG1 RPE/lgG2a FITC Tube C. Rat lgG2a PercP/CCR6 RPE/CD36 FITC Tube D. 
CD4 PercP/Rat lgG1 RPE/CD36 FITC Tube E. CD4 PercP/CCR6 RPE/Rat lgG2a FITC
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Figure 5.4 Gating strategies for CD4/CCR6/CD36. Initially, the CD4  ^T-cells gated using FSC-A vs 
SSC-A. CD4  ^T-cells were selected and named as P1 based on the unstained cells and isotypes 
control in Figure 5.3. Next, the P1 population was applied on dot plot of CD4 PercP-A vs CCR6 PE-A. 
The population of CD4'"CCR6"^  (P2) was gated based on tube A, B, C, D, E and F in Figure 5.3. The 
P2 was then applied in histogram to determine the MFI. P3 represented MFI for CD4^CCR6^CD36 .^
5.4.6 Intracellular detection of p-STAT-3
The p-STAT-3 analysis was carried out using human/mouse phosphor-STAT-3 (Y705) 
ELISA (R&D System, UK) according to manufacturer’s instructions.
5.4.6.1 Cell lysate preparation
Cells were stimulated as indicated in section 5.4.3. The floating cells culture flasks were 
transferred into a tube and centrifuged at 200 X g to obtain a pellet. The cell pellet was then 
washed twice with cold PBS. The cells were lysed by adding 0.5 ml RIPA buffer (Sigma 
Aldrich, UK) together with 5 pi of a protease inhibitor cocktails (Roche, UK). Cells were 
resuspended and incubated on ice for 5 minutes. Next, the mixture was transferred to a new 
microcentrifuge tube and centrifuged at 12000 X g for 15 minutes. This was carried out to 
separate total soluble proteins (supernatant) from the cellular debris (pellet). The supernatant 
was transferred into a new tube and the protein concentration was quantified by Micro BCA 
protein assay (Thermo Scientific, UK) as described in section 5.4.6.1.1. One hundred pg of 
total protein was diluted into 100 pi of reagent diluent for the ELISA assay.
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5.4.6.1.1 Measurement of protein concentration
Protein concentration was measured using the Micro BCA™ Protein Assay Kit (Thermo- 
Scientific, UK) according to manufacturer’s instructions. The kit is a detergent-compatible 
bicinchoninic acid formulation for the colorimetric detection and quantitation of total protein. 
The patented method utilises bicinchoninicacid (BCA) as the detection reagent for Cu^\ 
which is formed when Cu^  ^ is reduced by protein in an alkaline environment. A purple- 
coloured reaction product is formed by the chelation of two molecules of BCA with one 
cuprous ion (Cu^^). This water-soluble complex shows a strong absorbance at 562 nm that is 
linear with increasing protein concentrations.
The protein sample was diluted 1:50 in PBS according to BSA standards, and was diluted to 
obtain a range of concentrations between 0.5 pg/mL and 200 pg/mL in PBS. One hundred 
fifty pL each from the standard and the sample were added to a 96-well plate. This was 
followed by the addition of 150 pL of freshly prepared assay working solution. Mixture of 
the reagents was achieved by shaking the plate for 30 seconds followed by incubation at 37°C 
for 2 hours in a humidified chamber. The plate was allowed to cool at room temperature after 
which the absorbance was determined at 562 nm using an automatic plate reader. The protein 
concentration was calculated graphically using the linear part of the standard concentration 
curve. The purified protein samples were stored at -20°C in 100 pi aliquots.
S.4.6.2 Assay procedures
The components included in the kits were p-STAT-3 capture antibody, p-STAT-3 detection 
antibody, p-STAT-3 standard and streptavidin-HRP. The protocol was performed according 
to the manufacturers instructions. The capture antibody was diluted to a working 
concentration of 2.0 mg/ml in PBS without carrier protein. One hundred pi of diluted capture 
antibody per well were immediately added to each of the 96 well plates. The plates were 
sealed and incubated overnight at 4 C.
After aspirating the wells to remove the liquid, the plates were washed 5 times using 300 pi 
of washing buffer (0.05% Tween-20 in PBS) per well. The plates were immediately blocked 
with 200 pi per wells of reagent diluent (5% BSA in washing buffer). The plates were sealed 
and incubated at room temperature for 1 hour. The top standard solution (50 ng/ml) was 
prepared by reconstituting each vial containing 180 ng/ml of p-STAT-3 with 500 pi of 
reagent diluent. One hundred pi of standard per well were added in duplicate. Two fold serial
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dilutions of the top standards were prepared to make a standard curve. One hundred pi of 
sample was added to each well in duplicate and incubated overnight at 4 C.
The detection antibody was diluted to a working concentration of 100 ng/ml in reagent 
diluent. After washing the plate 5 times with 300 pi of washing buffer per well, 100 pi of 
detection antibody were added to each well and the plate was sealed and incubated at room 
temperature for 1 hour. The plates were washed 5 times with 300 pl/well of washing buffer 
and 100 pi of Streptavidin-HRP diluted in Ix assay diluent were added per well and 
incubated at room temperature for 30 minutes. The wells were aspirated and washed 5 times 
using washing buffer. In this wash step, the wells were soaked in washing buffer for 2 
minutes prior to aspiration. Then, 100 pi per well of TMB substrate solution were added and 
the plates were incubated for 15 minutes at room temperature for colour development. The 
reaction was stopped by adding 50 pi of 1 M H2SO4 to each well. The plates were read at 450 
nm wavelength using Bio-Tek ELxSOO plate reader (Bio-Tek Instruments, Inc., Ontario, 
Canada).
134
5.5 Results
5.5.1 No changes in TLR-2 and TLR-4 expression level in all culture conditions
In order to investigate the expression of TLR-2 and TLR-4 on Thl7 cells, CD4^ T-cells were 
cultured as described in section 5.4.3. The expression level of TLR-2 and TLR-4 on Thl7 
cells were determined by flow cytometry using the combination of CD4/CCR6/TLR-2/TLR-4 
antibodies. As shown in Figure 5.5G and 5.5F, all of culture conditions did not alter the 
expression levels of TLR-2 and TLR-4.
5.5.2 CD36 expression levels increased in Thl7 cell induced cell culture and TCR 
treated CD4
CD36, a class B scavenger receptor, is a macrophage receptor for oxLDL and play an 
important role in atherosclerotic foam cell formation (Nicholson 1995). The expression levels 
of CD36 on Thl7 cells was determined by flow cytometry using the combination of 
CD4^CCR6^CD36\ CD4^ T-cells were cultured as described in section 5.4.3. Figure 5.6F 
shows that treated Thl7 cell induced culture significantly induced CD36 expression levels on 
CD4^CCR6^ compared to untreated CD4 and treated CD4 (p<0.01). In addition, the 
expression of CD36 also increased in TCR treated CD4 culture condition compared to 
untreated CD4 and treated CD4 (p<0.05).
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Figure 5.5 The expression of TLR-2 and TLR-4 by Th17 ceils. CD4* T-cells were cultured as 
described: A. Untreated CD4 B. Treated CD4 C. Cytokine treated CD4 D. TCR-treated CD4 E. 
Treated Th17 cells induced. The median fluorescence intensity (MFI) of CD4^CCR6^LR-2* (F) and 
CD4*CCR6^LR-4* (G) for each treatment was determined by flow cytometry analysis and 
represented in the bar graphs. Values represent the mean + SD. The experiment was performed 
three times in triplicate.
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Figure 5.6 The expression of CD36 on Th17 cells. CD4"^  T-cells were cultured as described: A. 
Untreated CD4 B. Treated CD4 C. Cytokine treated CD4 D. TCR-treated CD4 E. Treated Th17 cells 
induced. Flow cytometry analysis was carried out to determine the median fluorescence intensity 
(MFI) of CD4'"CCR6^CD36  ^(F). MFI for CD4'"CCR6^CD36* for each treatment are represented as bar 
graphs. Values represent the mean + SD. The experiment was performed three times in triplicate. 
(*P<0.05; **P<0.01).
5.5.3 S tim u la tio n  o f  CD4^ T-cells in d u ced  th e  exp ression  o f  p-ST A T -3
The engagement of oxLDL via certain surface receptors on Thl7 cells may regulate its 
functions. In order to test whether oxLDL could influence the expression of Thl7 cells 
transcription factor, STAT-3, CD4^ T-cells was treated in different culture conditions and the 
concentration of STAT-3 was measured using in an intracellular ELISA. Figure 5.7B shows 
that treated CD4^ significantly increased the expression of p-STAT-3 compared to untreated 
CD4^ (p<0.01). Cytokines treated CD4^ significantly enhanced the expression of p-STAT-3 
compared to the same control (p<0.001). TCR treated CD4^ and treated Thl7 cell induced 
culture, and also significantly increased the expression of p-STAT-3 compared to control 
(p<0.001). The concentration of p-STAT-3 induced by treated Thl7 cell induced culture was 
the highest compared to concentration arisen from other culture conditions (350 pg/ml).
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Figure 5.7 The effect of oxLDL on pSTAT-3 expression. 004^  ^T-cells were cultured as described 
in section 5.4.3. Cell lysates were prepared of each condition and then the expression of p-STAT-3 
was determined by measuring its concentration using ELISA. Panel A shows standard curve for p- 
STAT-3 range from 390 pg/ml to 50 ng/ml Panel B shows graph represent the level of p-STAT-3 
expression in different conditions. Values represent the mean + SD. The experiment was performed 
three times in duplicate. (*P < 0.05; **P<0.01; ***P<0.001).
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5.5.4 Stimulation of CD4  ^T-cells induced the secretion of IL-17A and IL-17F
STAT-3 was found to bind with both IL-17A and IL-17F promoters (Chen 2006). It is likely 
that the effect of oxLDL on STAT-3 may influence the secretion of IL-17A and IL-17F by 
Thl7 cells. Therefore, we measured the concentration of secreted XL-17A and IL-17F in 
every culture condition using an ELISA. As shown in Figure 5.8A, TCR treated CD4^ cells 
and treated ThI7 cell induced cultures significantly induced the secretion of IL-17A 
compared to untreated CD4^ cells (p<0.001). Treated Thl7 cell induced culture induced more 
IL-17A compared to TCR treated CD4^ (p<0.05).
Similar results were obtained for the expression of IL-17F as shown in Figure 5.8B.
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Figure 5.8 Effect of oxLDL on the secretion of IL-7A and iL-17F. CD4  ^T-cells were cultured as 
described in section 5.4.3. The secretion of IL-17A (A) and IL-17F (B) were measured using ELISA. 
Panel A show the standard curve for IL-17A range from 4 pg/ml to 500 pg/ml and graph represents 
the concentration of IL-17A in different conditions. Panel B show IL-17F standard curve range from 15 
pg/ml to 2 ng/ml and graph represents the IL-17F levels in different conditions. Values represent the 
mean + SD. The experiment was performed three times in duplicate. (*P < 0.05; **P<0.01; 
***P<0.001).
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5.6 Discussion
It is known that oxLDL is recognised and internalised by various types of scavenger receptors 
including SRA and CD36 expressed on macrophages and other APCs (Steinbrecher 1999; 
Greaves 2005). OxLDL is also recognised by TLR-2 and TLR-4 (Walton 2003). In this study, 
investigation was focussed on the expression of TLR-2, TLR-4 and CD36 on the surface of 
newly characterised Thl7 cells following in vitro treatment with oxLDL.
Several reports have shown and characterised the expression of TLR-4, TLR-1, TLR-2, and 
to a lesser extent TLR-5, in human atherosclerotic plaques in murine models of 
atherosclerosis (Xu 2001; Edfeldt 2002), where they have been mainly localised to 
macrophages and ECs. Interestingly, TLR expression is closely related to the fimctional 
status of various subsets of T-cells where TLR-3, -6, -7 and -9 have been demonstrated to be 
expressed on CD4^ T-cells (Sutmuller RP 2006). Our results showed that there were no 
changes in expressions of CD4^CCR6^ expressing TLR-2^ and TLR-4^ in all culture 
conditions. These findings were consistent with previously published results that showed no 
detection of TLR expression on CCR6^ ap TCR T-cells that are highly enriched with Thl7 
cells. They only detected expression of TLR-2, TLR-1 and dectin-1, but not TLR-4 in IL-17- 
expressing subset of yô T-cells (Martin, Hirota et a l 2009). In addition, other studies have 
shown that naïve CD4^ T-cells do not express significant levels of mRNA and intracellular 
protein levels of TLR-2 and TLR-4, but only a few CD3^ T-cells expressed TLR-1, -2 and -4 
on the cell surface in a resting state (Babu 2006). However, activated or memory T-cells 
expressed considerable levels of cell surface TLR-2 and TLR-4 (Liu 2006; Sutmuller 2006). 
However, TCR stimulation using cross-linked anti-CD3 monoclonal antibody (mab) has been 
shown to increase TLR-2 and TLR-4 cell surface expression on naïve human and murine 
CD4^ T-cells (Komai-Koma 2004; Liu 2006). However, the wide array of TLRs expressed by 
various T-cell subsets which may include Thl7 cells suggest the potential involvement of 
these TLRs in the direct regulation of these cells (Liu 2007; Rahman 2009).
In addition, CD36 is also a major cellular receptor for oxLDL (Kunjathoor 2002). We have 
shown for the first time that treated Thl7 cell induced culture and TCR treated CD4 culture 
induced the expression of CD36. To date, there are no reports regarding the surface 
expression of CD36 in Thl7 cells. Previous studies have only found the expression of this 
molecule on yô T-cells at the RNA and protein levels (Lubick 2006). The expression of CD36 
by resting yô T-cells increased following PMA/ionomycin treatment (Lubick 2006). In
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addition, it has been shown that oxLDL can enhance its own uptake by increasing the 
expression of CD36 in J774 cells, a murine macrophage cell line (Han 1997). The mechanism 
by which oxLDL upregulates the expression of CD36 involves the activation of the 
transcription factor PPARy, which is a member of a the nuclear hormone superfamily that can 
heterodimerise with retinoid X receptor (RXR) and can act as a transcriptional regulator of 
genes encoding proteins involved in lipid metabolism (Nagy 1998; Tontonoz 1998). The 
expression of CD36 especially in the treated Thl7 cell induced culture may suggest that the 
oxLDL may directly interact with Thl7 cells via CD36 which may regulate the functional 
activity of Thl7 cells, especially their cytokines secretion such as 1L-17A which plays an 
important role in the development of atherosclerosis.
The differentiation of naïve T-cells into effector T-cells is regulated by the cues derived from 
their microenvironment, especially cytokines (Chaudhry, Rudra et ah 2009). Cytokine 
receptor signalling leads to activation of the signal transducer and activator of transcriptions 
(STAT), a family of transcription factors (Chaudhry, Rudra et a l 2009). The activation of 
STAT-3 in response to pro-inflammatory cytokines such as lL-6 induces the expression of 
RORyt and RORa, key transcription factors in the differentiation of Thl7 cells (Mangan 
2006; Veldhoen 2006; Zhou 2007). Our study demonstrates that oxLDL, IL-6 and TGF-p 
increased the expression of the phosphorylated form of STAT-3 in CD4^ T-cells. TCR treated 
CD4^ further increased the expression of p-STAT-3, whereas treated Thl7 cells induced 
culture had the highest increment in concentration of p-STAT-3 among other treatments, 
which indicates the increased number of Thl7 in that culture. These results also suggest that 
oxLDL regulates the Thl7 cells fimctions by modulating STAT-3 phosphorylation. Our 
findings were supported by previous studies that showed that oxLDL can induce the 
expression of STAT-1 and STAT-3, two transcription factors that mediate the effect of 
cytokines and growth factor in lymphoid cells (Maziere 1999). Despite the fact that different 
groups have shown the stimulatory effect of oxLDL on the secretion of cytokines and growth 
factors (Maziere 1999), the effect of oxLDL on STAT transduction pathway has not yet been 
reported.
lL-17 is the hallmark cytokine for Thl7 cells that has been extensively studied in several 
inflammatory and autoimmune disorders. IL-17A and IL-17F (which are 55% homologous) 
are both secreted by Thl7 cells and the most characterised to date (Chen, Crother et al 
2010). Our results demonstrated that TCR treated CD4^ increased the secretion of 1L-17A
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and IL-17F, and these cytokines further increased in the treated Thl7 cell induced culture. 
This observation may correlate with the previous finding that oxLDL induced 
phosphorylation of STAT-3 and mediates the secretion of 1L-17A and IL-17F by the binding 
with i/i  7n/7/7 ^ promoter (Chen, Laurence et al. 2007). Thl7 cells are not the only source of 
1L-17A and -F  as these cytokines can also be synthesised by CD8^ T-cells, yÔ T-cells and 
polymorphonuclear cells (PMN) (de Boer, van der Meer et al. 2009). Mast cells have also 
been found to be capable of secreting 1L-17F (Weaver, Hatton et al. 2007). The local 
expression of IL-17A and IL-17F have also been demonstrated in the atherosclerotic plaques 
from all stages of plaque development and in the adventitia of normal, as well as diseased, 
arteries (Bid, Rao et al. 2009). Therefore, the regulation of STAT-3 phosphorylation by 
oxLDL may modulate the secretion of 1L-17A and BL-17F not only by Thl7 cells but the 
other lL-17-producing cells in the atherosclerotic plaque.
There were several limitations of our study. Since, the chemokine receptor CCR6 is not only 
expressed by Thl7 cells but also on a distinct subset of mouse Treg cells (Kleinneweitfeld
2005), there is a possibility that TLR-4 and CD36 expression derived from mouse Treg cells. 
It also has been reported that naive CD4^CD25^ Treg cells express TLR-4 (Caramalho 2003). 
Besides that, the numbers of events for detection of TLR-2, -4 and CD36 by using flow 
cytometry need to be increased during acquisition in order to obtain reproducible results. 
Furthermore, the levels of p-STAT-3 detected in all the treatments are below the detection 
limit because the p-STAT-3 standard curve has range from 390 pg/ml to 50 ng/ml. The level 
of 1L-17A and 1L-17F detected in the supernatant of untreated CD4, treated CD4 and 
cytokine treated CD4 were also below detection limit possibly because all the culture 
conditions did not differentiate CD4^ T-cells into Thl7 cells which secreted both of the 
cytokines. Furthermore, the effect of oxLDL which induced IL-17A and IL-17F secretion is 
not supported by the data due to lack of proper control such as TCR treated CD4 without 
oxLDL and treated Thl7 cells induced without oxLDL.
From the present study, we can suggest that during atherogenesis, oxLDL may directly 
internet with Thl7 cells via CD36 expressed on their surface. However, whether CD36 
engaged directly on Thl7 cells influences the parameters of Thl7 cell function needs to be 
further explored. Furthermore, whether the engagement of oxLDL by Thl7 cells may induce 
the phosphorylation of STAT-3, which may mediate the secretion of 1L-17A and IL-17F by 
these cells, need further investigation, which should include proper control. Understanding of
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this mechanism may prove to be crucial in manipulating the fonction of Thl7 cells in the 
atherosclerotic plaques as a potential strategy for atherosclerosis management strategy.
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C H A P T E R  6
T H E  R O L E  O F  T H 1 7  C E L L S  IN  A T H E R O S C L E R O S IS  D E V E L O P M E N T  IN
A P O E  M IC E
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6.1 Introduction
The mechanism of Thl7 cell differentiation in atherosclerotic plaques has been described in 
the preceding chapters. The secretion of lL-6 and TGF-P following oxLDL-treated DCs and 
oxLDL-treated SMCs may stimulate the differentiation of Thl7 cells from CD4^ T-cells. 
Other intra-plaque sources of these cytokines may influence the differentiation of Thl7 cells 
in the atherosclerotic plaque. Furthermore, direct interaction of oxLDL with Th7 cells via 
CD36 may regulate their ftinctional activity in the plaques. However, the role of this subset in 
the atherogenesis is not clear and merits ftirther investigation to determine whether induction 
of Thl7 cells has pro- or anti-atherogenic effects. Therefore, this chapter describes an 
important investigation regarding the role of Thl7 cells in the atherosclerosis development in 
apoE' "^ mice.
ApoE’^ ' mice on a C57BL/6 background have been widely used to investigate the 
pathogenesis of atherosclerosis because of their close similarities with the pathophysiological 
process in humans (Zhang SH 1992). These mice spontaneously develop atherosclerotic 
lesions on a standard chow diet and the disease progression can be accelerated by feeding 
them with a western diet (Nakashima 1994). Fatty streak formation is usually first observed 
in the proximal aorta after 3 months when they are fed, whereas foam cells are observed as 
early as 10 weeks of age (Piedrahita 1992; Plump 1992). The apoE" '^ strain of mice have 4 
times higher levels of cholesterol compared to their background strain litter mates: 8 mmol/L 
compared to 2 mmol/L in C57BL/6J mice. In addition, apoE"^ " mice composed only 45% of 
the normal levels of HDL and they have 68% more triglycerides than wild-type mice, and are 
also characterised by a dramatic shift in the plasma lipoprotein profile, from HDL to VLDL 
(Jawien J 2004).
In order to increase Thl7 cells population in apoE'^’ mice, pertussis toxin (PTx) and an anti- 
CD25 monoclonal antibody, PC61 were used. PTx is a major virulence factor of Bordetella 
pertussis, the causative agent of whooping cough in humans, and belongs to the A-B structure 
class of bacterial toxins (Andreasen, Powell et ah 2009). PTx is known to induce the 
maturation of DCs leading to the differentiation of naïve CD4^ T-cells into Thl and Th2 cells 
(Hofstetter 2002; Hou 2003). Several reports have demonstrated that in vivo treatment of PTx 
in C57BL/6, B6 and BALB/c mice can reduce the number of mouse Foxp3^CD4^CD25^ 
regulatory T-cells (Treg), and impair their immunosuppressive functions (Cassan 2006; Chen
2006). Recently, Cheng et al revealed that PTx can also promote the synthesis of lL-17-
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producing CD4 T-cells both in vivo and in vitro via pro-inflammatory cytokines, such as lL-6 
and IL-lp (Chen, Howard et ah 2007). Therefore, PTx can promote the differentiation of 
Thl 7 cells by inhibiting Treg cells (Cassan 2006; Chen 2006).
Since both Treg cells and Thl? cells require TGF-P for their differentiation, the depletion of 
Treg cells using anti-CD25 and PC61 may increase Thl 7 cell number. TGF-p induces Thl 7 
cell differentiation in a concentration dependant manner (Zhou 2008). At low concentrations, 
TGF-p synergises with lL-6 and IL-21 to stimulate Thl 7 cell differentiation, whereas at 
higher concentrations TGF-p promotes Treg cell (Bettelli, Carrier et a l 2006; Mangan 2006). 
A study showed that mice treated with anti-CD25 mab displayed lower numbers of Treg cells 
(Kohm 2006). The injection of lOOpl of PC61 intra-peritoneal induced a reduction of Treg 
cells by 75.5%, which lasted for approximately 10 days (Matsushita 2008). It has been also 
shown that the use of PC61 can induce a marked loss of cell-surface IL-2Ra chain expression 
after its administration, with an associated elimination of up to 60% of FoxP3^ cells and 
CD25 down-regulation in the remaining population of Treg cells (McNeill 2006). The 
previous studies by our group member. Dr. Chrysoula Pyriedes also demonstrated that PC61 
treatment significantly reduced Treg cells in the apoE"^ " mice fed with normal diet and HFD 
for 8 weeks (unpublished data). Therefore, this supports the hypothesis that PTx and PC61 
can induce Thl 7 cells by suppressing Treg cells, and may affect the subsequent progression 
of atherosclerosis.
6.2 Aim
To investigate the effect of the induction of Thl 7 cells on the atherosclerosis development 
using apoE" '^ mice following intraperitoneal injection of PTx and PC61, or a combination of 
both.
6.3 Objectives
The aim will be achieved by the following objectives:
1. To assess the expression of IL-17A^ and IL-17F^ on both CD4^CD25^ expressing 
cells and CD4'lRORyt^ expressing cells after all treatments using flow cytometry 
analysis.
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2. To study the mRNA expression of signature cytokines for Thl/Th2ATreg/Thl7 cells in 
splenocytes derived from treated animals.
3. To quantify the cytokines using plasma samples of immunised mice using cytometric 
bead array (CBA).
4. To examine the effect of PTx and PC61 treatment on the plasma lipid profiles (total 
cholesterol, high density lipoprotein (HDL) and triglycerides) using commercial kits.
5. To determine the effect of PTx and PC61 on atherosclerotic plaque development in 
the aortic sinus of immunised mice.
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6.4 Materials and methods
6.4.1 A n im al a n d  ex p e rim e n ta l design
Six week old of female apoE‘^‘ mice (strain B6.129P2-ApoetmlUnc/J), bred in house, were 
used. The animals were divided into 4 groups, 5 mice in each, and fed with a high fat diet 
(HFD) (Harlan, UK) for 12 weeks. The high fat diet contains 5% lard, 1.25% cholesterol and 
0.25% sodium cholate. A group of mice were left untreated and used as controls; the other 3 
groups were intraperitoneally injected with 400 ng of PTx (Sigma Aldrich, UK), 200 pg 
PC61 (prepared by Dr. Chrysoula Pieredes), or a combination of both, respectively. Mice 
were injected at weeks 6, 8 and 10, and euthaniased at week 12. Blood fi*om the abdominal 
aorta, the heart and the spleen were collected at termination for further analysis.
6.4.2 D etec tion  o f  T h l7  cells b y  flow  c y to m e try  ana lysis
Splenocytes were isolated and counted as described previously in Chapter 2 section 2.2.2.1. 
Cells (1x10^ per sample) were stimulated with phorbol 12-myristate-13-acetate (PMA) (50 
ng/ml, Fluka, UK) and ionomycin (800 ng/ml. Sigma Aldrich, UK) for 5 hours in the 
presence of 2 pM of monensin (eBioscience, UK). The staining protocol involved first the 
staining of cell surface markers, such as CD4 (PerCP) and CD25 (RPE), followed by 
intracellular labelling to detect RORyt (RPE), 1L-17A (Alexa Fluor 647) and IL-17F (Alexa 
Fluor 488) cytokines using a cocktail of anti-mouse fluorescently labelled monoclonal 
antibodies (AbD Serotec, UK and eBioscience, UK). Samples were analysed by flow 
cytometry using a BD FACS Canto (BD Biosciences, UK) and BD FACS Diva Software 
v5.1. Events (100,000) were recorded and analysed. All staining protocols and gating 
strategies were described previously in Chapter 2 section 2.2.5.
6.4.3 D etection  o f  cy tok ines a n d  tra n s c r ip tio n  fac to rs  m R N A  b y  R T -P C R
Total RNA extracted from isolated splenocytes was reverse-transcribed into cDNA as 
previously described in Chapter 2 sections 2.2.3.1 and 2.2.3.2, respectively, and further 
amplified by PCR. Levels of mRNA encoding mouse Thl and Th2 cytokines (IFNy and IL- 
4), Thl 7 cytokines (IL-17A and IL-17F), and the transcription factors for Thl (T-bet) and 
Th2 (GATA-3), Treg (Foxp3) and Thl 7 (RORyt) cells were amplified by RT-PCR as 
described in Chapter 2 section 2.2.3.3. Semi-quantitative levels of cDNA expression were 
measured by agarose gel densitometric analysis using SynGene Bioimaging controlled by
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GeneSnap software and normalised to GAPDH mRNA housekeeping gene as described in 
Chapter 2 section 2.2.4.3. The primer sequences and products size are shown in Table 6.1.
Table 6.1 The primer sequences and product size
Name Primer Sequences Product size
T-bet Forward CCTGGACCCAACTGTCAACT 157
Reverse AACTGTGTTCCCGAGGTGTC
GATA-3 Forward CCGAAACCGGAAGATGTCTA 258
Reverse AGGGCTCTGCCTCTCTAACC
RORyt Forward TGCAAGACTCATCGACAAGG 177
Reverse AGGGGATTCAACATCAGTGC
IL-17A Forward GCCCTCCACAATGAAAAGAA 382
Reverse TTTCACCCCATTCAGAGGAG
IL-17F Forward TCCCCTGGAGGATAACACTG 127
Reverse GGGGTCTCGAGTGATGTTGT
IFNy Forward CACGGCACAGTCATTGAAAG 676
Reverse CGCAATCACAGTCTTGGCTA
IL-4 Forward TCAACCCCCAGCTAGTTGTC 351
Reverse TGGACTCATTCATGGTGCAC
FoxpS Forward CAACCTAGCCCCAAGATGAA 241
Reverse CCAGATGTTGTGGGTGAGTG
TGFp Forward GCTCCTGAATTGAGCAGAGG 399
Reverse TCTGGAGACAGGAGCCATCT
GAPDH Forward AGAACATCATCCCTGCATCC 110
Reverse CACATTGGGGGTAGGAACAC
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6.4.4 P la sm a  cy tok ine  p ro file  ana lysis
Plasma samples obtained at termination from the apoE"^ " mice were used to assess cytokines 
profile. Plasma levels of IL-2, IL-4, IL-6, fFN-y, TNFa, IL-17A and IL-10 were detected 
using a commercial cytometric bead array (CBA) kit for mouse Thl/Th2/Thl7 (BD 
Biosciences, UK) following the manufacturer’s recommendations. The kit uses bead array 
technology to simultaneously detect multiple cytokines in a variety of samples. Seven bead 
populations with distinct fluorescence intensities are coated with capture antibodies specific 
to IL-2, IL-4, IL-6, IFN-y, TNFa, IL-17A, and IL-10 proteins. The seven bead populations 
are mixed together to form the bead array, which is resolved in a red channel (ie, FL3 or FL4) 
of a flow cytometer. During the assay procedure, the cytokine capture beads are mixed with 
recombinant standards or plasma samples and incubated with the PE-conjugated detection 
antibodies to form sandwich complexes. The intensity of PE fluorescence of each sandwich 
complex reveals the concentration of that cytokine. Samples were analysed by flow 
cytometry using FACS Canto and FACS Diva software version 5.2 (BD Biosciences, UK) by 
Dr. Alexandra Bermudez-Fajardo.
6.4.5 L ip id  p ro file  ana lysis
Plasma samples obtained at termination from the apoE'^" mice wer used to assess the levels of 
total cholesterol, high density lipoprotein (HDL) and triglycerides. Plasma HDL-cholesterol, 
total cholesterol and triglycerides were determined using commercial kits based on the 
manufacturer’s recommendations. Measurements in mmol/L were carried out using a ILab- 
650 clinical chemistry auto-analyzer (Instrumentation Laboratory UK Ltd) by Dr. Max 
Wong.
1) Q u a n tif ic a tio n  o f  to ta l  ch o leste ro l level
Cholesterol in all lipoprotein sub classes was measured to determine the total cholesterol 
level in plasma. Measurement of total cholesterol alone is not the right indicator for CVD 
risks as it includes HDL and LDL measurement. However, it can still be used for initial 
screening, but complete lipid profile analysis is always required to determine the risk of 
CVD. Plasma samples were prepared in a dilution 1:5 in saline solution (total volume per 
sample was 80 p.1). Total cholesterol levels were determined using a commercial kit from 
Instrumentation Laboratory UK Ltd (Cheshire, UK) according to manufacturer’s 
recommendation. The analysis was carried out using ILab-650 clinical chemistry auto­
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analyzer (Instrumentation Laboratory UK Ltd). The principle of the test is demonstrated in 
Figure 6.1, and the results are displayed in mmol/L.
IL Test*™ Cholesterol principle
Cholesterol esterase
Cholesterol + H2O ----------------------------------------►Cholesterol + Fatty acids
Cholesterol oxidase
Cholesterol ester + O2 ------------------------------------► Choles-4-en-3-one + H2O2
Peroxidase
2H2O2 + 4-aminoantipyrine + phenol------------------► Quinoneimine + 4H20
Figure 6.1 Total cholesterol principle. The end point analysis is based on the above reaction. 
Quinoneimine production is proportional to the cholesterol concentration in the plasma. The 
measurements of absorbance were taken at a primary wavelength and a blanking wavelength of 
510/700 nm.
2) Q u a n tif ic a tio n  o f  trig ly ce rid es  levels
Triglycerides are the major component of animal fats and vegetable oil. High levels of 
triglycerides are correlated with the increased atherogenicity of LDL. Triglycerides levels are 
elevated after a meal, and high levels can influence the accuracy of HDL and LDL 
measurements. Samples were processed as detailed in the protocol for cholesterol level 
quantification above.
IL Test™ Triglycerides Principle
Lipoprotein lipase
Tnglycendes-------------------------------------► Glycerol + Fatty acids
Glycerol kinase
Glycerol + ATP--------------------------------- ► Glycerol-3-phosphate + ADP
Glycerol phosphatise oxidase 
Glycerol-3-phosphate + O2 -----------------------------►Dihydroxyacetone Phosphate + H2O2
Peroxidase
H2O2 + 4-choIorophenol ------------------------------- ►Quinoneimine dye + H2O2
+ 4-aminoantiprytine
Figure 6.2 Tyglycerides measurement principle. The end point analysis is based on the above 
reaction. Quinoneimine production is proportional to the triglycerides concentration in the plasma. The 
measurements of absorbance were taken at a primary wavelength and a blanking wavelength of 
510/700 nm.
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3) Quantification of HDL levels
HDL is known as good cholesterol because of its role in transporting cholesterol from tissues 
to liver. Samples were processed as detailed in the protocol for cholesterol level 
quantification above.
A clearance method is used for detecting HDL in plasma because it can improve the 
specificity and accuracy of the samples containing abnormal lipoproteins by removing it from 
the sample.
C le a ra n c e  s tep s
Cholesterol esterase Catalase
CM, LDL, VLDL —  ------——---- ► Cholestenone + H2O2 ---------------► H2O + O2
Cholesterol oxidase
A ssay  steps
Cholesterol esterase Peroxidase
HDL  Cholesterol oxidase~~*‘ Cholestenone + H2O2 ------------► Colour development
Figure 6.3 The principle of HDL measurement. A randox two steps clearance method is used to 
prevent the unspecificity and inaccuracy due to abnormal lipoprotein in the plasma. The removal of 
non-HDL will enhance the specificity and accuracy of the test.
6.4.6 A nalysis o f  a th e ro sc le ro tic  p laq u e s  a n d  p la q u e  v u ln e ra b ility
The proximal 150 pm of the aortic sinus were sectioned into 8 pm sections. The sections 
were stained; and the total plaque areas and collagen contents were measured using the 
following protocol:
1) F o rm a lin  fixed , w ax  em b ed d ed  section  s ta in in g  u s in g  H aem ato x y lin  a n d  E o sin  
(H & E )
The tissues were immersed in the fixative (10% neutral phosphate buffer formalin) for a 
minimum of one week before being processed.
2) T issu e  selection  a n d  p re p a ra tio n  fo r  p rocessing
Tissue sections of 2-3 pm in thickness were selected for each samples and any roughly cut 
surface was trimmed off. One or more tissues were placed in a plastic cassette and the metal 
lids were attached. A mesh insert and a finer mesh lid were utilised to avoid any small pieces
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of tissues being washed out via the holes in the cassette. The cassette was placed in a basket 
containing formaldehyde solution.
3) D e h y d ra tio n , c le a rin g  a n d  im p re g n a tio n  w ith  w a x  u s in g  tissue  p ro cesso r, h is to k in e tte
The baskets of cassettes were placed in the automatic tissue processor, with the histokinette 
preloaded with processing reagents. The histokinette timer was set to process the tissues 
based on the following schedule:
Dehydration 70% alcohol 
85% alcohol 
95% alcohol 
100% alcohol I 
100% alcohol II 
100% alcohol III
2 hours 
2 hours 
2 hours 
2 hours 
2 hours 
2 hours
Clearing Toluene I 
Toluene II
2 hours 
2 hours
Impregnation Paraffin wax I 
Paraffin wax II
2 hours 
2 hours
The alcohol solution was prepared from ethanol 96 whereas 100% alcohol was prepared from 
absolute ethanol. The wax used was fibrowax (BDH Ltd, UK) with a melting point of 56°C. 
The wax reservoir on the wax embedding section was turned on to melt the wax overnight.
4) B lock ing  o u t th e  tissues to  fo rm  w ax  b locks
The basket containing the cassette was removed from the histokinette carefully to prevent the 
wax from dripping. The cassettes were slid out of the basket and into the molten wax in the 
wax bath of the embedding station with the cold plate turned on. The cassettes were then 
removed from the wax bath and the lid was removed carefully to avoid any tissues adhering 
to the lid. Some molten wax were dispensed into a metal base mould and placed on the hot 
plate. All the tissue pieces were transferred quickly from the cassette into the molten wax in 
the mould using the heated forceps. The tissue was placed in the correct orientation so that
155
the surface to be cut was resting on the base of the mould. The mould was then transferred 
onto the cold plate to harden the wax at the bottom for the tissues to be held in place. The 
plastic cassettes were placed onto the mould and topped up with molten wax before placed 
back on the cold plate to solidify. The blocks were removed from the moulds once the wax 
had gone cold. Any excess wax from the edges of the block was scraped using a scalpel to 
enable the block to fit into the holder of the microtome.
5) S ection  c u ttin g  u s in g  a  m ic ro to m e
The wax block was attached into the block holder of the Microtome 2040 Autocut 
(Cambridge Instruments Co. Inc, USA). The angle of the block in the holder was lined up 
correctly in relation to the blade holder. Initially, the section thickness was set around 15 pm 
and the excess wax was trimmed until the required portion of tissue was reached using the 
rough blade. The waste wax sections were removed using soft paint brush from the blade. 
Once the block was trimmed to a suitable depth, it was removed and placed face-down into a 
tray of ice for a minimum of 10 minutes, but not more than 30 minutes, before starting the 
final section. This helped the section remained firm and intact.
Then, the section thickness was set to 5 pm for the final section. The cold block was placed 
in the block holder and adjusted to required angle. A new blade was used for final sections. 
The sections were lifted using forceps and were floated in warm distilled water in the water 
bath pre heated at 40°C to 50°C. The half submerged slide in the water was positioned near 
the section and withdrawn it so as the flatten sections to be brought with it. The slides were 
then dried on the slide-fiying hot plate for one to two hours to ensure that it was dry enough 
for the subsequent staining process.
6) S ta in in g  w ith  H aem ato x y lin  a n d  E o sin  (H & E )
Haematoxylin binds to acidic groups found in the nucleic acids. Such components of cells are 
known as ‘basophilic’. Haematoxylin is water-soluble and has a reddish colour in acidic 
solutions, but turns blue in alkaline and become permanently fixed in tissues. This is a 
regressive staining method in which sections are over-stained and the stain is then selectively 
removed in acid alcohol. On the other hand, Eosin is a background stain which will stain 
mainly the cytoplasm and other non-nuclear components referred to as ‘eosinophilic’ or 
‘acidophilic’.
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Section slides were placed on a rack and the following staining procedure was carried out: 
De-wax In xylene - 3 mln 
Transfer to 100% alcohol -1 mln 
Rehydrate in 70% alcohol -1 mln 
Rehydrate in 50% alcohol - 1 mln 
Rehydrate in distilled water -1 min 
Stain in haematoxylin -15 min 
Rinse in running tap water -1 mln 
Differentiate in 1% acid alcohol - 5-10 sec 
'Blue' in running tap water -10 min 
Stain in 1% eosin - 2 mln
Rinse briefly in tap water to wash away excess stain.
Dehydrate in 85% alcohol - 0.5 min
Dehydrate in 100% alcohol twice - 0.5 min
Clear in xylene twice - 0.5 min 
Mounting with DPX
7) Orcein-Van Gieson staining
This tri-chromic technique is used to differentiate elastin from collagen, as both give the 
same colour in normal H&E stain. Orcein is a vegetable stain very specific for elastin fibres, 
and it’s capable of staining the very fine fibres with a deep brown colour. Van Gieson is a 
specific staining for collagen and gives a pink red coloration. Weigerts iron haematoxylin is 
used to stain the nucleus in dark blue.
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Solutions required for Orcein/Van Gieson staining
Weigerts iron haematoxylin: Weigerts iron haematoxylin was prepared by mixing equal 
parts of solution A and B. The mixed solution has a very dark purplish colour and should be 
used immediately. However, solutions A and B can be stored separately.
Solution A: 1% (w/v) Iron haematoxylin in absolute ethanol
For 500 ml solution: 500 ml of absolute ethanol was put in a 500 ml bottle and placed and 
stirred on a magnetic stirrer, and 5 g of iron haematoxylin was added while stirring. The 
solution was left for mixing for another 5 minutes. The magnetic stirrer was then removed, 
and the bottle was labelled as Solution A for Orcein/Van Gieson staining.
Solution B: 4% (v/v) aqueous ferric chloride solution and 1% (v/v) of concentrated HCl 
dissolved in distilled water
For IL solution: First, 30% (w/v) ferric chloride solution in distilled water was prepared by 
mixing 12 g of ferric chloride with 40 ml of distilled water in a glass bottle. The solution was 
mixed until the ferric chloride has completely dissolved. In the fume hood, 950 ml of distilled 
water was added into a IL glass bottle. The solution was then stirred and 10 ml of 
concentrated HCL was added slowly. The solution was kept stirring for another 2 minutes, 
before 40 ml of 30% aqueous ferric chloride solution prepared in step 1 was added. The 
solution was then mixed for another 3 minutes. The magnetic stirrer was removed and the 
bottle was labelled as Solution B for Orcein/Van Gieson staining.
Orcein Solution: 1% (w/v) Orcein, 1% (v/v) concentrated HCl in 80% Ethanol
For 300 ml solution: In the fume hood, 300 ml of 80% ethanol was added to a glass bottle and 
3 g of Orcein was added while stirring. The solution was kept stirring until it completely 
dissolved, and 3 ml of concentrated HCL was then added.
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The section was stained according to the following protocol:
6
7
8
9
10 
11 
12
13
14
15
16
17
18 
19
Process
De-waxing
Rehydrate
Elastin staining
Rinse
De-coloration
Wash
Nuciei staining
Wash
Differentiate
Wash
Rinse
Coiiagen staining
Rinse
Dehydrate
Mounting
Soiution Time
Xylene 3 min
96% Ethanol 1 min
70% Ethanol 1 min
70% Ethanol 1 min
Distilled H2O 1 min
Orcein (1) 30 min (2)
Distilled HgO 1 min
95% Ethanol 2 min
100% Ethanol
1 % Acid alcohol 8 min
Tap water 5 min
Weigerts Iron haematoxylin (3) 15 min
Tap Water 1 min
1 % Acid Alcohol (4) As required
Tap water 10 min
Distilled water 30 s
Van Gieson solution 2 min
Distilled water 30 s
80 % Alcohol 30 s
96% Alcohol 30 s
96% alcohol 30 s
Xylene 30 s
Xylene 30 s
DPX
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6.4.7 Morphometric analysis
Photography
Images of stained sections were captured using a Leica microscope connected to a Leica 
camera and the corresponding software. All images were captured at the same number of 
pixels (764 width x 574 height) and at the same lens objective (lOx). Prior to analysis, a 
matrix of all the images was compiled in Adobe Photoshop (V 7.0) and saved as a Jpeg file 
that could be opened later in ImageJ.
Image analysis
Analysis of the captured images was carried out using an open source software known as 
ImageJ (Version 1.36b), developed by Wayne Rasband fi’om the National Institutes of 
Health, USA, available at httpV/rsb.infbjuh.gov/ij/. This software was used to measure the 
area of the atherosclerotic plaques and collagen content in the plaque of apoE‘^‘ mice 
(Rasband 1997-2009; AbramofT2004).
Images calibration
The scale was set up using a measuring calibrating graticle by drawing a straight line on top 
of the graticle by setting a known distance of 100 pm and a pixel aspect ratio of 1:1.
Measuring procedure
Plaque Size: The Jpeg matrix created for each animal was opened in ImageJ and the image 
was calibrated. Area and Perimeter were taken as the measurement. The measurement was 
carried out by drawing around each of the plaque using the polygon tool. The total plaque 
area was determined by calculating the sum of all the plaque areas obtained ft-om one image.
SMCs and Collagen Content: A Jpeg matrix was created consisting of 2 sections taken from 
the intermediate plaque level for each animal and was opened in ImageJ. The system was 
calibrated as described before. The polygon tool was used to select each plaque in the aortic 
sinus. Then, the image of the plaque was copied and saved as a new Jpeg image. Prior to 
analysis, the image type was converted to an 8-bit black and white image. The measurements 
were performed by setting the area, area fraction, mean gray value perimeter and limit to 
threshold. Firstly, the total plaque area and perimeter were measured for each plaque in the 
image. Next, the image threshold was adjusted to determine the collagen/SMCs rich areas
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that were highlighted in red. The area and perimeter reading were then taken. The modified 
images showing the collagen/SMCs rich areas were saved as new Jpegs for future reference 
and masks of the images were also created and saved. The collagen/SMCs rich area of each 
plaque was expressed as a percentage of the total plaque area. The average % collagen/SMCs 
rich area was calculated by obtaining the mean collagen/SMCs fi-om all the plaques in each 
image. The average from the two images for each animal was then calculated to give one 
value for the average % collagen/SMCs in the plaque for each animal.
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6.5 Results
6.5.1 A  co m b in a tio n  P T x  a n d  PC 61 in c re ase d  IL -1 7 A  expression  on  C D 4 CD 25^ 
ex p ressin g  cells
Splenocytes from immunised animals were stimulated with PMA and lonomycin and treated 
with monensin before staining with specific markers to Thl7 cells. Cells were extracellularly 
labelled with CD4 (PerCP) and CD25 (RPE), then followed by intracellular labelling of 
RORyt (RPE), IL-17A (Alexa Fluor 647) and IL-17F (Alexa Fluor 488).
The expression of IL-17A^ on CD4^CD25’ expressing cells was significantly increased in a 
combination of PTx and PC61-treated mice compared to untreated mice (p<0.05) (Figure 
6.4). In addition, the expression of IL-17A^ on CD4^CD25" expressing cells were also 
increased following PTx and PC61 treatment compared to untreated mice, but was not 
statistically significant.
On the other hand, PTx, PC61 and a combination of PTx and PC61 treatment increased the 
expression of IL-17F^ on CD4^CD25' expressing cells compared to untreated mice but not 
statistically different (Figure 6.4).
The expression of IL-17A^ on CD4^0Ryt^ expressing cells also increased in mice treated 
with PTx, PC61 and combination of both, although this was not statistically significant 
(Figure 6.5).
Likewise, PTx, PC61 and a combination of PC61 and PTx treatment did not significantly 
increased the expression of IL-17F^ on CD4^0Ryt^ expressing cells in mice fed with HFD 
(Figure 6.5).
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Figure 6.4 Effect of PTx, PC61 and the combination of both on the differentiation of Th17 cells.
Splenocytes were stimulated with PMA (50 ng/ml) and ionomycin (800 ng/ml) for 5 hours in the 
presence of 2 pM of monensin. The MPI of IL-17A  ^and IL-17F  ^expression on CD4^CD25" expressing 
cells were determined by flow cytometry analysis and representative dot plots and histogram of MPI 
are shown above. The gating was applied based on control in Figure 2.1. A. Untreated mice fed with 
HFD B. PTx treatment on mice fed with HFD C. PC61 treatment on mice fed with HFD D. PTx and 
PC61 treatment on mice fed with HFD. The MPI for IL-17A* expression on CD4^CD25' expressing 
cells (E) and IL-17F  ^expression on CD4^CD25' expressing cells (F) were represented as a bar graph. 
Values are represent as the mean + SD. (n=3) (*P< 0.05).
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Figure 6.5 Effect of PTx, PC61 and combination of both on Th17 ceil differentiation. Splenocytes 
were stimulated with PMA (50 ng/ml) and ionomycin (800 ng/ml) for 5 hours in the presence of 2 pM 
of monensin. The MFI of IL-17A* and IL-17F  ^ expression on CD4^R0Ryt^ expressing cells were 
determined by flow cytometry analysis and representative dot plots and histogram of MFI are shown 
above. The gating was applied based on control in Figure 2.5. A. Untreated mice fed with HFD B. PTx 
treatment on mice fed with HFD C. PC61 treatment on mice fed with HFD D. PTx and PC61 treatment 
on mice fed with HFD. The MFI for IL-17A  ^expression on CD4^R0RYt  ^expressing cells (E) and IL- 
17F* expression on CD4^R0Ryt* expressing cells (F) for each treatment was represented as a bar 
graph. Values represent the mean + SD. (n=3).
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6.5.2 PTx and PC61 treatment induced the mRNA expression Thl7 but not Thl/Th2
and Treg related genes
Analysis of ThlATh2/Thl7 mRNA expression from splenocytes was carried out using RT- 
PCR (Figure 6.6). As shown in the Figure 6.7, our results indicated that PTx, FC61 and the 
combination of both significantly increased the mRNA expression of IL-17A compared to 
untreated mice (p<0.01 and p<0.05). PTx-treated mice significantly induced the mRNA 
expression of IL-17F compared to either untreated (p<0.05) or any other treated group 
(p<0.01). Similar to IL-17A expression, PTx (p<0.05), PC61 (p<0.01) and the combination of 
both (p<0.05) induced the synthesis of RORyt in comparison to untreated mice.
Figure 6.7 also shows that PTx, PC61 or the combination of both had no effect on the 
expression of IFNy, IL-4 or Foxp3. Noticeably, untreated mice were found to have 
significantly higher mRNA levels of TGF-p (p<0.001) and GATA-3 (p<0.01) compared to 
other treated mice, which also had significant higher mRNA expression levels of T-bet 
compared to PC61-treated mice (p<0.05).
6 .5 3  P T x  a n d  P C 61  t r e a tm e n t  in creases  th e  se c re tio n  o f  IL -1 7 A  in  a p o E   ^ m ice fe d  a  
H F D
We used a mouse Thl/Th2/Thl7 CBA kit to determine the levels of IL-2, IL-4, TNFa, IFNy, 
IL-6, IL-10 and IL-17A in the plasma of apoE' '^ mice (BD Bioscience, USA). We found that 
PTx and PC61 treated mice had significantly higher levels of IL-17 (p<0.005) compared to 
untreated (p<0.01) and PTx-treated mice (p<0.05) (Figure 6.8). Neither PTx nor PC61 
increased IL-17A. PTx, PC61 or a combination of the two had no effect on the secretion of 
IL-2, IL-4, TNFa, IFNy, IL-6 and IL-10 (Figure 6.8).
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Figure 6.6 Representative gel electrophoresis for the mRNA expression of Th1/Th2/Treg/Th17 
related genes in splenocytes from treated mice. Total RNA was extracted from the splenocytes 
and cDNA was then obtained. The expression of mRNA encoding IL-17A, IL-17F, RORyt, IFNy, IL-4, 
TGF-p, T-bet, GATA-3, Foxp3 and GAPDH were detected by RT-PCR. The PCR products were 
electrophoresed in a 1.5% agarose gel containing 0.5 pg/ml Gel Red® nucleic acid at 100 V for 30 
minutes. The DNA fragments were then visualised under UV light and the image was captured using 
Syngene® Bio-Imaging System. The intensities of product bands were assessed by densitometrlc 
analysis using the Image Master Gene Snap software.
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Figure 6.7 Effect of PTx, PC61 or a combination of both on the mRNA expression of Th1, Th2,
Treg and Th17 celis cytokines and transcription factors in splenocytes from apoE  ^ mice fed a 
HFD. Total RNA were extracted from the splenocytes and converted into cDNA. The mRNA 
expression of IL-17A (A). IL-17F (B), RORyt (C), IFNy (D). IL-4 (E). TGF-p (F), T-bet (G), GATA-3 (H) 
and Foxp3 (I) were amplified by RT-PCR. The intensities of product bands were assessed by 
densitometric analysis using the Image Master Gene Snap software. The mRNA expression levels of 
IL-17A (A), IL-17F (B), RORyt (C). IFNy (D), IL^ (E), TGF-p (F), T-bet (G), GATA-3 (H) and FoxpS (I) 
were calculated based on ratio against GAPDH. The values represent the mean + SD. (n=3) (*P< 
0.05;**P<0.01; ***P<0.001).
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Figure 6.8 Effect of treatment with PTx, PC61 or both on plasma levels of Thi, Th2 and Th17 
cytokines as measured In apoE^ mice fed a HFD. Plasma levels of IL-17 (A), IL-2 (B), IFNy (C), IL- 
4 (D), IL-6 (E), IL-10 (F) and TNFa (G) were detected using a CBA kit for mouse Th1/Th2/Th17 
following the manufacturer’s recommendations. Samples were analysed by flow cytometry with a BD 
FACS Canto and BD FACS Diva Software v5.1. Values represent the mean + SD. (n=3) (**P<0.01; 
***P<0.001).
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6.5.4 PTx and/or PC61-treated apoE mice fed with HFD had higher total cholesterol 
levels but not HDL and triglycerides
The plasma of treated apoE’^ ' mice fed with HFD were analysed for differences in lipid levels 
as described in section 6.4.5. As shown in Figure 6.9, the mice that were treated with PTx 
(p<0.001), PC61 (p<0.01) and the combination of both (p<0.05) had significantly higher 
levels of total cholesterol compared to untreated mice. The total cholesterol in the PTx- 
treated mice was higher than when PTx and PC61 were used in combination (p<0.01). In 
addition, PTx, PC61 or both used together had low levels of high density lipoprotein (HDL) 
compared to untreated mice, although this was not statistically significant. Triglyceride levels 
in the plasma of all treated mice were higher compared to untreated mice but not statistically 
significant.
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Figure 6.9 Effect of PTx, PC61 and combination of both on plasma llplds profile In apoE^ mice 
fed with a HFD. Plasma total cholesterol (A), HDL-cholesterol (B) and triglycerides(C) were 
determined using commercial kits according to manufacturer’s recommendations. Measurements 
were carried out using a I Lab-650 clinical chemistry auto-analyzer. The values represent the mean 4- 
SD. Levels of significance are indicated as follow: *P < 0.05; **P < 0.01 ; ***P < 0.001. (n=3).
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6.5.5 PC61 alone or the combination of PTx and PC61 increased atherosclerotic lesion 
in the aortic sinus of apoE ^  mice
Following termination, the aortic sinus was stained with H&E and morphometrically 
analysed to obtain the plaque size (Figure 6,10). Histological analysis showed a 
corresponding increase in plaque size, which mirrored the severity of atherosclerosis. As 
shown in Figure 6.10, PC61 (p<0.05) and combination of PTx and PC61 (p<0.001) treated 
mice significantly increased plaque size in the aortic sinus compared to untreated mice. In 
addition, plaque size in mice treated with both PTx and PC61 was bigger than in PTx treated 
mice (p<0.01). PTx treatment in apoE*^ ' mice fed with HFD also increases the plaque size in 
the aortic sinus compared to untreated mice, but this was not statistically significant.
6.5.6 No changes in the collagen content of the plaque developed in the aortic sinus were 
observed upon treatment of apoE ^  mice with PTx, PC61 and a combination of both
The effect of PTx and PC61 treatment on plaque stability was also examined by measuring 
the content of collagen within atherosclerotic plaques using Orcein-Van Gieson staining. 
Figure 6.11 shows that PTx, PC61 and combination of both treatments in the apoE"^ " mice fed 
with HFD reduced the collagen content in the atherosclerotic plaque developed in the aortic 
sinus of those mice, but this was not found to be significantly different.
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Figure 6.10 Effect of PTx, PC61 or both on atherosclerotic plaque size. Representative 
histological sections of aortic sinus from apoE^ mice fed with HFD stained with H&E. A. Untreated B. 
PTx-treated C. PC61-treated D. PTx and PC61-treated. Images were taken at the same number of 
pixels (764 width x 574 height) and the same objective (10x) was used for all the pictures. The graph 
(E) represents the results of the computerised morphometric analysis to determine the size of the 
aortic sinus lesion. The values represent the mean + SD. Levels of significance are as follows: *P < 
0.05; **P < 0.01; ***P < 0.001. (n=3).
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Figure 6.11 Effect of PTx, PC61 or both In atherosclerotic plaque collagen content.
Representative histological sections of aortic sinus from apoE-/- mice fed with HFD stained with 
Orcein/Van Gieson to measure elastin/collagen content. A. Untreated B. PTx-treated C. PC61-treated 
D. PTx and PC61-treated. Images were taken at the same number of pixels (764 width x 574 height) 
and the same objective (10x) was used for all the pictures. The graph (E) represents the plaque 
collagen content expressed as percentage of the total plaque area. The values represent the mean + 
SD. (n=3)
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6.6 Discussion
Thl7 cells are characterised by the secretion of the inflammatory cytokine IL-17, which has 
been demonstrated to participate in autoimmune diseases such as experimental arthritis, 
autoimmune encephalitis and colitis (Dong 2006; Ouyang, Kolls et a l 2008). While the role 
of Thl7 cells has been widely studied in several inflammatory and autoimmune disorders, its 
role in the development of atherosclerosis, another disease with well-known autoimmune and 
inflammatory component, remains controversial.
In the present study, the role of Thl7 cells in atherosclerosis in vivo was investigated. ApoE*^ ' 
mice were treated with PTx and PC61 to induce Thl7 cells. The use of these two compounds 
is known to reduce immunosuppressive Treg cells resulting in an increase of Thl? cells 
(Cassan 2006; Chen 2006; Matsushita 2008). Our study corroborated the above, but we also 
found that the treatment of a combination of PTx and PC61 was found to increase the 
expression of IL-17A^ on CD4^CD25" expressing cells in the splenocytes of apoE’^’ mice. 
The treatment with PTx, PC61 and a combination of PTx and PC61 also increased the 
expression of IL-17F^ on CD4^CD25" expressing cells in the splenocytes of apoE"^ " mice but 
not statistically significant. Likewise, treatment with the PTx, PC61 and combination of PTx 
and PC61 did not significantly increased the expression of IL-17A^ and IL-17F^ on 
CD4^0Ryt^ expressing cells in the splenocytes of apoE' "^ mice fed with HFD. In order to 
support our intracellular staining results, we also assessed the effects of PTx and PC61 on the 
expression of Thl 7 related genes and proteins in splenocytes and plasma of HFD-treated 
apoE' '^ mice, respectively. The treatment of PTx and PC61 and combination of PTx and PC61 
in the apoE"^ " mice fed with HFD increased the expression of the main Thl 7 related cytokine 
gene, IL-17A and Thl7 transcription factor, RORyt gene. However, only PTx injection 
increased another Thl 7 related cytokine gene, IL-17F. These results may suggest that PTx, 
PC61 and a combination of both boost maximal TCR signalling in apoE"^ " mice. IL-17A 
expression sensitive to the strength of TCR signalling, requiring full activation of Ca^^- 
mediated pathways, in addition to signals fi*om the induction and activation of RORyt and 
STAT-3 (Julio 2009). Whether there are other factors that more specifically affect IL-17F 
secretion remains interesting question and need further studies to be carried out. The maximal 
TCR signalling requirement by IL-17A also may relate to its role as a powerful mediator of 
inflammation, strong inducing inflammatory chemokines and neutrophil recruitment (Dong 
2008; Ouyang W 2008). The recent comparisons of IL-17A and IL-17F function also showed
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that IL-17A played a pivotal role in the induction of certain inflammatory and autoimmune 
responses (Yang XO 2008; Ishigame, Kakuta et al. 2009).
On the other hand, at the protein level, only treatment with the combination of PTx and PC61 
increased the secretion of IL-17 cytokine. Different effect of PTx and PC61 treatment on the 
IL-17A at the RNA and protein levels may be due to the defect of translational process in the 
apoE' '^ mice. Translational is the process where the mRNA is translated to produce a protein. 
However, a combination of PTx and PC61 may stimulate other IL-17 producing cells, such as 
CD8 and yô T-cell in the treated apoE‘^‘ mice to secrete more IL-17 in the serum of HFD- 
treated apoE"^ " mice.
Besides the Thl? cells, Thl/Th2 and Treg cells at the gene and protein level in the HFD- 
treated apoE"^ " mice also were determined. At the gene level, PC61 treatment reduced the 
expression of T-bet but the combination of PTx and PC61 did not have any significant effects 
on IFNy, which are the main Thl cells cytokine. PTx, PC61 and the combination of both 
treatments reduced the mRNA expression of Th2 transcription factor GATA-3, but all 
treatments did not have any significant effect on IL-4, also a Th2 related cytokine. 
Furthermore, PTx, PC61 and combination of both treatments reduced the mRNA expression 
of Treg related cytokine; TGF-p but none of the treatments had any significant effects on 
Foxp3, the Treg transcription factor. Likewise, none of the treatments had any significant 
effects on Thl, Th2 or Treg cell related cytokines at the protein level. Reduction in the 
expression of T-bet and GATA-3 following PTx and PC61 treatment may promote Thl 7 cells 
induction in vivo because Thl and Th2 cells are capable of suppressing Thl 7 (Harrington 
2005). However, the possible reduction of the Treg population following PTx and PC61 
treatment may lead to a reduced mRNA expression of TGF-p compared to untreated mice 
(Li, Wan et al 2007). TGF-P produced by Treg cells and other sources provide unique 
mechanisms in balancing the population and immunoregulatory role of Thl 7 cells and Treg 
cells. In addition, there were insignificant fluctuations (p>0.05) of Thl, Th2 and Treg cell 
related gene and cytokines observed in the animals treated with PTx, PC61 and combination 
of both. This observation probably occurred because the animals were sacrificed two weeks 
following the last vaccination at week 10. The effects of all treatment possibly may begin to 
disappear, and the levels of Thl, Th2 and Treg cells start to increase to the normal level.
An atherogenic lipid profile is generally characterised by high levels of total cholesterol, 
triglycerides and LDL-c in combination with low levels of HDL-c (Menown, Murtagh et a l
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2009). Our study showed that PTx, PC61 or treatment with a combination of both increased 
total cholesterol levels without affecting HDL and triglyceride levels in the apoE'^‘ mice fed 
with HFD. These results indicate that the induction of Thl 7 cells by these treatments was 
closely related with the increase of total cholesterol. In support of our speculation, Gao et al 
showed that Thl and Thl 7 cells were highly correlated with the levels of total cholesterol in 
the plasma of apoE' '^ mice (Gao, Jiang et al. 2010). However, they also revealed no 
significant correlation between Thl7 or Thl cells with triglycerides, whereas Thl7 and Thl 
cells did not correlate with the HDL/LDL ratio (Gao, Jiang et al. 2010). The depletion of 
Treg cells by PC61 treatment in apoE" " mice fed with normal and HFD also significantly 
increased the total cholesterol as demonstrated by our group member. Dr. Crysoula Pyriedes 
(unpublished data). She also observed the PC61 treatment significantly increased of 
triglycerides and HDL level in apoE" ' mice fed with normal diet and HFD for 8 weeks. 
Maganto Garcia et al. (2011) demonstrated that splenic Treg cells increased after 4, 8 and 20 
weeks in cholesterol-diet-fed-mice. However, the number of circulating and lesional Treg 
peaked at 4 weeks and reduced significantly at 8 and 20 weeks, concomitant with increased 
number of CD4^ effector T-cells and increased lesion size during this hypercholesterolemia 
period. The decline in the Treg response during prolonged hypercholesterolemia is associated 
with selective decrease of selection ligand such as P and E-selectin, LFA-1 and GITR, which 
reduced their ability to bind to aortic endothelium. They also found more apoptotic Treg cells 
during prolonged hypercholesterolemia (Maganto Garcia 2011). However, further studies 
need to be carried out to determine the mechanism of how removing Tregs cells and 
increasing Thl 7 cells results in different levels of total cholesterol, HDL and triglycerides in 
serum of apoE" ' mice fed with HFD.
This study also assessed, for the first time, the effect of intraperitoneal injection of PTx, PC61 
and the combination of both on the size and composition of atherosclerotic plaque lesions in 
apoE^" mice (Paigen 1987; Rosenfeld 2000). The aortic sinus is the initial segment, of 
approximately 300 pm, of the ascendant aortic arch containing the aortic valves, which are 
characterised by the development of homologous atherosclerotic plaques (Paigen 1987). Our 
results show that PC61 alone or in combination with PTx can accelerate atherosclerotic 
plaque development in the aortic sinus of apoE'^’ mice. Interestingly, the increase of 
atherosclerotic plaque development in the aortic sinus correlated with the induction of Thl 7 
in the apoE*^ ' mice. This observation is supported by a previous study by Gao et al who 
showed that the area of plaque correlated with the proportion of Thl, and was also closely
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associated with Thl 7 cell subset (Gao, Jiang et a l 2010). This further strengthens the notion 
that Thl7 cell is associated with atherosclerosis development.
The measurement of collagen content is also important to determine the inflammatory status 
of arteriosclerotic plaque lesions. A stable fibrous cap is characterised by a rich content of 
collagen and the presence of abundant SMCs, providing flexibility to the blood vessel and 
therefore a lower propensity to rupture (Bauriedel 1999; Newby 1999; Rekhter 2000). PC61 
and a combination of PTx and PC61 reduced the collagen content of the plaque developed in 
aortic sinus eventhough it was not statistically significant. This observation may be 
associated with the reduction of Treg cells, which facilitate the induction of Thl 7 cells 
following PTx and PC61 treatment. The co-transfer of Treg cells have been shown resulted in 
a marked reduction in the infiltration of T-cells (85% reduction) and macrophages (35% 
reduction) into plaques, and substantial increase in collagen content (58%), suggesting 
reduced plaque inflammation and increased plaque healing (Ait-Oufella 2006). The possible 
depletion of Treg cells by PC61 in apoE’^ ' mice may reduce collagen accumulation but 
increased T-cells and macrophages infiltration, indicating enhanced plaque inflammation and 
reduced plaque healing (Ait-Oufella 2006). In addition, this observation may have correlation 
with the composition of SMCs in the plaque because SMCs themselves are responsible for 
the production of collagen. No significant changes of IFNy expression at the gene and protein 
levels in treated apoE'^" mice may conserve the SMCs content in the plaque. IFNy is capable 
of inhibiting the proliferation and differentiation of vascular SMCs that lead to the reduction 
of collagen production by these SMCs (Hansson 1989; Amento 1991).
Our findings of Thl? cells play a critical role in atherosclerotic plaque development were 
supported by the study by Gao et a l (2010) eventhough the approach that we applied in our 
experiment set up was totally different with them. We were using female apoE'^' mice which 
known to develop larger atherosclerotic lesion whereby they were using male apoE" '^ with the 
similar C5?BL/6 mice background. Calgiuri et a l (1999) showed that in young female apoE"^ " 
mice (C57 genetic background) (16 weeks old) fed a normal chow diet developed larger and 
more advanced atherosclerotic lesions compared with young male mice. The differences in 
atherosclerotic lesions between genders may be related to differences in the cellular immune 
responses to the atherosclerotic-related autoantigen, oxLDL in the different sexes (Caligiuri 
1999). However, when apoE' "^ mice aged 48 weeks old where the blood levels of estrogen 
decreased in females, there was no longer a sex difference in lesion size (Caligiuri 1999). In
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addition, other studies also demonstrated that female apoE' '^ mice fed with a standard chow 
diet (Surra 2010) or a western type diet (Kuhlencordt 2001; Smith 2010) exhibit larger area 
of vascular atherosclerotic lesions than male mice. In order to induce atherosclerotic plaque 
in the mouse model, we fed the apoE'^" for 12 weeks in comparison with them who treated 
HFD for 16 weeks. We injected intraperitoneally our mice with PTx, PC61 and a 
combination of both in order to suppress Treg cells, which then facilitates the induction of 
Thl 7 cells in vivo. Nevertheless, our findings which showed the induction of Thl 7 cells at 18 
weeks of age of apoE"^ " mice was consistent with their finding who demonstrated that Thl 7 
cells increased at early stage of atherosclerosis (16 weeks of age apoE' '^ mice) and further 
increased in the apoE' '^ mice with advanced plaque (24 weeks old). The positive correlation 
between percentage of Thl 7 and development of atherosclerotic plaque, and also with the 
serum levels of total cholesterol in apoE' "^ mice observed in both studies. However, we did 
realised that Gao et at. (2010) study was more details and comprehensive compared to our 
study because they also demonstrated the role of Thl7/IL-17 cells as potential therapeutic 
targets for atherosclerosis by injecting the apoE'^’ mice with anti-IL-17 and rIL-17 ab 
respectively. They showed treatment of apoE' "^ mice with anti-IL-17 ab dramatically inhibited 
the development of atherosclerotic plaque, whereas rIL-17 treatment significantly accelerated 
the formation of atherosclerotic plaque in respective mice (Gao, Jiang et at. 2010).
One of limitation of our in vivo study was limited numbers of animals per group. We did start 
with 5 animals per groups. However, some of the animals firom each group had serious skin 
problem and need to be terminated as soon as possible. We also have plan to repeat this in 
vivo experiment with larger number of animals per group and make modification of 
experiment set up by comparing with PTx, PC61 and a combination of both treated apoE' '^ 
mice fed with normal diet but it did not materialise due to financial and time constraint.
In conclusion, our study showed that the new subset of CD4^ T-cells, termed as Thl 7 cells, 
have important roles in the development of atherosclerotic lesions. These results identify a 
new target for modulation of atherosclerosis and may shed light on potential mechanisms 
relating to atherosclerosis.
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CHAPTER?
GENERAL DISCUSSION AND FUTURE STUDIES
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7.1 General discussion
T-cells play an important role in regulating atherosclerosis by augmenting chronic 
inflammatory responses. Even though most T-cells aggravate atherosclerosis, certain T-cell 
subsets have been found to reduce inflammation and prevent plaque complications (Anderson
2010). Modifications of T-cell responses may, therefore, provide a viable therapeutic 
strategy, and several studies supported this idea via vaccination or transfer of Treg cells into 
the mouse model of atherosclerosis (Anderson 2010). This strategy led towards an anti­
inflammatory balance of T-cell responses within the plaque rather than the usual pro- 
atherogenic Thl response (Anderson 2010). This modulation would then reduce the 
atherosclerosis progression and improve the clinical outcomes (Anderson 2010). However, in 
order to successfully modulate therapeutic T-cell responses, it is necessary to have a real 
understanding on the exact role of each T-cell subset during atherogenesis (Anderson 2010). 
The current study focuses on the mechanisms of newly characterised CD4^ T-cells, Thl? cell 
differentiation fi*om CD4^ T-cell precursors in the plaque and their roles in atherosclerosis 
development.
CDllb^CDllc^ DCs plays a critical role for T-cell activation and inflammation during 
atherosclerosis (Koltsova 2012). GDI Ib^CDl Ic^ DCs is highly infiltrated the atherosclerotic 
aorta, where they resided both in the plaque and adventitia, potentially giving rise to 
GDI Ib^CDl Ic^ foam cells in the plaque after extensive accumulation of oxLDL (Koltsova 
2012). These cells showed high surface expression levels of CD40, CD86 and MHC class II 
following treatment with oxLDL, PTx and combination of oxLDL and PTx, indicating them 
as specialized and mature APCs. The high levels expression of MHC class II and other co­
stimulatory molecules in CDllb^CDllc^ DCs may emerge these double positive cells as 
central drivers in the atherosclerosis process (Koltsova 2012).
Beside the upregulation of DCs activation markers, the current study also found that all the 
treatments also induced CDllb^CDllc^ DCs to secrete IL-6 and TGF-p. IL-6 is a 
multifunctional cytokine that has major biological effects on proliferation and differentiation 
of B and T lymphocytes and regulation of acute-phase response (Kopf 1995; Rincon 1997). It 
produces by macrophages/monocytes, T-cells, ECs, fibroblasts, SMCs, osteoblasts and 
chondrocytes following stimulation by IL-lp, TNFa, TGF-p or lipopolysaccharide (Huber 
1999). IL-6 is an independent risk factor for coronary artery disease (Schuett 2012). It also 
has been shown to accelerate fatty lesion development in atherosclerosis prone mice, apoE'^’
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mice (Huber 1999). On the other hand, TGF-p is a widely expressed cytokine secreted by 
SMCs, ECs, macrophages/monocytes, and T-cells (Sarzani 1989; Bobik 2006). Studies show 
that TGF-p is anti-atherosclerotic, having a negative correlation between plasma TGF-P 
concentration and the severity of atherosclerosis (Stefoni 2002; Tashiro 2002). Blocking of 
TGF-P signalling in mouse model of atherosclerosis lead to the formation of unstable plaques 
(Tse 2012). This plaque phenotype is probably as results of two consequences of inhibiting 
TGF-P: first, blockade of TGF-P's role in promoting plaque fibrosis would make the plaques 
less stable, and, secondly, the absence of TGF-p signalling lead to an increased numbers of 
pro-infiammatory T-cells such as Thl cells that reside in the atherosclerotic lesions (Mallat Z 
2001; Gojova A 2003; Robertson AK 2003). Furthermore, TGF-P stimulates the expression 
of Foxp3 in naive T-cells, whereas IL-6 inhibits the TGF-p-driven expression of Foxp3, and 
the combination of TGF-P and IL-6 induce RORyt triggering the differentiation of Thl 7 cells 
(Betelli E 2007). Hence, IL-6 is switch factors between the induction of Treg cells and Thl 7 
cells.
The present study showed the effect of IL-6 and TGF-P on the differentiation of Thl 7 cells 
following the engagement of CD4^ T-cells with oxLDL-treated DCs. The results showed that 
CD4^ T-cells co-cultured with oxLDL-treated DCs in the presence of exogenous IL-6 and 
TGF-p increased the expression of IL-17A^ on CD4^R0Ryt^ expressing cells. The results 
may correlate with the high level of TGF-p than IL-6 secreted by oxLDL-treated DCs, which 
suppress the differentiation of Thl 7 cells and the addition of these cytokines from other cells 
sources relieve the suppression and favour Thl 7 cell differentiation. On the other hand, 
MMC treatment reduced the expression of IL-17A^ on CD4^0Ryt^ expressing cells. These 
data was in agreement with previous study, which showed that the co-cultured of T-cells with 
MMC-DCs significantly suppressed T-cells proliferation (Temess, 2007). Temess et al 
(2007) also showed that mouse DCs loaded with MBP and treated with MMC significantly 
suppress specific syngeneic T cells of Tg4 mice. However, the mechanism of suppression 
induced by MMC-oxLDL-treated DCs has not fully clarified because we did not measure the 
IL-6 and TGF-P secretion in the supernatant of 3 days culture and the expression of 
maturation markers expressed by MMC-oxLDL-treated DCs.
Beside CDllb'^CDllc'*^ DCs, SMCs is an important component of atherosclerotic plaques 
located at the intima and media layer of the arteries. Therefore, a typical technique (Ray 
2001; Kobayashi 2005) of isolating SMCs from the murine aorta was applied which involves
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explanting small pieces of vascular tissue and then allowing time for SMCs to migrate out 
from the explanted tissue fragments. The generated SMCs were treated with atherogenic 
stimuli, oxLDL for 24 hours and secreted Thl 7 cells related cytokines, IL-6 and TGF-p. The 
high levels of IL-6 than TGF-p secreted in the supernatant of oxLDL-treated SMCs together 
with addition of exogenous IL-6 and TGF-P may lead to the increased of IL-17A and IL-17F 
expression on CD4^CD25" expressing cells and CD4^0Ryt^ expressing cells following 
engagement with CD4^ T-cells. These observations clearly indicated the important role of IL- 
6 and TGF-p for the differentiation of Thl 7 cells.
However, there has been little disagreement that Thl 7 cells can be differentiated from naive 
CD4^ T-cells in the presence of IL-6 and TGF-p (Hatton 2011). Two recent works by 
Gutcher et al. (2011) and Ghoreschi et ah (2010) confirmed this assumption. Gutcher et a l 
dissects the T-cell population responsible for TGF-P driven Thl 7 cell differentiation. They 
initially found that all progeny of naive CD4^ T-cells have the potential to express TGF-p. 
They also found Treg cells derived TGF-p critical for Treg cells maintenance and 
unsufficient to direct Thl7 cell development. Therefore, the role for Treg cells in promoting 
Thl 7 cell differentiation remains plausible (Gutcher, Donkor et a l 2011). Gutcher et a l 
(2011) then demonstrated that in vitro polarised Thl, Th2 and Thl7 cells can express TGF-P 
but it is most higly expressed in Thl 7 cells. Hence, TGF-p acts in an autocrine manner to 
promote Thl? cell differentiation (Gutcher, Donkor et al. 2011). However, Ghoreschi et a l 
(2010) found that Thl 7 cells can derive in the absence of TGF-p signaling, a contradictory to 
Guther et al (2011) finding. They showed that IL-17^ T-cells can be generated from mouse 
naive CD4^ T-cells solely by IL-6, IL-23 and IL-lp, though significant fewer IL-17^ cells 
arise in comparison to TGF-p plus IL-6 generated cells and those cells possess a more 
pathogenic phenotype than TGF-p derived cells (Ghoreschi K 2010). Ghoreschi et al. (2010) 
shows that TGF-P-derived Thl 7 cells secrete the regulatory cytokines IL-9 and IL-10 
whereas those derived without TGF-P produce Thl-associated cytokines including IFN-y and 
migrate to inflammatory sites. If they continue exposed to TGF-p alone, Thl 7 cells can 
develop into cells expressing both IL-17 and IFN-y, demonstrating an intrinsic property of 
Thl 7 cells to deviate to a cell that has Thl-like characteristics (Lee et a l, 2009). Therefore, 
further studies focusing on the environmental requirements for Thl 7 cells generation both at 
steady state and during inflammatory conditions including atherosclerosis are really needed.
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The expression of CD36 which appears to play a major role in oxLDL uptake in the yÔ T- 
cells and TLRs in various T-cell subsets suggest the possible expression of CD36, TLR-2 and 
TLR-4 on the surface of Thl 7 cells, facilitating direct interaction of oxLDL with Thl 7 cells. 
The current study showed treated Thl 7 cell induced culture induced CD36 expression. This 
observation is quite intresting and warrant further studies. The engagement of oxLDL via 
either CD36 may important in expanding Thl 7 cells in atherosclerotic plaque. OxLDL 
engagement with Thl 7 cells may stimulate the expression of TGF-p as Thl 7 cells is highly 
expressed TGF-P as demonstrated by Ghoreschi et al. (2011) and therefore can act in 
autocrine manner in driving the differentiation of Thl 7 cells. OxLDL also has direct effect on 
Thl7/Treg imbalance which may lead to plaque instability and pathogenesis of acute 
coronary syndrome (Li, Wang et al. 2010).
IL-6, IL-21 and IL-23 are all cytokines that activate the transcription factor STAT-3, which 
has been established to be important for various aspects of the Thl 7 cells biology (Chen, 
Laurence et a l 2007). The present results showed that oxLDL and Thl 7 related cytokines; 
IL-6 and TGF-p increased the expression of a transcriptionally active, phosphorylated form 
of STAT-3 in the CD4^ T-cells. TCR treated CD4^ also increased the expression of p-STAT- 
3. Treated Thl7 cell induction culture further induced the expression of p-STAT-3. The 
downfall of our result is the levels of STAT-3 detected in all the treatments were below the 
detection limit. This finding may be expected, as STAT-3 protein is also susceptible to 
degradation by proteases or the samples may contain materials that interfere with the assay. 
We also demonstrated that TCR treated CD4^ and treated Thl 7 cell induced culture higly 
secreted IL-17A and IL-17F. However, direct interaction of oxLDL with Thl 7 cells influence 
various Thl 7 cell parameters such as STAT-3 expression and secretion of IL-17A and IL-17F 
need further clarification. The fully understanding of direct role of oxLDL on Thl 7 cells may 
help us in developing powerful adjuvants for controlling the role of Thl 7 cells on the 
atherosclerosis development.
Following the determination of the possible mechamsm of Thl 7 cell differentiation during 
atherosclerosis development, the investigation on the effect of Thl 7 cells induction on 
atherosclerotic plaque development using apoE"'"' mice was carried out. ApoE"'"’ mice have 
constitutively high levels of cholesterol; namely LDL-c and VLDL-c, and low levels of HDL- 
c, and are susceptible to the development of atherosclerotic lesions in the arterial tree even 
when fed a normal chow diet (Jawien J 2004). This animal model was initially bred in 1992
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by mutating the apoE gene that encodes the protein required for the transport of cholesterol 
and other lipids from peripheral tissues to the liver (Greenow 2005). Chimeric mice were 
developed by blastocyst injection of C57BL/6J mice to propagate mutant embryonic stem 
cells. These mice produced chimeras that transferred the mutant apoE gene to their progeny. 
Mice homo2ygous for the disrupted gene were produced from heterozygotes after several 
crossings. Furthermore, apoE' '^ mice with C57BL/6J background utilised in this study 
because this the only atherosclerosis mouse model available in our lab. Thl 7 cells were 
induced in vivo by injecting the PTx, PC61, and combinations of both. The effect of Thl7 
cell differentiation on atherosclerosis development was examined by measuring the size and 
composition of atherosclerotic plaques formed in the aortic sinus (Paigen 1987). The effect of 
PTx and PC61 on the differentiation Thl 7 cells was examined at the protein and gene levels, 
and the effect of all treatments on cellular immunity was determined by measuring the 
cytokine milieu. Plasma lipid profiles were also investigated to detect any non- 
immunological effects that could manipulate atherosclerosis development.
The current study has found that intraperitoneal injection of PTx, PC61 and combinations of 
both increased the number of Thl 7 cells in the splenocytes of apoE' '^ mice fed with HFD. 
This observation is consistent with the previous finding which showed that in vivo treatment 
with PTx induced IL-17-secreting cells in wild-type mice, but not in IL-6'^’ mice (Chen, 
Howard et a l 2007). In vivo treatment of PTx was also capable in reducing the number of 
mouse Treg cells and impaired the anti-inflammatory response of Treg cells which in turn 
facilitate the induction of Thl 7 cells in the apoE’^’ mice (Cassan 2006). Beside PTx, PC61 
which used in our experiment also capable to deplete Treg cells population (Zelenay 2006). 
PC61, an anti-CD25 monoclonal antibody has a molecular weight of 55 KDa and able to 
block IL-2 binding to its receptor which inhibit IL-2 stimulated cell growth, resulting in the 
depletion or functional inactivity of Treg cells in the population, leading to 
immunodeficiency (McNeill 2006). The reduction of Treg cells may important in reducing 
the competition of TGF-P consumption, as TGF-p plays critical role in generating IL-17- 
producing cells (Chen, Howard et a l 2007).
Even though all of the apoE'^" mice, which were fed with HFD, PTx, PC61 and its 
combinations, have increased total cholesterol levels but there were no significant effects on 
HDL and triglyceride levels. The high cholesterol may facilitate the differentiation and 
maintenance of Thl 7 cells in vivo. To support our assumption, previous studies showed that
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cholesterol stimulates prostaglandin E2 (PGE2) production in intact rat aorta (Paris D 2000). 
PGE2 is a strong differential regulator of IL-23 production in mouse antigen presenting cells 
in general (Chizzolini, Chicheportiche et al. 2008). Cholesterol has also been shown to 
induce resident VSMC in the lesions to secrete IL-23, with VSMC in arterial walls as the 
main producer of IL-23 in IL-18’^ 'ApoE*^ ' mice on HCD compared to LCD treatment, which 
leads to the expansion and increased stimulation of Thl 7 to produce more IL-17 and the 
resultant in vivo pathophysiological effects of accelerated atherosclerosis development 
(Pejnovic, Vratimos et a l 2009).
Nevertheless, there is a growing body of evidence suggesting that, contrary to what has been 
classically accepted, correlations between lipid profiles and atherosclerotic plaque 
development may not be reliable, especially in animal models (Davenport and Tipping 2003; 
Elhage, Jawien et al 2003; Van Eck, Twisk et a l 2003). Doubts have been cast on the real 
suitability of the apoE"^ " mouse model (single knockout) to study the effect of any treatments 
on the lipid profile due to genetic modification in apoE gene (Ishibashi, Herz et al. 1994; 
McGillicuddy, Carrier et al. 2001). In this sense, the results derived from our study may 
require further investigation using a different model and/or a human intervention study to 
determine the effect of this treatment on the lipid profile.
The effect of Thl? cell differentiation on atherosclerotic plaque development was also 
revealed. Interestingly, the present results indicated the positive correlation between the 
induction of Thl 7 cells at protein and gene levels following PC61 and combinations of PTx 
and PC61 treatment with the increased of total plaque areas in aortic sinus in the apoE'^' mice. 
This may suggest that elevated Thl 7 cells have considerable link with atherosclerosis 
development. The Thl 7 cells mediator, IL-17 has previously shown to be involved in the 
attraction and activation of macrophages in atherosclerotic lesions via upregulation of IL-17 
receptor in vascular walls (Michon 2003), which may lead to lesion progression by secretion 
of proteolytic factors such as matrix metalloproteases (MMP) (Michon 2004). The increase of 
vascular IL-17 and TNFa levels may work in concert to create a pro-infiammatory micro­
environment in accelerating atherosclerotic vascular disease development (Ciszar 2004). 
They also observed the phenomenon in which Thl 7 related mediators were induced 
tremendously and reached their maximum expression values at an early stage (8-16 weeks of 
age) in apoE'^" mice, which may lead to the initiation of atherosclerosis. In addition, the 
detection of Thl 7 cells in the atherosclerotic plaque and tremendous increased of IL-17 and
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RORyt expression in vascular walls with atherosclerotic plaque in apoE' '^ mice strongly 
confirm the causative role of Thl 7 cells in atherosclerosis (Gao, Jiang et a l 2010).
A summary of the proposed mechanism of Thl 7 cell differentiation in the atherosclerotic 
plaque and the effect on plaque development is shown in an illustration in Figure 7.1.
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Figure 7.1 Summary of mechanism of Thl7 cell differentiation from CD4* T-cells, direct 
interaction of oxLDL with Thl7 cells and the effect of Thl 7 cells induction on atherosclerotic 
plaque development. (1) The atherogenic stimuli, oxLDL and PTx (surrogate) upregulates the 
expression of DCs maturation markers such as B7-2, CD40 and MHC (I as well as low levels of IL-6 
and high levels of TGF-p secretion which did not significantly increased Thl7 cells. The addition of 
high levels of IL-6 but low levels of TGF-p increased the differentiation of Th17 cells. The engagement 
of CD4^ T-cells with MMC-oxLDL-treated DCs reduced Th17 cells. However, the mechanism of MMC 
reduced Th17 cells need further verification. (2) Intra-plaque cells; SMCs treated with oxLDL induced 
secretion of high levels of IL-6, low level of TGF-p and IL-23. CD4* T-cells co-cultured with oxLDL- 
treated SMCs with or without exogenous IL-6 and TGF-p stimulate the differentiation of CD4* T-cells 
into Thl7 cells. (3) OxLDL may directly interact with Th17 cells via CD36 which express on the 
surface of Th17 cells. The engagement of oxLDL by Th17 cells may activate STAT-3, Thl7 cells 
transcription factor that may mediate the release of IL-17A and IL-17F by Th17 cells. However, further 
experiment need to be carried out using the proper control. (4) Treatment with PTx, PC61 or a 
combination of both increased Thl7 cells in vivo with a concomitant increased in Th17 related gene 
(IL-17A, IL-17F and RORyt) and cytokine (IL-17A) secretion. PC61 alone or in combination with PTx 
Increased the size of the atherosclerotic lesion. These results suggest a pro-inflammatory role for 
Th17 cells in atherosclerosis development by increasing inflammation and promoting plaque 
development.
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7.2 Future studies
The current study has demonstrated the possible mechanism of Thl 7 cell differentiation in 
the atherosclerotic plaques and their role in the atherosclerosis development. Nevertheless, 
further studies need to be carried out on the limitations that have been highlighted in every 
results chapter. The other approaches could be used need to be explored in order to 
investigate the exact role of Thl 7 cells in the atherosclerotic plaques.
This study heavily relied on a single methodology, intracellular IL-17A and IL-17F staining 
to monitor the effects of oxLDL and Thl 7 cell differentiation. Since the gating strategies that 
we used to identify Thl 7 cells have their respective limitation, the new combination of 
markers such as CD3/CD4/IL-17A/IL-21 or CD3/CD4/CD45/IL-17A could be applied for 
determination of Thl 7 cells. Beside that, in the case of CD4, CCR6 and RORyt staining, the 
isotype controls used to determine background signals need to purchase from the same 
companies to match their corresponding partner. Each company producing fluorescence- 
tagged antibodies uses its own fluorescence protein ration resulting in different intensities of 
staining for the same antibody concentration which affecting background signals.
In the chapter 3, CD4^ T-cells co-cultured with MMC-oxLDL-treated DCs was reduced Thl7 
cells. However, the mechanism how MMC effect on DCs need to be answered by measuring 
IL-6 and TGF-p secretion in the supernatant of 3 days culture. In addition, measurement the 
expression of maturation markers on MMC-treated DCs could be speculated with the 
reduction of Thl 7 cells. Beside that, the number of events acquired to determine DCs 
maturation markers and Thl 7 cells also need to be increased in order to obtain reproducible 
results.
In the chapter 4, the positive control of PECAM-1 staining needs to be presented in order to 
prove that this antibody works. We have shown that oxLDL-treated SMCs able to secrete IL- 
6, TGF-p and IL-23 for 6, 12 and 24 hours. However, these results only applicable for the 
cytokine secreted for 24 hours because we only compared with supernatant from untreated 
SMCs for 24 hours. Therefore, the oxLDL-treated SMCs supernatant for 6 and 12 hours need 
to compare with the supernatant from untreated SMCs for 6 and 12 hours respectively. In 
addition, the IL-6 cytokine levels detected in the oxLDL-treated SMCs at respective time 
need to be diluted because the value obtained was above linear the range of IL-6 standard 
curve. On the hand, the levels of TGF-p and IL-23 detected in the oxLDL-treated supernatant
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at respective time were below the detection limit. Therefore, the amount of sample used for 
each wells need to be increased. Furthermore, the addition of anti-IFNy and anti-IL-2 in the 
experiment set up may increase Thl 7 cell differentiation from CD4^ T-cells in order to 
suppress the Thl cells that may arise in the culture, which will inhibit Thl 7 cells. 
Measurement of MHC class II and B7-1 and B7-2 and other co-stimulatory expression such 
as ICOSL on oxLDL-treated SMCs also need to be carried out in order to confirm the role of 
SMCs as APCs. Beside that, other studies have showed Thl 7 cells has capability to secrete 
TGF-p, therefore further studies need to be carried out whether Thl 7 cells itself can secrete 
TGF-P which can act in autocrine manner for promoting Thl 7 cells in the atherosclerotic 
plaque.
In the chapter 5, although current study showed the expression of CD36 on the surface of 
Thl 7 cells, how or whether CD36 engagement with oxLDL directly on Thl7 cells influence 
various parameters of Thl 7 cell function, such as cytokine secretion and cytokine receptor 
expression, is an important aspect that needs to be further clarified especially using proper 
control such as TCR treated CD4 without oxLDL and treated Thl 7 cells induced without 
oxLDL and also using CD36 agonist. Beside that, the numbers of events for detection of 
TLR-2, -4 and CD36 by using flow cytometry need to be increased during acquisition in 
order to obtain reproducible results. The expression of CD36 on Thl 7 cells also needs further 
confirmation by quantitating using Real Time PGR. Furthermore, the amount of sample used 
for each wells need to be increased in order to obtain the value of p-STAT-3 within the range 
of standard. Beside ELISA, p-STAT-3 also can be detected by using western blot and the 
levels of expression can be quantified by densitometric analysis of the bands. Beside in vitro 
differentiation of Thl 7 cells that have been applied in our study, Thl 7 cells also can be 
automatically sorted based on the combinations that have been suggested above using BD 
FACS Aria. The purified Thl 7 cells can be used for further experiment in determining the 
direct interaction of oxLDL with Thl 7 cells.
In the chapter 6, for higher confidence limit, it may be necessary, statistically, to carry out 
experiment on a larger population of mice to identify the precise effects of Thl 7 cells 
regulation in plaque progression and destabilisation in atherosclerosis of animal models. 
Beside the large number of animals per group, modification of experiment set up such as 
comparing with PTx, PC61 and a combination of both treated apoE"^ " mice fed with normal 
diet also required to investigate the effect of Thl 7 cells induction on atherosclerosis
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progression. In addition, the mechanism how removing Tregs cells and increasing Thl 7 cells 
influence the different levels of total cholesterol, HDL and triglycerides in apoE'^" mice also 
need to be investigated. Beside that, the experiments also need to be carried out in other 
animal model such as STAT-3’^ 'ApoE' ‘^ mice or RORyf^'ApoE’^ ' mice in order to confirm the 
causative role of Thl 7 cells in atherosclerosis.
The effect of other isoforms of Thl 7 cells mediator, especially IL-17F and IL-17E which 
detected in the atherosclerotic plaque, on the atherosclerosis development also needs to be 
investigated by treating IL-17F/IL-17E ab or anti-IL-17F/IL-17E on apoE"^ " mice fed with 
HFD or normal diet. Moreover, the existence of T-cell clones were shown in the intestines of 
patients with inflammatory bowel disease and in EAE lesion in mice that produce both IL-17 
and IFNy, designated as Thl/Thl7 cells. These dual producers also express Thl7-inducing 
transcription factor, RORyt, and Thl-inducing transcription factor, T-bet. Further studies 
need to be carried out to explore the biological importance of this hybrid Thl/Thl7 clone, 
since both IL-17 and IFNy play important roles in atherosclerosis development.
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